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Abstract
Oestrogen (E) is thought to be protective within the cardiovascular system. Pre-menopausal
women have a lower risk of developing cardiovascular disease than age-matched men but
this difference is lost at the menopause. E initially protects the myocardium following
myocardial infarction (MI), yet there is evidence that pre-menopausal women have a higher
acute mortality rate following MI, an effect that is also seen in experimental MI. Recent
clinical trials show that hormonal replacement therapy is not effective for prevention of
cardiovascular disease in post-menopausal women.
This thesis aimed firstly to investigate the effects of E on the myocardium during healing
after MI. In ovariectomised female mice, E treatment results in an increase in acute mortality
due to cardiac rupture following induction of MI by coronary artery ligation. We
hypothesised that E modifies the remodelling process, particularly through regulation of
matrix metalloproteinase (MMP) enzyme activity. After MI, there was a reduction in
necrotic myocardial tissue and inflammatory response in E treated compared to placebo
treated mice. However there was no concomitant reduction in MMP-2 and MMP-9 activity.
E treatment was also associated with a reduction in MMP-13 expression and an increase in
tissue inhibitor of metalloproteinase type 2 activity. These data show that E disrupts matrix
degradation during infarct healing after MI. In the mouse this results in an increased
incidence of cardiac rupture.
A second aim of the thesis was to determine the roles of the E receptor (ER) a and ER(3 in
mediating the initial cardioprotective effects of E following MI. E reduced infarct size,
neutrophil infiltration and generation of oxidant stress following myocardial ischaemia with
reperfusion in rats. This effect was not blocked by a novel ERP antagonist but was mimicked
by a novel ERa agonist. The ERa agonist also protected the isolated buffer perfused heart
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from reperfusion injury showing that it has both neutrophil dependent and independent
effects.
A third aim of the thesis was to determine whether inclusion of a progesterone analogue in
hormone replacement therapy (HRT) regimes modifies the cardioprotective effects of E. In
ovariectomised female rats, E supplementation reduced infarct size and neutrophil
infiltration following ishaemia and reperfusion compared to placebo treated animals. This
protection was lost in animals receiving the progesterone analogue medroxyprogesterone
acetate (MPA) in addition to E. Co-administration of MPA therefore negates the beneficial
effects of E in myocardial reperfusion injury.
In conclusion, the data confirm the initial cardioprotective effects of E following myocardial
infarction with or without reperfusion. At least in the rat, this protection is mediated through
stimulation of the ERa, through direct effects on the heart and additional effects on
neutrophils. This protective influence of E is lost if E is co-administered with MPA, as it
frequently is in HRT regimes. In addition, despite the initial cardioprotection E can influence
subsequent matrix remodelling during healing of the myocardial infarct through modification
of MMP activity. In the mouse this destabilises the infarct and results in an increased
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1.1. Female gender and cardiovascular disease
Cardiovascular disease (CVD) including coronary heart disease (CHD) that
encompasses heart failure, stroke and myocardial infarction (MI) is the leading single
cause of mortality in the developed world. In 2004 216,379 deaths in the UK were due
to CVD (Heartstats.org 2005). Current lifestyles within the western world do not
indicate that this trend will abate soon, although over the next 5 years the British
government aim to reduce the number of CVD related deaths in under 75 yr olds by
40%. With increasingly ageing populations the number of people at risk from CVD is
also escalating, thus making it even more important for us to understand the mechanisms
of CVD and develop strategies for its prevention and treatment (Herrington et al.
2003a). There is a general misconception that CVD is a disease predominantly effecting
males. CVD including CHD, stroke and peripheral vascular disease is actually the
number one killer of females. In 2004 in the UK CVD accounted for 36% of deaths in
females compared to all cancers, which accounted for 24% of deaths (Figure 1.1).
A possible reason for this misconception is that the onset of CVD occurs on average 10
years later in females than in males (Lerner et al. 1986). In peri-menopausal women the
incidence of CVD is 1 in 6, and lower than the incidence in age-matched men. After the
menopause the incidence rate of CHD and CVD related mortality rises to 1 in 3 and
matches the rate in males (Vaccarino et al. 1999). Figure 1.2 demonstrates that prior to
the menopause (<45 years of age) males have a higher incidence of CVD but this gender
difference is reversed after the menopause (55-64 years). Association of the menopause
with an increased risk of CVD has resulted in the belief that oestrogen (E) protects
females prior to the menopause. Plasma levels of E drop significantly during the
menopause, which coincides with the increased incidence of CVD. The importance of E
within CVD is supported by observations in younger women who have premature
ovarian failure (POF). These women undergo premature menopause and consequently
have lower E levels and are at an increased risk of mortality, especially from CVD
including stroke and coronary artery disease (van der Schouw et al. 1996). These
observations of young women with POF highlight the significant role E has within CVD
2
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Figure 1.1. Female mortality, grouped by cause in the UK.
Data is from 2004, www. heartstats, org. Reprinted with permission from The British
Heart Foundation
i i Male
20-34 35-44 45-54 55-64 65-74 75+
Age
Figure 1.2. The Prevalence of CVD
The prevalence of CVD in Americans, grouped by age and sex. The data includes CHD,
heart failure, stroke and hypertension in Americans. Data is from National Health and
Nutrition Examination Survey (NHANES) 1999-2002, Centre for Disease/ national
Centrefor Health Science (CDC/NCHS).
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1.2. Oestrogen synthesis and storage
There are three predominant naturally occurring Es in the human body, estradiol, estriol
and estrone. Estradiol is the most abundant and efficacious E prior to the menopause,
after which estrone becomes the most profuse. E is predominantly synthesised in the
ovaries and corpus luteum, outside of the ovaries, lesser quantities are synthesised in the
liver, adrenal glands, adipose tissue, breasts, blood vessels and heart (Dubey et al. 2004).
Characterised as a steroid hormone, the initial precursor of E synthesis is cholesterol,
whilst the immediate precursor varies depending on the E. Estradiol is synthesised from
testosterone, whilst estrone from androstenedione, these two Es inter-convert through
the action of 17(3-hydroxysteroid dehydrogenase (Figure 1.3). The plasma
concentrations of E are relatively constant in men, whilst in women the concentration
varies depending on the phase of the estrous cycle. Post-menopause the plasma level is
greatly reduced (O'Shaughnessy et al. 2001; Table 1.1). Synthesis of Es outside the




Follicular phase 5-35 ng
Luteal phase 10-20 ng
Post-menopause 1-2 ng
Table 1.1. Human 17P-estradiol plasma concentrations.
Concentration of 17(3 estradiol in males and at different phases of the female oestrous
cycle andpost-menopause (Knobil and Neill 1988).
Metabolism of E occurs in the liver through the action of 17p-hydroxysteroid
dehydrogenase, or in the kidney to water-soluble compounds, such as catecholestradiols
(Figure 1.3). A wide range of physiological processes are influenced by E, including the
4
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growth and differentiation of reproductive cells, brain and bone development as well as
roles in regulation of blood vessel diameter, and hence blood flow, and pathologically
for instance in breast cancer (Erlandsson et al. 2005; McEwan 2002; Seeger et al. 2005).
This project is focused upon the cardiovascular effects of E and therefore the other








Figure 1.3. Oestrogen synthesis and degradation pathways.




E diffuses freely in and out of cells. High affinity binding to specific ligand activated
receptors retains E in cells and mediates its effects. The majority of Es actions are
through it acting upon classical steroid receptors, these classical genomic effects are
observed hours and days after the administration of E. Currently there are two known E
receptor (ER) subtypes, ERa and ER(3.
1.2.1.1. Classical oestrogen receptors
Both ERa and ERP are classified as nuclear receptors and sub-classified in the steroid
receptor family, sub-family 3, group A (Nucleur Receptors Nomenclature Committee,
1999). The receptors are resident in the nucleus, whether free or bound to ligand (Parker
1995; Figure 1.5, page 9). ERa was first identified and cloned from the rat uterus in
1987; the molecular weight of the protein is approximately 67 kDa (Koike, 1987), it
shares 88% homology with the human ERa. An additional nine years were required to
identify and clone the second receptor, ERp, this has a molecular weight of 54.2 kDa
(Mosselman et al. 1996). The two receptors have a similar over all homology; both
contain six regions, termed A-F. Figure 1.4 illustrates the homology between the
receptors; the greatest homology is within the DNA and ligand binding domains
(domain C and E respectively; Kuiper et al. 1996; Tremblay et al. 1997). The ligand
binding domain is the region of the receptor that hormone or ligands bind to (Tsai et al.
1994). The high homology in the ligand binding domain is evident from the similar
binding kinetics of ligands, 17pE2 has a Kj of 0.13nM and 0.12nM for ERa and ERP
respectively (Kuiper et al. 1997). The high homology in the DNA binding domain
allows ERa and ERP to recognise and bind to a specific palindromic DNA sequence,




23% 95% 24% 55% 12%
_COOH
Figure 1.4. ERa and ERp and the relative homology between them.
Domain A contains the transcription activationfactor AF-1, domain C is responsible for
DNA binding and domain Efor ligand binding and contains transcription activation
factor AF-2. (Taken from Ness, 2005)
The ER is an inactive monomer bound to a chaperone such as a 'heat shock protein'
(HSP). Upon ligand binding, a conformational change causes the HSP to dissociate and
the receptors to dimerise, this dimerisation can be homologous or heterologous. The
conformational change promotes and stabilises the interaction of ER with other co-
factors. The co-factors may be activators or repressors, activators link the ER with
histones or components of basal transcription, whilst repressors attenuate transcription
by competing with activators, they also associate to the ER in the presence of
antagonists (Nilsson et al. 2001).
The co-factors bind to transcription activation factor-1 (AF-1) in the regulatory domain
(domain A) or AF-2 within the ligand binding domain (Ruff et al. 2000). AF-1 activity
is ligand independent, dependant on the cellular environment and regulated by growth
factors. AF-1 may undergo phosphorylation and forms a site for interaction of
transcription factors, it is also involved in protein-protein interactions (Nilsson et al.
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2001). In contrast to AF-1, AF-2 binds both agonists and antagonists to cause a
conformational change, AF-2 activity is solely dependant on ligand binding (Pike et al.
2001). Variations in ERa and ERp activation and responses are thought to arise from
cell specific co-activators and co-repressors, low homology at the amino terminus end
and different AF-1 and AF-2 expression (Hall et al. 2001). Human ERp does not contain
an AF-1 domain, where as mouse ERP does, this makes comparison studies more
difficult to interpret (Hall et al. 1999).
Crystalisation studies have revealed the importance of AF-2 in the determination of ER
response to ligand binding. Within AF-2 there are a number of helix motifs which cover
and line the binding cleft (Brzozowski et al. 1997; Pike et al. 1999). Upon ligand
binding the position of these helixes changes, the crystalisation studies have highlighted
the importance of helix 12. The conformational position of helix 12 is a major
determinant of ligand activity. When ERa is bound to an agonist, such as 17PE2 helix 12
forms the binding site for co-activators (Brzozowski et al. 1997). In contrast, when an
antagonist such as raloxifene is bound to the receptor helix 12 is displaced, co-activators
are no longer able to bind to the receptor-ligand complex (Brzozowski et al. 1997;
Reviewed by Nilsson et al. 2001). After dimerisation the receptor-ligand complex acts
as a transcription factor on a wide range of genes. ERa and ERp have distinct but over
lapping cellular localization, within a tissue each receptor may be localized to a different
cell type, thus producing varied responses. Both receptors are expressed within the
cardiovascular system (CVS; Gustafsson 1999).
There is also an ERE independent pathway of transcription regulation, where E interacts
with the DNA indirectly. The activated ER forms a complex with DNA-bound
transcription factors through the AP-1 binding site and therefore does not require an
ERE. In addition to these genomic pathways there is also a non-genomic pathway
discussed in Section 1.2.1.2. (Taylor et al. 2000; Figure 1.5).
Recently receptor specific ligands have been developed to selectively activate
(Herrington et al. 2003b) or antagonise the receptor of interest. Prior to these selective
8
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ligands non-selective agonists and antagonists limited the ability to investigate the
individual receptors. Mice have been genetically altered to remove either ERa (ERKO)
or ER|3 (BERKO; Krege et al. 1998). Experiments with these models are limited due to
compensatory and complementary mechanisms of the remaining receptor, the possibility
that the receptors are not removed entirely and species difference in expression (Couse
et al. 1995). A double knock out (KO) mouse has also been used to study the role of
ERs. These experimental results with E show that some of the cardiovascular protection
including inhibition of vascular smooth muscle cell (VSMC) proliferation remain
despite both ERs being removed. The results suggest that there is a third receptor, these
properties are ER independent, non-genomic (Karas et al. 2001a). There is also evidence
supporting the concept of receptor splice variants in the KO animals and that these
receptors may confer some of the receptor properties (Smithson et al. 1998). For the
reasons stated here and the limitations of the KO mice in the work carried out during this










Figure 1.5. The classical and non-classical pathway of oestrogen signalling within
the cell.
(1.) The classical activation requires E to diffuse into the cell across the cell membrane
and enter the nucleus where it binds to ERs. Binding of E to ERs causes a
conformational change enabling the receptor-ligand complex to dimerise and bind to the
oestrogen response element (ERE) on DNA. (2) The ER can be activated and bind to the
ERE by phosphorylation, independent of ligands. (3) Once the ER is activated by ligand
binding it is able to act independently of the ERE through other sequences with in the
DNA such as the AP-1 site. (4.) In the non-genomic pathway E interacts with ERs on the
cell membrane that activates intracellular signalling pathways. The non-genomic
pathway results in a rapid response, within seconds to minutes compared to the classical
genomic activation that creates a response in minutes to hours.(Hall et al. 2001)
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1.2.1.2. Non-genomic properties of oestrogen
The idea of a non-genomic ER is not new. The non-genomic responses of E are
observed within minutes and hours of administrating E. Studies 30 years ago with E
conjugated to bovine serum albumin (BSA), which is too large to penetrate the cellular
membrane, demonstrated that E has cell surface receptors which are responsible for the
rapid non-genomic effects of E (Pietras et al. 1977, 1980). Since these studies
fluorescence microscopy has shown 17|3E2 bound to BSA at the cell surface (Kim et al.
1999) and immunoblot studies have detected ERa 67 kDa epitopes at the cell membrane
(Chambliss et al. 2000). Within the CVS immunofluorescent studies show staining on
both the nuclear and cytosolic membranes of cardiomyocytes and fibroblasts indicating
that these cells posses ERs in both locations (Grohe et al. 1997).
Numerous studies have been carried out to try to identify and characterise such a
receptor (Chen et al. 1999; Pappas et al. 1995; Wehling 1997). The structure of the
membrane ER has not been determined, but transfection of Chinese hamster ovary cells
has demonstrated that a single RNA and cDNA is capable of synthesising both the
membrane and nuclear receptors (Razandi et al. 1999). Debate arises because the ER
gene does not encode a hydrophilic domain for anchorage into the plasma membrane.
The ER may be tethered through glycophosphatidly-inositol links or localised to the
caveola signalling transduction and vesicular trafficking domains in the plasma
membrane (Reviewed by Losel et al. 2003). The membrane receptor is most likely to be
G-protein linked and activate signalling pathways accordingly (Razandi et al. 1999).
Recently striatin has been identified as a key protein essential in non-genomic E
mediated response and the formation of a complex to G-protein coupled pathways (Lu et
al. 2004). Over expression of striatin in cultured cells causes a shift in the cellular
distribution of ERs towards the cell membrane (Lu et al. 2004). These studies suggest
the ERs may be 'pulled' to the plasma membrane from the nucleus.
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Orphan E related receptors have recently gained experimental interest within cancer
biology, these receptors are closely linked to ERs and bind to EREs (Ariazi et al. 2006).
At the moment this research has concentrated on these receptors in cancer and not CVD
(Sun et al. 2006).
1.3. Oestrogen and the cardiovascular system
Clinical observation studies (Reviewed by Herrington et al. 2003a) and experimental
models have demonstrated the beneficial properties of E within the CVS (Reviewed by
Mendelsohn et al. 1999). These experiments have determined some of the
cardiovascular parameters that E modulates, which include both genomic and non-
genomic properties.
Both ERa and ERp are expressed in cardiac myocytes and fibroblasts in the rat (Grohe
et al. 1998), mouse (Gustafsson 1999) and human (Mendelsohn et al. 1999). Within rat
and human vasculature both ER's are expressed in the smooth muscle cells (Mosselman
et al. 1996; Nakamura et al. 2004) and endothelial cells (Simoncini et al. 2004b). ERa is
also expressed within fibroblasts (Mahmoodzadeh et al. 2006).
It is well known that E protects against atherosclerosis and plaque formation within the
vasculature (Mendelsohn et al. 1999). Within the CVS E favourably alters the ratio of
plasma lipid levels by decreasing the level of low density lipoproteins (LDLs) and
simultaneously increasing the high density lipoproteins (HDLs). E also acts as an
antioxidant reducing oxidative damage of myocardial cells and preventing the oxidation
of LDLs. E moderates endothelial function and accelerates endothelial cell growth, it
also enhances vasodilation in the presence and absence of intact endothelium. E is anti-
apoptotic preventing cell death and consequently provides protection against
atherosclerosis and plaque formation. Through enhanced nitric oxide (NO) release E
also decreases blood pressure (Reviewed by Mendelsohn et al. 1999). After injury and
during periods of inflammation E reduces the inflammatory response through decreased
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expression of vascular adhesion molecules and inhibiting VSMC proliferation.
Membrane receptors mediate a large number of E responses within the CVS, these
include enhanced NO release, inhibited cardiomyocyte apoptosis and hypertrophy (Kim
et al. 2006). These properties of E within the CVS will be discussed in more detail in
relation to their response in MI.
1.3.1. Endothelial function including Nitric Oxide release, cell
proliferation and the role of oestrogen
Endothelial cells provide a protective barrier against clot formation and release
vasodilators, such as NO, that mediate vascular tone (Mullane et al. 1987). Endothelial
dysfunction and injury are thought to be early initiators of atherosclerosis. Impaired NO
release during endothelial dysfunction contributes to disease progression. VSMC
proliferation during endothelial dysfunction is an important step in lesion formation and
atherosclerosis (Ross et al. 1973). NO released from the endothelium not only acts as a
vasorelaxant, but is also involved in endothelial regeneration, reduction in platelet
adhesion and inhibits leukocyte chemotaxis (Barbato et al. 2004). Rapid release of NO
and vasodilation is the predominant non-genomic property of E within the CVS.
Administration of E to ovariectomised (ovx) animals and primates ex vivo and in vivo
results in rapid non-genomic vasodilation within minutes (Sudhir et al. 1997; Williams
et al. 1992). Experimentally, in cultured endothelial cells this response to E is blocked
by ER antagonists and ERa stimulation directly activates eNOS (Chen et al. 1999;
Gilligan et al. 1994). Increased NO decreases blood pressure, platelet aggregation,
leukocyte adhesion, vascular smooth muscle mitogenesis (Moncada et al. 1993) and
inhibits VSMC proliferation (Chen et al. 1996; Leiberman et al. 1995).
Studies investigating the effect of E on the function of the endothelium in humans have
employed forearm blood flow analysis (Higashi et al. 2001; Lima et al. 2005). These
studies have demonstrated that treatment with E increases forearm blood flow in
postmenopausal women, thus E stimulates vasodilator release from these cells in vivo as
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it does in vitro (Gerhard et al. 1998). Menopause and a decrease in E levels is
accordingly associated with endothelial dysfunction; an early predictor of coronary
artery disease (Mercuro et al. 1999a).
1.3.2. Serum lipids and oestrogen
High serum lipid levels and cholesterol are risk factors for developing atherosclerotic
plaques within coronary arteries. Pre-menopausal women have reduced atherosclerosis
compared to their age matched male counter parts (Mendelsohn et al. 1999). This sex
related difference in plaque formation is accounted for by E (The writing group for the
PEPI trial 1995). Through regulation of hepatic apoprotein genes E decreases plasma
levels of LDLs, cholesterol and serum Lp(a) lipoproteins, whilst simultaneously
increasing the circulating levels of beneficial HDLs (Kushawaha 1992; Reviewed by
Mendelsohn et al. 1999). The ability of E to alter the ratio of plasma lipids is thought to
account for around a third of its cardiovascular benefits (Bush et al. 1987; Mendelsohn
etal. 1994)
1.3.3. Oxidation and oestrogen
Oxidation of LDLs enhances vascular damage through chemotactic and cytotoxic
properties and the formation of foam cells. Oxidative damage plays a significant role in
a range of human CVDs, including MI, ischaemia-reperfusion and atherosclerosis
(Darley-Usmar et al. 1997). Systemically E acts as an anti-oxidant and suppresses free
radical induced peroxidation through its phenoxyl radical (Sugioka et al. 1987). E also
regulates the expression of genes that regulate local production and degradation of
superoxide, including superoxide dismutase (SOD) and glutathione (Strehlow et al.
2003). E also improves the ratio of NO to nitric dioxide (NO2) through down regulation




MI is caused by a lack of oxygen and nutrients to part of the coronary muscle. This is
commonly caused by the rupture of an atherosclerotic plaque which exposes a
thrombotic surface within a coronary artery (Corrado et al. 1994). It is now recognised
that the pathology of MI and sudden death is different in pre-menopausal women, where
it is due to plaque erosion, compared to the distinct process of plaque rupture in males
and post-menopausal women (Burke et al. 1998). The recent Women's Ischaemia
Syndrome Evaluation (WISE) study identified the atypical symptomatic nature of
presentation of CHD in women (Quyyumi 2006). Twenty percent of the women studied
had evidence of myocardial ischaemia with chest pain, but had normal coronary arteries
on angiography. The defect in these women seemed to lie in the coronary
microvasculature.
1.5. Myocardial remodelling post-myocardial infarction
MI results in cell death leading to muscle loss and consequently decreased function of
the heart. If severe the loss of myocardial function causes arrhythmias and immediate
death. In less severe cases of MI survival is more likely and there is a healing process to
replace the damaged and necrotic tissue.
The acute remodelling process lasts for approximately four days and is a combination of
overlapping and complementing mechanisms, including an inflammatory response, new
tissue formation and tissue remodelling including collagen deposition and then
angiogenesis (Frangogiannis et al. 2002; Kawakami et al. 2004). Scar tissue formation
to replace necrotic myocardial tissue is one of the main remodelling processes following
MI. Acute remodelling is involved in cardiac failure, arrhythmias and cardiac rupture.
These conditions all develop through the degradation of matrix proteins and collagen
from within the extracellular matrix (ECM; Takano et al. 2003).
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1.5.1. The extracellular matrix
The ECM is a dynamic tissue comparable between all mammalian species and is
fundamental to most tissues and organs, although the composition of it varies between
organs (Williams 1989). The ECM provides physical support and structure to tissues.
The ECM also determines the three dimensional organisation of the cells it surrounds,
and hence the physical properties of tissues. Interactions between cells and the ECM
influence cell signalling which can directly manipulate cell behaviour and function
within remodelling thus effecting differentiation, proliferation, growth and survival of
cells (Lukashev et al. 1998; Ogawa et al. 2000). In most tissues, including the
myocardium the ECM consists of fibrillar collagen, elastin, microfibrillar proteins,
proteoglycans and adhesive proteins such as laminin (Fedak et al. 2005). The
myocardial ECM consists predominantly of fibrillar collagen, of this approximately 85%
is type I. One of the major properties of collagen type 1 is high tensile strength which
helps to prevent over stretching and deformation of the ECM. Collagen type III accounts
for approximately a further 11% of the total collagen, this has thin fibres providing the
ECM with its resilience (Assoian et al. 1997; Buck et al. 1993; Hornberger et al. 2000;
Ross et al. 2001; Simpson et al. 1994).
The ECM is able to alter both its composition and organisation to have profound effects
on the surrounding tissue. Diseases resulting from gene deletion or mutation within the
ECM have demonstrated the major role the ECM has on organs within the body and the
diverse range of organs that are effected by it (Burlew et al. 2000). Major CVDs
including left ventricular hypertrophy from volume overload, dilated cardiomyopathy,
MI and hypertension are all affected by altered ECM composition. Both human and
animal studies have shown that during remodelling post-MI there are changes in left
ventricle (LV) collagen content (Cleutjens et al. 1995b; Sackner-Bernstein 2000). The
amount, type, stability and organisation of the fibrillar collagen within the ECM are all
likely to play a key role in these diseases (Ju et al. 1996). An excess of collagen is
typically laid down in the infarcted myocardium during remodelling post MI. The
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increased collagen content forms a stable scar to provide protection and prevent the
weakened area from cardiac rupture (Sun et al. 2000b).
Despite the main function of the myocardium and its ECM being to work as a muscular
pump cardiomyocytes only account for around 33% of the total cells, although they
occupy about 66% of the myocardial volume (Zak et al. 1973). The most abundant cell
within the myocardium are fibroblasts (Robinson et al. 1983), their primary role is the
synthesis and regulation of components of the ECM (Eghbali et al. 1988; Zak et al.
1973), the abundance of these cells suggests that there is a continuous need for new
components of the ECM.
1.5.1.1. Extracellular matrix degradation
Physiologically the myocardial ECM is constantly turning over at a rate of
approximately 0.6% per day. Continuous turnover of the ECM is essential for the
physiological active metabolism in the myocardium and blood vessels (Weber 1989).
Although not rapid this continuous turnover suggests there is a constant requirement for
low levels of proteolytic enzymes. Degradation of the ECM in the myocardium is
predominantly through serine and metal ion proteinases, such as matrix
metalloproteinases (MMPs; reviewed in Fedak et al. 2005; Mott et al. 2004).
1.5.2 Plasmin
Serine proteinases are released from neutrophils and macrophages during an
inflammatory response, inactive plasminogen is also present in the ECM. Active plasmin
is a potent serine protease that hydrolyses bonds between arginine and histamine.
Plasmin plays a key role in remodelling post MI (Knoepfler et al. 1995; Rohde et al.
1999) and activates growth factors released from the ECM including vascular




There are two plasminogen activators (PA) that hydrolyse plasminogen into plasmin.
The two PAs, urokinase-PA (u-PA) and tissue-PA (t-PA) are associated with different
physiological roles within the body (reviewed by, Dano et al. 1985; Mignatti; Saksela et
al. 1988). Active plasmin is capable of degrading the majority of ECM components. The
development of mice with genes of the plasminogen system KO has helped ascertain the
role and importance of various components of the plasminogen system during the
process of cardiac remodelling (Creemers et al. 2000; Heymans et al. 1999; Knoepfler et
al. 1995). Mice with the plasminogen gene disrupted have delayed infarct healing after
MI (Creemers et al. 2000). u-PA KO mouse have impaired healing and are predisposed
to heart failure after MI (Heymans et al. 1999). Administration of PA inhibitor (PAI-1)
through adenoviral gene transfer prevented cardiac rupture after MI (Heymans et al.
1999). These studies have demonstrated that the plasminogen system is a prerequisite for
the disruption of collagen and essential for functional recovery after MI. Collagen
disruption is vital for cell infiltration enabling wound healing but is also the initial stage
in rupture. These studies reported a decrease in MMP-2 and MMP-9 activity and
significantly reduced LV wall thinning in KO mice compared to wild types, thus
illustrating that plasmin activates these MMPs within the myocardium (Creemers et al.
2000; Matrisian 1992).
1.5.3. Matrix Metalloproteinases
The MMPs are a family of over 20 zinc-dependent proteases. Most MMPs are secreted,
but recent research (Miyamori et al. 2000) has identified a sub-group with an additional
domain enabling anchorage in the cell membrane. There are five sub-groups of MMPs,
and MMPs are numbered in the order of their identification. The five sub-groups
comprise of the collagenases (MMP-l, -8 and -13), capable of cleaving intact fibrillar
collagen, mice naturally express MMP-l3 as the major collagenase compared to humans
who express MMP-l. The gelatinases (MMP-2 and -9) cleave fibrillar collagens further
and basement membrane type IV. The stromelysins (MMP-3, -10 and -11) have a broad
substrate specificity including fibronectin, laminin and proteoglycans, the matrilysins
(MMP-7) also have broad specificity including elastin, enactin and osteopontin. The
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membrane bound MMPs (MT-MMPs) have collagenolytic activity (Ohuchi et al. 1997)










MMP-1 55 45 Fibrillar collagens, casein, gelatin,
proteoglycan







proteoglycan, collagen X, XI,
collagenase,
As MMP-3 and elastin
Proteoglycan, fibrillar collagens,
gelatin
Gelatin, collagens IV, V, VIII, X,
denatured collagens
MMP-13 66 48 Fibrillar collagens, aggrecan, gelatin















Table 1.2. MMPs identified post-MI (Modified from Vanhoutte et al. 2005).
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1.5.3.1 The structure of matrix metalloproteinases
All the MMPs share common domains. The catalytic protease domain is maintained
throughout the MMP family, this domain contains the catalytic Zn2+ atom at the centre
that is essential for cleaving collagen. The gelatinases have an additional fibronectin-
type II domain, which enables interactions with gelatin and collagen (Allan et al. 1995).
The signal pro-domain is responsible for maintaining the latency of MMPs and is
conserved throughout all MMPs. The pro-domain contains a 'cysteine (Cys) switch', the
Cys ligates the catalytic Zn2+ which maintains the protease in a latent state until cleaved
(Becker et al. 1995; Van Wart et al. 1990). The haemopexin domain, consists of four
anti-parallel p-strands and an a-helix to facilitate cleavage of the triple helical interstitial
collagens (Bode 1995). Differences in the topology of the active site cleft and differing
numbers of structural domain repeats produces MMP substrate specificity and
differences in tissue inhibitor of MMPs (T1MP) activity (Nagase et al. 1999). The

























Figure 1.6. The structure of MMPs.
The subunits of the MMP sub-groups are highlighted. It is clear to see the similarities
and differences between them, this provides the sub-groups with a degree of substrate
specificity. Taken from merckbioscience.
1.5.3.2. Regulation of matrix metalloproteinases
Collectively the MMPs are capable of degrading the entire ECM and are thus vital in
physiological and pathological tissue remodelling. Pathologically MMPs are involved in
a wide range of conditions including cardiac remodelling (Curran et al. 1999;
Lichtinghagen et al. 2001; Pap et al. 2000; Spinale 2002).
Stringent MMP activity regulation at three levels prevents excessive detrimental and
inappropriate activity of MMPs (Figure 1.6; Cleutjens et al. 2002). The first regulatory
step is gene expression and transcription. Cytokines such as tumour necrosis factor
(TNF)-a, interleukin (IL)-l and IL-6 stimulate MMP expression (Alexander et al. 1998;
22
Chapter 1
Nagase et al. 1999). Physical stress, cell-matrix and cell-cell interactions can also induce
MMP activity (Biswas et al. 1995), whilst factors such as glucocorticoids suppress
MMP expression (Fini 1998).
Cleavage of latent-MMP and disruption of the Cys-switch is the second level of
regulation. Step-by-step cleavage is the predominant mechanism of activation. Cleavage
of the pro-domain causes a conformational change exposing the activation site. A second
cleavage commonly by another MMP, such as MMP-3 then fully activates the MMP
(Mann et al. 1998). MMPs are also activated at the cell surface by MT-MMPs, which
cleave and activate other MMPs. MMP-2 is activated at the cell surface through a
trimolecular complex consisting of pro-MMP-2, TIMP-2 and MT1-MMP (Butler et al.
1998). The third mechanism is the intracellular activation of MMPs, although few
MMPs are activated this way and the full mechanism is poorly understood (Pei et al.
1995; Sato et al. 1996).
Finally active MMPs are inhibited by TIMPs. The TIMPs are the only inhibitory
mechanism of MMPs once activated. TIMPs are expressed by a large variety of cells and










Figure 1.7. Pathways of MMP release and regulation.
The regulation ofMMP activity involves three pathways. The initial regulation is within
the cell and the rate of gene transcription Once secreted proMMPs are cleaved by
plasmin (and other proteases such as trypsin and elastase). Membrane bound MMPs
may also activate MMPs at the cell surface. TIMPs and PAI-1 inhibit the activation of
MMPs, either directly or through the inhibition ofplasminogen cleavage. The balance of
MMP activation and inhibition regulates the degradation of the ECM (Creemers et al.
1.5.3.3. Tissue inhibitors of matrix metalloproteinases
TIMPs inhibit MMPs by forming non-covalent bonds at the active site of MMPs. The
binding of TIMPs and MMPs has a stoichiometric ratio of 1:1; therefore the ratio of
MMPs to TIMPs is important in determining the amount of MMP activity (Goldberg et
al. 1989).
The TIMPs are a family of four proteins, which share a 40 - 52% sequence homology. A
conserved tertiary structure assists in largely indiscriminate binding to MMPs (Sato et
al. 1996; Willenbrock et al. 1994). TIMP-1 and -3 are readily inducible, TIMP-2 is
constitutively expressed whilst TIMP-4 has higher expression in the myocardium (Fedak




the N- and C- terminal domain. The N terminal domain is the main inhibitory unit that
interacts with the Zn2+ binding site of MMPs. The C terminal domain also interacts with
MMPs, these interactions are thought to ameliorate TIMP inhibition of MMP activity
(Willenbrock et al. 1994; Williamson et al. 1990). Studies using specific peptides and
antibodies to block regions within TIMPs have helped identify the function of distinct
areas (Bodden et al. 1994) while x-ray crystallography studies have aided understanding
of the structural changes that occur upon complexes forming between MMPs and TIMPs
(Gomis-Ruth et al. 1997). Similar studies have also demonstrated the ability of TIMP-2
to bind to MT1-MMP (Fernandez-Catalan et al. 1998). The binding of TIMP-2 with
MT1-MMP displays a unique property of TIMP-2, enabling it to cleave and activate pro-
MMP-2 (Kolkenbrock et al. 1991).
1.5.3.4. Matrix metalloproteinases in extracellular matrix degradation.
The MMPs are the predominant regulatory mechanism controlling the degradation and
turnover of the myocardial ECM following an episode of Ml and accordingly have
gained a wealth of experimental interest (Reviewed by Fedak et al. 2005; Vanhoutte et
al. 2005). In addition to degrading the ECM, MMPs also stimulate cytokine release to
promote fibroblast migration and proliferation. This stimulation is necessary for
synthesis and deposition of new ECM and scar tissue (Lindsey et al. 2001; Petrov et al.
2002). Exacerbated activation of MMPs and therefore ECM degradation post-MI may
also have detrimental consequences resulting in cardiac rupture, LV dilation and
dysfunction (Spinale 2002).
1.5.3.5. Matrix Metalloproteinases post-myocardial infarction
Myocardial MMP activity is increased within hours of Ml and is correlated to an initial
decrease in collagen content in the myocardium within 48hrs (Herzog 1998; Villarreal et
al. 2003). In this thesis I looked at the activity of MMPs at four days after MI when
myocardial remodelling is thought to be at an optimal rate. The activity of MMPs is
described as being in the acute remodelling period post-MI. Although this is not in the
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immediate period post-MI, it was the acute remodelling period in comparison to the
remodelling that is observed weeks and months after the initial infarct.
MMP-2 and MMP-9 have gained the most experimental interest post-MI. Myocardial
activity of MMP-2 and MMP-9 is increased during the first seven days post MI (Lindsey
et al. 2001; Lindsey et al. 2002; Nagaoka et al. 2000). Activated macrophages,
fibroblasts and myocytes are all likely sources of MMP-2 during the remodelling period
after MI (Table 1.2; Heymans et al. 1999; Romanic et al. 2001). Increased MMP-9
protein synthesis is associated with active neutrophils (Nagaoka et al. 2000). Lindsey et
al have demonstrated that active MMP-9 is co-localized with infiltrating neutrophils
post-MI (Lindsey et al. 2001). MMP activity is still raised during the granulation period
and chronic remodelling (Pfeffer et al. 1990) although gelatinase activity begins to
decline up until day 14 (Peterson et al. 2000). Other MMPs that have increased activity
after MI and in the failing heart include MMP-3 and MMP-1, which has increased
expression 2-7 days after MI in the rat model (Cleutjens et al. 1995b; Spinale et al.
2000; Thomas et al. 1998). The differences in MMP activation profiles after MI suggest
that they have different functions within the ECM break down and remodelling process,
including allowing inflammatory cell infiltration into the infarct region.
The difference in the cellular origin of MMPs, such as MMP-8 and MMP-9 from
neutrophils (Lindsey et al. 2001) and the MMP-2 from cells constitutively expressed in
myocardium is likely to play a significant role in the temporal expression of the
proteinases in remodelling (Tao et al. 2004). Therefore the substrates of specific MMPs
will be degraded in a time ordered manor. Disrupting the order of stimulated MMP
expression and activity is likely to have detrimental effects on remodelling.
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1.5.3.6. Oestrogen and Matrix Metalloproteinases
The activity of MMPs and TIMPs are regulated by E in the reproductive tract and uterus
(Helvering et al. 2005; Marbaix et al. 1992) as well as non-reproductive tissues
including tumour cells and the CVS (Potier et al. 2001; Wingrove et al. 1998).
Experimentally treatment with E increases MMP-2 activity and attenuates age related
LV remodelling and ECM changes that result in collagen accumulation which is more
pronounced in females (Smith et al. 2000; Xu et al. 2003). The role of E in acute
remodelling post-MI is not known, the possibility that E regulates MMP expression and
activity, either directly or in-directly post-MI and consequently results in the detrimental
remodelling that leads to cardiac rupture has not been investigated to date.
1.6. The Inflammatory response
The inflammatory response is imperative for infarct healing and scar formation (Entman
et al. 1994). The duration of coronary artery occlusion is crucial for inducing an
inflammatory response; rapid reperfusion that prevents cellular injury is not associated
with an inflammatory response. Continued occlusion of an artery induces infarction and
concomitantly instigates an acute inflammatory response, involving a humoral response
and cell infiltration. The inflammatory response differs if reperfusion occurs following
the ischaemic period. In the presence of reperfusion the inflammatory response is
accelerated and intensified (reviewed by Frangogiannis et al. 2002; Hansen 1995).
The importance of the inflammatory response in infarct healing after MI was first
demonstrated in canines (Libby et al. 1973). The discovery that reperfusion enhances the
inflammatory response and improves infarct healing (Jugdutt 1997) is supported by
studies in humans with non-steroidal anti-inflammatory drugs. These studies resulted in
attenuated wound healing and increased cardiac rupture post-MI (Stern MD, 1988;
Solodky A, 2001). Similarly, studies with corticosteroid suppressed the inflammatory




Myocardial cell necrosis results in the release of the mitochondria rich fragments which
initiates the activation of the complement cascade (Rossen et al. 1994). The influx of
inflammatory cells is stimulated through C5a within hours of MI. There have been
numerous studies on the inhibition and depletion of the complement cascade, all of
which support the notion that activation of the cascade enhances infarct healing and has
a significant role in the recruitment of monocytes and neutrophils to the ischaemic
region of the myocardium (Reviewed in Frangogiannis et al. 2002).
1.6.1. Neutrophils
The primary function of neutrophils is to destroy and remove foreign micro-organisms
and inflammatory debris. Granules within the cytoplasm are required for the storage of
bacteriocidal and cytotoxic species vital for the non-specific immune response
(Wysocka et al. 2001).
The neutrophil cell membrane contains adhesive proteins, membrane channels and
receptors for ligands, cytokines and chemotatic factors, as well as ectoenzymes and ion
pumps (Murphy 1994). These features regulate neutrophil activation and ensure
accumulation at the site of injury (Reviewed by van Es et al. 1999). Neutrophil
activation stimulates the granules within them to fuse with phagocytic vesicles and
release their contents. The granules are involved in a number of neutrophils properties
during inflammation, including complement activation, leukocyte adhesion and collagen
removal (Wright et al. 1977). Granule contents may be bacteriocidal such as
myeloperoxidase (MPO); MPO catalyses the production of hypochlorite (OCf) from
chloride and hydrogen peroxide (Paul et al. 1970). Neutrophil granules also contain
MMP-9 and MMP-8 (Knauper et al. 1993). Neutrophils infiltrate the ischaemic area up
to 4 days post-MI (Reimer et al. 1989), the proteases released in this time assist in the





Chemokines are leukocyte specific chemoattractants that allow rapid and selective
accumulation of leukocytes at areas of injury and inflammation. IL-8 is thought to play a
fundamental role in the accumulation of neutrophils and TNF-a plays a central role in
the inflammatory cascade (Stancovski et al. 1997). The complement cascade and
reactive oxygen species (ROS) induce release of cytokines and chemoattractants at the
site of injury (Shingu et al. 1984).
The process of chemotatic factors binding to their respective receptors on neutrophils
activates the neutrophil. Upon activation neutrophils undergo polarisation that assists
their directional movement to the site of inflammation and release their granule contents
(Reviewed by van Es et al. 1999). Once activated neutrophils release autocoids that act
locally such as thromboxane At and LTB4 to promote vasoconstriction and platelet
activation, they also release more cytokines such as IL-8 that acts as a positive feedback
attracting more neutrophils (Ivey et al. 1995; Kukielka et al. 1995a; Sekidoeta/. 1993).
1.6.1.2. Neutrophil adhesion
Adhesion molecules, including selectins, integrins and the immunoglobulin super family
mediate neutrophil adhesion to and passage through endothelial cells to ultimately
achieve neutrophil accumulation at the inflamed site, as illustrated in Figure 1.7
(Frangogiannis et al. 2002).
The initial step of the adhesion cascade involves rapid interactions and weak bonds
between selectins and their ligands to bring neutrophils into close proximity with
endothelial cells (Figure 1.7; Alon et al. 1995; Springer 1994). The weak bonds increase
neutrophil rolling at the site of inflammation, which stimulates further chemoattractant
interactions (Figure 1.7). The resulting interactions between p2 integrins and
intercellular adhesion molecule (ICAM)-I are stronger than the selectins, and
consequently neutrophil adherence to the epithelium is also stronger (Lawrence et al.
1991). ICAM-1 expressed at the cell junction also plays an important role in the
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migration of neutrophils through the cell junction (Furie et al. 1991; Furie et al. 1992;
Smith et al. 1992). A third adhesion molecule, PECAM-1 forms interactions with
integrins on neutrophils and influences neutrophil movement through the endothelial
membrane and perivascular basement membrane. Neutrophils then pass into the
subendothelial matrix and finally to the site of inflammation (Dangerfield et al. 2002;












Figure 1.8. The highly co-ordinated step process for neutrophil adhesion and
transmigration through the endothelial cells to the site of injury.
Neutrophils are activated due to the release of chemotatic mediators released by the
endothelial cells. (A) The initial interaction between neutrophils and endothelial cells is
a weak interaction mediated by the selectins. (B) This interaction enhances neutrophil
rolling and the 'detection' of activating factors, such as IL-8 and C5a. (C) Stronger
bonds are formed through integrins and ICAM-1. Once the neutrophil is firmly adhered
to the endothelium it can transmigrate through the endothelium into the tissue and to the
injured and inflamed site. It is here that the neutrophil will phagocytose debris from
necrotic cells. (Taken from Frangogiannis et al. 2002).
Neutrophil infiltration is a prerequisite for defence against bacterial disease yet
inappropriate and excessive activation plays a major contributory factor in the pathology
of inflammatory diseases, such as ischaemia-reperfusion injury (Reviewed by van Eeden
et al. 1999). The high concentration of inflammatory mediators that attract neutrophils to
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the endothelium can result in endothelial cell damage, microvascular permeability and
haemorrhage if left unabated. If neutrophil recruitment and cell injury is so great, the
aggregating neutrophils can block small vessels and cause local ischaemia (Engler et al.
1983). Finally, the migration of neutrophils out of the vasculature can result in tissue
damage and organ dysfunction, known as no-reflow reperfusion injury (Reimer et al.
1989). Despite these detrimental effects of the inflammatory response following MI, the
wound healing that results from an inflammatory response is essential (reviewed in
Frangogiannis et al. 2002).
1.6.2. Macrophages in ischaemia
Macrophages are large monocyte derived immune cells. C5a of the complement cascade
is predominately responsible for the initial monocyte infiltration within hours of
reperfusion, after which TGF-(31 and monocyte chemoattractant protein (MCP-1) feature
(Birdsall et al. 1997). Differentiation into macrophages occurs after monocyte
recruitment to the infarct. Differentiation is likely to be through the stimulation of
Macrophage Colony-Stimulating Factor (M-CSF; Reviewed in Frangogiannis et al.
2002).
Macrophages play a key role in all aspects of wound healing, their prevailing function is
to remove necrotic and foreign matter through phagocytosis. Macrophages release
fibrogenic and angiogenic growth factors that regulate the formation of granulation
tissue and angiogenesis. These factors are essential for developing a stable scar and
maintaining myocardial integrity, these are discussed further in Section 1.6.4. Cytokines,
such as TNF-a and fibroblast growth factor (FGF-1) released upon macrophage
stimulation prevent apoptosis and thus provide myocyte protection (Trial et al. 2004).
Monocyte secretion of MMPs and TIMPs are likely to regulate ECM degradation and
scar formation, although this is only known out with the heart (Arras et al. 1998).
Experimental models using anti-macrophage serum to diminish macrophages result in
impaired healing, decreased matrix production and fibrosis (Cohen et al. 1987;
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Leibovich et al. 1975). The infiltration of macrophages, just like the neutrophils also has
detrimental effects, activated macrophages release TNF-a, ROS and NO which all
decrease the contractility of the heart (Simms et al. 1999). The role of macrophages may
be beneficial in the early phases of remodelling and detrimental in the later stages of scar
formation and LV remodelling.
1.6.3. Oestrogen and the inflammatory response
Experimentally E is able to inhibit inflammatory cell infiltration and activation at sites of
injury, such as in atherosclerosis and after in vivo ischaemia-reperfusion (Booth et al.
2003; Delyani et al. 1996; Squadrito et al. 1997). This E mediated decrease in neutrophil
infiltration and adhesion is through direct inhibition of chemotaxis and L-selectin
expression. Isolated neutrophils express both ERa and ERp (Stygar et al. 2006) and E
directly regulates neutrophil function (Ito et al. 1995; Klebanoff et al. 1997). In cultured
endothelial cells expression of neuronal NOS (nNOS) in neutrophils is up regulated by E
through direct modification of the L-arginine pathway and NO synthesis (Hishikawa et
al. 1995; Ruehlmann et al. 1997). The NO produced by neutrophils prevents adhesion to
the endothelium, the resulting transmigration and phagocytosis leading to attenuated cell
necrosis and apoptosis in the myocardium.
1.6.4. Angiogenesis
Ml is associated with an early and pronounced increase in angiogenic factors including
VEGF, IL-8 and bFGF, this results in an imbalance of angiogenic and angiostatic factors
which favour angiogenesis (Carmeliet 2000; Kukielka et al. 1995b; Lee et al. 2000; Li et
al. 1996). Angiogenesis is crucial for supplying the infarcted myocardium with oxygen
and nutrients, experimentally this reaches a maximum at day 7 post-MI in the rat (Sherry
2000) and mouse (Small et al. 2005). Angiogenesis depends on interactions between the
ECM and endothelial cells. Degradation of the ECM is essential for angiogenesis, it
allows new vascular endothelial cells to pass through the basement membrane and
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migrate through the ECM prior to dividing and organizing into new vessels (Moscatelli
etal. 1988).
1.6.5. Fibroblasts and collagen formation
Physiologically fibroblasts regulate the ECM through the synthesis of it's components;
including pro-collagens and the cross linking enzyme lysyl oxidase (Reynaud et al.
1999). Fibroblasts also synthesis and release MMPs (Heymans et al. 1999; Romanic et
al. 2001), capable of degrading the ECM, therefore they maintain the integrity of the
ECM. Fibroblasts reside in the myocardium, upon stimulation, such as MI they
differentiate into myofibroblasts (Brown et al. 2005). Myofibroblasts are a unique cell
type that express contractile proteins but are yet more motile than smooth muscle
(Baudino et al. 2006). Fibroblasts express membrane CD 19 and discondin domain
receptor 2, it is possible to utilise this expression to measure fibroblast infiltration and
accumulation at the site of injury, such as the infarct (Squires et al. 2005). ERa also is
known be expressed in fibroblasts and E increases their proliferation (Lee et al. 1998).
Fibroblasts infiltrate the infarcted region from three days after MI and are abundant by
day seven, which coincides with the peak remodelling phase (Sun et al. 2000a). At this
time the proliferation and differentiation of fibroblasts is greatly increased at the infarct
border (Squires et al. 2005). Post-Mi, fibroblasts synthesize ECM components, namely
collagen, fibronectin and laminin to replace the necrotic myocytes (Weber 1989). The
fibroblasts regulate the synthesis of matrix components and co-ordinate the response to
MI and pressure changes within the heart (Kanekar et al. 1998). Some of the infiltrating
fibroblasts differentiate into myofibroblasts which allows the cells to function as a
contractile unit in the myocardium (Frangogiannis et al. 2000). A collagen rich scar is
the ultimate outcome of remodelling post-MI. The ultimate wound healing post-MI is a
collagen rich scar to replace the necrotic myocytes and maintain the integrity of the LV.




The cumulative amount of collagen within the scar post-MI is not an accurate measure
of the scar stability. The collagens synthesised within the infarct area vary in their
functional properties, collagen type I is the predominant collagen, this had high tensile
strength compared to type III, which is synthesised by 'young' fibroblasts (Weber 1989).
Along with the type of collagen synthesised the cross linking is just as vital. Cross-
linking of collagens is fundamental to their tensile strength and support (Balestrini et al.
2006; Brasselet et al. 2005). Analysing the collagen cross-links is therefore as
informative as the amount of collagen.
1.7. Fibrolytics and Reperfusion injury
Reperfusion of the myocardium results in an extensive remodelling period which leads
to a number of complications including cardiac rupture most commonly within days of
MI and heart failure within years of the initial infarct (O'Rourke 1973; Solomon et al.
2002). The recent introduction of thrombolytic drugs such as streptokinase,
administrated as soon as possible after MI have enhanced survival post-MI when
prophylactic measures such as coronary artery bypass grafts, and angioplasty have failed
(Blankesteijn et al. 2001).
Animal studies and patient profiles demonstrate advantageous results of early
reperfusion, including decreased infarct size and mortality (Reviewed in Bolli 1991).
Conversely, the restoration of blood flow and therefore oxygen to infarcted tissue causes
detrimental functional and morphological changes in coronary arteries and myocardial
tissue that result in cellular injury not previously caused from ischaemia (McCord 1985).
The reperfusion injury paradox limits the extent of functional recovery after a period of
ischaemia (Jeroudi et al. 1994). Reperfusion injury depends on the duration of
ischaemia, the collateral flow during reperfusion, neutrophil influx and free radical
generation in the effected region. The generation of oxygen derived free radicals,
neutrophil initiated damage, loss of antioxidant enzymes, calcium overload, loss of
physiological ATP concentrations, vascular endothelial and myocyte oedema and
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haemorrhage are all thought to contribute to reperfusion injury. Of all these mechanisms,
neutrophils and oxidative damage have generated the most interest (Jeroudi et al. 1994).
Experimentally 45 minutes of myocardial ischaemia is sufficient to cause irreversible
damage and stimulate an inflammatory response within minutes of reperfusion which
results in reperfusion injury (McCord 1985; Park et al. 1999). Injury in this model is
most likely due to increased neutrophils in the sub-endothelial space, that can directly
interact with endothelial cells (Jordan et al. 1999). Upon reperfusion, neutrophils invade
the myocardium, release superoxide anions, hydrogen peroxide and hydroxyl free
radicals in an oxidative burst (Bolli 1991; Jeroudi et al. 1994; Jordan et al. 1999). The
predominant free radicals released from neutrophils during oxidative stress are
superoxide anions (Tauber et al. 1977). These free radicals cause endothelial damage
and dysfunction in the coronary arteries and cell injury within the tissue (Reimer et al.
1989), they disrupt the cell membrane proteins including receptors and ion channels
(Kaminski et al. 2002). In comparison to the rat, humans treatment with fibrolytics
within 2 hrs of ischaemia improves LV function and reduces the infarct (Mathey et al.
1985), occlusion for longer than 4-6 hours leads to irreversible cell necrosis.
Consequently, the sooner thrombolytics are administered after the ischaemic episode the
less better (Fenton 2006).
One form of cell injury that occurs within the myocardium post-MI is termed 'lethal
injury' this occurs immediately after the on-set of ischeamia. Lethal injury is due to the
decrease in cell ATP levels, due to attenuated oxygen and supply for ATP synthesis
(Lazdunski et al. 1985). The depletion of ATP leads to the cessation of the Na+/H+
transporter pump and the Na+-K+ ATPase (Kusuoka et al. 1987). The consequence of
this is a rise in intracellular Na+, Ca2+ and a shift in cellular pH to a more acidic level.
Sudden reperfusion after this has occurred in the ischaemic area results in the Na+-K+
ATPase and Na+/H+ transporter pump starting again but with the cellular concentration
gradients disrupted and the osmolarity of the cell greatly increased the cell swells with
fluid and bursts. The cells in the neighbouring non-infarcted myocardium are
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subsequently damaged and die, through the cell-cell communication via gap junctions
(Jennings et al. 1991). This immediate death is in comparison to cell death that occurs
within hours and days of infarction. Cell death that occurs in the early remodelling
period is likely to occur in the presence of an inflammatory response and occur through
apoptosis and necrosis (Fliss et al. 1996).
Reperfusion prior to the critical period results in cellular damage extending from an
energy demand that is not met by supply. Reversible cell damage, also referred to as
'myocardial stunning', causes a rapid decline in ventricular performance. Upon
reperfusion ventricular performance slowly returns to normal and there is no permanent
damage (Hcyndrickx 2006). The period of stunning depends on the period of ischaemia,
experimental models use 10-20 minutes in the rat myocardium to assess this
phenomenon (Califf 1998; Heyndrickx 2006). During the period of stunning the
myocardium is less responsive to ionotropic drugs.
Gender based differences in ischaemia reperfusion injury, support a protective role for
17pE2 (Guerra et al. 1999). Females exhibit a decreased inflammatory response and
tissue injury as well as improved survival. In isolated buffer perfused rat hearts 17PE2
increases functional recovery through anti-oxidant effects and altered glucose
metabolism (Beer et al. 2002). In canine models of ischaemia-reperfusion 17pE2
attenuates hydroxyl radical production, reperfusion arrhythmias, myocardial systolic
dysfunction and temporary impairment of endothelial function (Kim et al. 1996;
McHugh et al. 1998). Of the two ER expressed within cardiomyocytes, myofibroblasts
and neutrophils, experimental models of ischaemia have not distinguished which
receptor is responsible for mediating the protective effects of 17pE2. The recent
development of selective agonists has increased our ability to determine the role of each




Factors that delay and jeopardise the healing process after MI result in disrupted
remodelling and even cardiac rupture. Other complications that may occur in the initial
days after MI include re-infarction, pulmonary oedema and cardiogenic shock. Of these
complication cardiac rupture has the greatest mortality rate. Cardiac rupture causes
bleeding from the heart into the pericardium and ultimately cardiac tamponade (Dellborg
et al. 1985; Reddy et al. 1989). The incidence of cardiac rupture is unpredictable and
tends to affect middle-aged patients (> 65yearrs) who have no prior history of MI or
angina. Additional risk factors include female gender and hypertension (Chandra et al.
1998; Lewis et al. 1969). The reasons for a higher mortality rate in females during the
initial days post-infarction are not clear, but maybe due to differences in honnone levels
and the response of vascular tissue to the initial insult. Figure 1.9 highlights the in-
hospital mortality after Ml in males and females, it's clear that mortality increases with
age. The mortality rate is higher in females than in males until >80 years. The cause of
mortality in this figure is not only cardiac rupture.
Cardiac rupture following Ml occurs at an incidence rate of 2-7% yet it accounts for
around 15% of all in-hospital mortalities post-MI and has a mortality rate over 90%
(Becker et al. 1996; Reddy et al. 1989). The lack of treatment means that rupture is
normally fatal. Surgery is the only possible intervention for cardiac rupture, it has a 27%
mortality rate and the long-term survival rate after surgery is only 31%. Due to such a
poor survival rate, a current lack of pharmacological treatment and the growing
incidence of rupture following MI, it is paramount that a successful intervention is
found. Clinically the most frequent form of rupture is LV free wall rupture (Dalrymple-
Hay et al. 1998).
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Figure 1.9. In hospital mortality after myocardial infarction.
The mortality rate of humans according to sex and age during hospitalisation for
myocardial infarction. Copyright permission granted from Vaccarino et al. (Vaccarino
et al. 1999).
Rupture may occur within hours of the initial Ml, approximately 50% of all cases occur
almost instantaneously without the manifestation of an inflammatory response. In these
cases cardiomyocyte apoptosis is likely to play a role in the defects that result in rupture
(Reviewed by Wehrens et al. 2004). Rupture can also occur up to three weeks after the
initial MI, although most cases of cardiac rupture in humans occur 3-5 days post MI.
These later incidences of rupture occur in the presence of tissue necrosis and an
inflammatory response (Solomon et al. 2002).
Following MI the myocardium undergoes a period of extensive remodelling. Inadequate
cardiac remodelling and scar formation following MI is a frequent cause of cardiac
rupture. Extensive myocardial expansion is correlated with an increased risk of
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detrimental events such as rupture, aneurysms and long term heart failure (Pfeffer et al.
1990). After MI the acute increase in MMP collagenase activity, developing necrosis,
oedema and inflammation degrades the matrix proteins and collagen. These processes
result in a temporary decrease in structural support, deformed tissue architecture and
wall thinning that may result in cardiac rupture. This period is sustained for 2-3 days,
after which time new matrix proteins and collagens are synthesised and deposited.
Consequently, the tensile strength is increased and the risk of rupture reduced (Reviewed
by Creemers et al. 2001).
Only a small decrease in the collagen content of the ECM is necessary for rupture to
occur, this is in contrast to an excess of collagen in the cardiac ECM, where a 2-3 fold
increase can be buffered after which it may result in stiffness and mild dysfunction. In a
canine model rapid-pacing is accompanied by diminished collagen content, which is
then reversed during normal pacing, thus suggesting that the integrity of the myocardium
is weakened by the abnormal pacing (Spinale et al. 1991). An increase in collagen
content is associated with MI ensuring a stable scar to prevent cardiac rupture. Due to
the narrow physiological range of collagen content in the ECM the components of the
ECM must be tightly regulated, as described in Section 1.5.3.2, to prevent adverse
pathological events (Ichihara et al. 2002; Jugdutt 2003). Experimental models of Ml and
cardiac rupture in the mouse have demonstrated the importance of MMPs in the
remodelling process proceeding cardiac rupture (Heymans et al. 1999; Rohde et al.
1999). Rohde et al used a non-selective MMP inhibitor to demonstrate an attenuation of
LV expansion after MI in mice (Rohde et al. 1999). More specifically Heymans et al
have verified that an MMP-9 KO mouse has decreased incidence of cardiac rupture
(Heymans et al. 1999)
Interestingly, younger women are more likely to die during the acute period after MI
than their male counterparts (Vaccarino et al. 1999), some studies have attributed this to
cardiac rupture (Hutchins et al. 2002; Nakano et al. 1985). The observation that this
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difference is lost in older women suggests that sex hormones have an influential role in
the mortality rates post-MI.
Experimentally in mice there is an increased mortality rate (Sharif 2002; van Eickels et
al. 2003) and detrimental remodelling (Cavasin et al. 2004; Smith et al. 2000) in ovx
females supplemented with 17(3E2 compared to control treated animals. This finding
suggests that E has a dual function within the CVS. The two fold properties of E seem to
be a beneficial protective mechanism serving to inhibit the onset of CVD, but after the
process of CVD has commenced in women E may have a detrimental role (Vaccarino et
al. 1999). Despite studies in the mouse model of MI to investigate the mechanisms of
detrimental remodelling the influence of 17(3E2 has not been investigated.
1.9 Oestrogen and Hormone replacement studies
Since the I940's E replacement therapy (ERT), comprised of conjugated equine E, has
been prescribed to post-menopausal women for suppression of menopausal symptoms.
The main reason for ERT use in this sub-section of the population is a reduction of
menopausal symptoms such as an increased incidence of osteoporosis and hot flushes
that result from decreased circulating E. In accordance with the known cardiovascular
properties of E, unopposed ERT decreases the rate of atherosclerosis in women who
have not had a previous coronary event (Hodis et al. 2001). Proudler et al have also
noted that there is as much as a 20% decrease in angiotensin converting enzyme (ACE)
activity in women taking ERT compared to post-menopausal women who are not
(Proudler et al. 1995).
Unopposed E in ERT increases the risk of endometrial cancer and is therefore not
appropriate for women who have an intact uterus. To circumvent the increased risk of
endometrial cancer a progesterone analogue, such as medroxyprogesterone acetate
(MPA) is incorporated into the ERT. Progesterone analogues have their own biological
properties, among which are modifications of Es effects. The modifications to Es
properties vary from acting synergistically, to having no influence at all or antagonizing
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the properties of E (Simoncini et al. 2004a). Combined hormone replacement therapy
(HRT) is now offered to women who have not previously undergone an ovariectomy,
whilst ERT is offered to those who have.
MPA has mild androgenic and progesterone actions (Muddana et al. 2003). Progesterone
receptors are expressed within VSMC and also within the heart (Ingegno et al. 1988;
Knauthe et al. 1996). Stimulation of the vascular progesterone receptor by MPA is likely
to have additional consequences on the E response, including adverse effects on
circulating HDL and thrombolytic protein levels (lruela-Arispe et al. 1996; The writing
group for the PEPI trial 1995). Stimulation of the progesterone receptor inhibits
vasorelaxation (Mercuro et al. 1999b) and in a mouse model progesterone increases
vascular injury (Karas et al. 2001b).
In 1976 121,700 female nurses aged 30-55 years completed questionnaires on their
hormonal status and medical history, including CVD for the 'Nurses' Health study'
(Stampfer et al. 1985). The outcome of this study confirmed findings of the Framingham
study (Feinleib 1976), demonstrating a positive correlation between ERT or HRT and a
decreased risk and incidence of CVD. These and other observational studies (Reviewed
by Herrington et al. 2003a) led to the concept that post-menopausal HRT could retain
the apparent pre-menopausal cardioprotection. Results from clinically controlled
primary and secondary prevention trials of hormone replacement, over 20 years later led
to a dramatic rethinking of guidelines for the use of HRT in relation to cardiovascular
risk.
The largest and most documented of these studies are the 'Women's Health Initiative'
(WHI) primary prevention trial, which started in 1992, designed to study ERT and HRT
for 8 years; and the 'Heart and Estrogen/progestin Replacement Study' (HERS),
secondary prevention trial that started in 1993, designed to investigate the use of HRT
for an average of 4.1 years.
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The HERS study was the first study to publish controversial and unexpected results
(Hulley et al. 1998). This study was designed to investigate HRT (0.626mg CEE and
2.5mg MPA) in post-menopausal women with pre-existing CVD. HERS looked at 2763
women with a mean age of 66.7 years and a subsequent HERS II study looked at the
same women after 6.8 years. The surprising conclusion of HERS was a null effect of
HRT on CVD, with an apparent detrimental effect of E in the first year and then an
apparent reduction in the risk of CVD in years 3 to 5 (Hulley et al. 1998). The follow up
study, HERS II concluded that the apparent beneficial effect of E seen in the 3rd to 5th
years of the trial did not continue in subsequent years and consequently it was stopped
with a conclusion that HRT should not be taken for prevention of secondary CHD
(Grady et al. 2002).
The WHI was designed in 1991 to investigate ERT and HRT on health outcomes when
used for primary prevention of CVD. The WHI enrolled 27,347 post-menopausal
women aged 50-74 years (average age 63; 20% 70-79 and 12 years post-menopause) and
randomised them to receive ERT (0.625mg CEE), HRT (0.625mg CEE and 2.5mg
MPA) or placebo treatment. The WHI hit the headlines and gained media attention in
2002 when the combined HRT arm of the study was stopped prematurely after an
average follow up of 5.2 years. The study was stopped due to an increased incidence of
breast cancer (Rossouw et al. 2002; Steinberg et al. 1991). At this time point there was
also a significant (P<0.05) increase in non-fatal MI and stroke in those taking HRT
compared to placebo (Rossouw et al. 2002). Since then, in 2004, after almost 7 years the
ERT arm of the WHI was also terminated due to an increased incidence of stroke and a
null effect on CVD (Anderson et al. 2004).
The present advice from the 'American Heart Association', based principally on the
outcomes of the WHI and HERS, is that ERT and HRT should not be used for primary
or secondary prevention of CHD (Mosca et al. 2004). In addition, it has been
recommended that women who choose to take ERT or HRT for other menopausal
symptoms should have their CV risk assessed before commencing the treatment.
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We do not know the effect that MPA has on the cardioprotective properties of E when
given in HRT regimes. These clinical trials suggest that the progesterone analogue may
inhibit E's beneficial properties and therefore attenuate any protection provided by E.
The mechanisms behind this apparent attenuation within the myocardium are not known.
A more accomplished and complete understanding of the pre-menopausal mechanisms
of E both physiologically and pathophysiological^ will enable post-menopausal E
supplementation to be prescribed and managed correctly.
1.10. Study aims
The first aim of this thesis was to determine the ER responsible for the observed
cardioprotection displayed by 17(3E2 including neutrophil infiltration, oxidative stress
and cell necrosis displayed by 17pE2. This was investigated using an experimental rat
model of ischaemia-reperfusion with the use of a novel selective ER agonist and
antagonist.
In light of the results from clinical trials on HRT the second aim of the thesis was to
investigate the effect of MPA on the cardioprotective properties of 17PE2. To study the
effect of MPA on the protective properties of l7pE2 we used an experimental rat model
of ischaemia-reperfusion. After ischaemia-reperfusion cell necrosis and neutrophil
infiltration were measured, and the impact of MPA on these measured.
The final aim of the thesis was to investigate the finding that despite the initial
cardioprotective effects of 17pE2 there is a higher mortality rate during the acute
remodelling phase of chronic MI. We aimed to explore the influence of 17PE2 on MMP
and TIMP expression and activity post-MI in a mouse model. We also aimed to examine








All animal procedures were conducted and conform with the Guide for the Care of
Laboratory Animals published by the US National Institutes of Health (NIH publication
No 85-23, revised 1996) and in accordance with Home Office guidelines as outlined in
the Animals (Scientific Procedures) Act 1988 under the project license 60/2813 and
personal license 60/9013.The studies were approved by both the UK Home Office and
the University of Edinburgh ethical review committee.
All animals were housed in a controlled environment of a 12 hour light/dark cycle
(lights on 0700-1900 hrs) and a constant temperature of 21 + 2°C and humidity. All
animals were fed a standard laboratory diet composed of 75.09% carbohydrate, 14.38%
protein, 2.71% oil and 0.25% salt (Special Diet Services (SDS), Witham, Essex, UK)
and had free access to water.
Rats used were female Wistar (170-21 Og; Charles River, Margate, UK). Rats were
allowed an acclimatisation period of one week in their new environment prior to
commencing any surgical or experimental procedures. Mice used were C57bl6/129/SvJ
(25-30g; Dr G.A.Gray's colony at the University of Edinburgh).
2.2. Surgical procedures and tissue collection
Animals were weighed prior to all surgical procedures. All surgery was carried out
under aseptic conditions, skin clippers (Series 8900, WAHL, USA) were used to remove
hair prior to surgery after which the area was swabbed with antiseptic wipes (Spontex,
Professional discovery 1500). Animals were kept on a heating mat (37°C) to maintain
body temperature throughout surgery. Buprenorphine hydroxychloride analgesic was
administered subcutaneously prior to all recovery surgery (0.05mg.kg_1 and 0.5mg.kg"'




2.2.1.1. Regulation of the oestrous cycle by bilateral ovariectomy
Circulating E levels vary throughout the oestrous cycle in female animals and this
variation can cause problems with inconsistency within experiments. Controlling the
circulating E levels overcomes this problem and inter-experiment variation. Control of
the circulating E level is achieved through ovx to remove the ovaries, which are the
primary organ responsible for E synthesis, and implantation of 17pE2 releasing pellets
(0.05mg.pellef', 21 day release, 50-lOOpg.mr1, Innovative Science, Sarasota, USA).
Surgical techniques: Anaesthesia was induced either by inhalation of halothane
(Halothane-vet, Merial Animal Health Ltd. UK) or isoflourane. Inhalation anaesthetic
was administrated with a mixture of O2 (1.51 min"1) and N2O (0.51 min"1) for halothane
or O2 alone for isoflurane through a nasal cone after initially being induced in a chamber
(4% induction and 1.7-2.5% maintenance for rats; 3% induction and 1.7-2% for mice).
The ovaries were exposed via an incision (5mm long in the mouse and 10mm long in the
rat) in the dorsal flank and penetration of the abdominal cavity. The parovarian fat pad
was identified and moved aside allowing the ovary and the associated oviduct and
uterine horn to be exposed. A ligature (5/0 W581 Mersilk, Ethicon, UK) was secured
tightly around the oviduct and ovarian vasculature prior to the ovary being severed. This
procedure maintained haemostasis. The uterine horn was returned to the abdominal
cavity and the incision closed. The abdominal wall was closed first with discontinuous
sutures (5/0 W581 Mersilk, round bodied, Ethicon, UK), the skin was closed with 9mm
metal wound clips (Reflex wound clips, Interfocus, Cambridgeshire, UK) in rats, and
sutured in mice (5/0 W529 Mersilk, cutting, slim blade, Ethicon, UK). The animals were
then randomly assigned to a treatment group and the appropriate pellet implanted
subcutaneously at the nape of the neck between the scapula, this small incision was
closed with sutures (5/0 W581 Mersilk, Ethicon, UK). The animals were then allowed to
recover from anaesthesia. The animals were returned to cages once they were ambulant,
they were caged with a maximum of three other animals, all having undergone the same
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surgery. All animals were caged with animals receiving the same E treatment to prevent
exposure to E through grooming of each other. Mice were then left for a minimum
period of 7 days, and the rats were left for at least 14 days. During this period the
animals were weighed regularly to ensure they maintained and gained weight.
Confirmation of E levels and activities: Body and uterine weights were recorded at the
experimental endpoint to determine the influence of hormone supplementation. The
implanted pellets achieve and maintain physiological E concentrations. Female mice and
rats were randomised to receive either E or placebo pellets. E levels increase pre- and
post- ovulation. E stimulates vascularisation and thickening of the endometrium through
promotion of cells in the basal stroma of the uterus to enter mitosis (Frasor et al. 2003).
In contrast at low E levels the endometrium is thin and atrophied, due to only the stratum
basalis of the endometrium remaining. Consequently, the uterus weight can be used to
confirm E status after ovx and as an indication of the circulating levels of E. At the
experimental endpoint the uterus was removed and weighed (Figure 2.1 and Figure 2.2).
2.2.1.1.1. Detection of plasma oestrogen levels
Radioimmunoassay for 17pE2 was carried out to determine the plasma concentration of
l7pE2 in ovariectomised mice and rats receiving placebo or 17PE2 pellets. Blood
samples were collected by cardiac puncture, from placebo and 17(3E2 treated group. The
blood was mixed with 50pl (5000 I.U.ml"1) of heparin the plasma was then separated by
centrifugation at 4°C, 20,000g for 20 mins and stored at -20°C prior to assay. Plasma
17PE2 levels were measured using radioimmunoassay (MAIA RIA kit, Bio-Stat
Diagnostic systems, Stockport, Cheshire, UK), as previously described (Glasier et al.
1989). 17PE2 extraction efficiency was greater than 90% and the detection limit of the




17|3E2 levels were typically within the levels found in the proestrous phase of the mouse
oestrous cycle in those mice receiving 17f3E2, whilst those receiving placebo had
significantly lower plasma levels of 17(3E2 (Table 2.1). In rats treated with 17pE2 plasma
levels were in the middle of the physiological range (Table 2.1). The presence of low
levels of 17(3E2 in placebo treated mice and rats is most likely to be due to the other sites
of production in the body after the ovaries have been removed.
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Figure 2.1. Effect of oestrogen status on uterine weight
Uterine weight of (A.) mice having undergone sham ovariectomy (n-10), ovariectomy
and implantation ofa placebo (n-16) or 17/3-estradiol pellet (0.05mg/pellet; n=20) and
(B.) of rats having undergone ovariectomy and implantation of either a placebo pellet
(n=8) or 17fi-estradiol pellet (0.05mg/pellet; n-9). Data is expressed as mean + SEM
and analysed using a One-way ANOVA followed by a Bonferroni's post-hoc test for the
mouse data and a Student's unpaired two-tailed t-test for the rat data, ***P<0.001







Mouse -17pE2 42.56 + 4.46
Mouse +17pE2 106.2 +.3.19***
Rat -17PE2 20.68 +.3.92
Rat +17pE2 61.42 +.7.7*
Table 2.1. The effect of oestrogen status on the plasma estradiol levels in mice and
rats.
Data is expressed as mean + SEM and analysed using a Student's unpaired two-tailed t-







Figure 2.2. Oestrogen on uterine proliferation
Mouse uteri after (A.) sham ovariectomy or ovariectomy with (B.) placebo pellet or (C.)




2.2.1.2. Mouse chronic coronary artery ligation
Ovx mice were anaesthetised by intraperitonial (i.p). injection of ketamine, xylazine,
atropine (doses per 100g were lOmg, 2mg and 0.06mg) and prepared for surgery as
described in Section 2.2. Once prepared for surgery the mice underwent endotracheal
intubation with a blunted 12 G needle and were ventilated (HSE-Harvard MiniVent,
Harvard Apparatus Ltd, Kent UK) with a mixture of room air and oxygen at 120
breaths-a-minute with a stroke volume of 200pl.
The eyes were coated with Lacri-lube® gel (Genusxpress, Aberdeen, UK) to prevent
desiccation. Using a surgical microscope (Leica MZ7s, Milton Keynes, UK) at lOOx
magnification a left thoracotomy 1cm long was performed via the fourth intercostal
space. The exposed muscles were separated and tied back using a suture (5/0 W581
Mersilk, Ethicon, UK). This revealed the ribs and intercostal space, allowing the
respiratory movement of the left lung and heart to be observed. The fourth intercostal
space was confirmed by the curvature of the left lung, the rib spacing and the extra-
thoracic emerging branch of the internal thoracic artery, which is visible at the fifth
intercostal space. An incision was made in the fourth intercostal muscle, by lifting the
fifth rib and making an initial puncture with blunt curved forceps. The forceps were then
rotated and inserted into the chest cavity so that the long axis of their curve was laid
inline with the ribs away from the heart. Spring scissors were used to cut through the
intercostal muscle between the out-stretched forceps.
At this point the magnification of the dissection microscope was increased to 160x. A
1cm tissue clamp was inserted in the fourth intercostal space at the site of the incision.
With the heart and medial border of the left lung visible the pericardium was gently
disrupted enabling access to the heart. The pericardium was disrupted in a manner such
that a sheet was laid over the lower left edge of the incision. The sheet was pulled more
laterally to rotate the heart on its long axis as required to visualise the origin of the left
coronary artery (LCA). Controlling the illumination through the microscope and
elevating the left atrium using fine smooth tipped forceps, assisted identification of the
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LCA. The LCA was typically found appearing beneath the left atrium at the atrial notch
coursing towards the anterior aspect of the LV, with rapid pulsation of bright red blood
visible in its walls.
A proline suture (6/0 W8271 Ethicon, UK) was inserted into the myocardium 2-3mm
inferior to the intersection of LCA with the left atrial notch. The suture was passed
beneath the artery but not into the ventricular cavity and brought out approximately
1mm medial to the insertion site. The suture was tied, the heart rhythm was immediately
noted to alter and the ventricular myocardium seen to pale. The pericardium was
replaced, the clamp removed and the intercostal space sutured (5/0 W581 Mersilk,
Ethicon, UK) with discontinuous sutures. The Mersilk ties in the borders of the chest
muscles were removed; the muscle borders were teased into their former positions.
Negative pressure was created within the chest cavity with gentle pressure and this held
the muscles in place over the 4th intercostal space.
The skin was closed with continuous sutures (5/0 W581 Mersilk, Ethicon, UK). On
completion of surgery animals received i.p atipamazole (AntiSedan, an a-adreno-
receptor antagonist; 5mg.kg"!). Recovery sufficient for extubation was characterised by
self-breathing movements and whisker twitching. At this time mice were transferred to a
recovery cage with a heating pad, oxygen (delivered by funnel into which the mouse
head was placed) and ad lib saline. The oxygen was removed once the animals were
moving freely within the cage. The cage remained on a heat pad for the next 24-48 hrs.
Control operated mice underwent the same surgical procedure, but the suture was passed
underneath the LCA and removed rather than being tied to occlude the artery.
Tissue collection for necrosis, apoptosis and neutrophil infiltration analysis: Post-
Mi surgery the mice were re-anaesthetised as described above. The chest was opened
and the heart removed from the chest cavity. The left atrium was removed and the
remaining portion of heart was cut in half transversely from the apex to the base through
the middle of the infarcted LV. Control hearts were cut in half transversely through the
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LV in the same manner as the infarcted hearts (Figure 2.3). The heart was weighed and
processed as described in Sections 2.3 and 2.4.2 for necrosis, apoptosis and neutrophil
infiltration analysis respectively.
Tissue Collection for MMP and TIMP analysis: Post-Mi surgery, the mice were
anaesthetised as previously described in Section 2.2. Hearts from these mice were
dissected into distinct areas, right ventricle (RV), non-infarcted LV, infarcted LV (I),
infarct border (B) and the septum (S). Hearts from control, operated mice were dissected
into areas representing those in the infarcted hearts.
Normal heart Infarcted heart
Left ventricle
Figure 2.3. Non-infarcted and infarcted heart post-MI.
Mouse hearts cut transversely through the left ventricle infarct or the equivalent area.
Thinning of the left ventricularfree wall in the infarcted heart is clearly visible.
Tissue Explant Culture: The dissected areas were washed in Dulbecco's phosphate
buffered saline without calcium and magnesium (DPBS; Gibco, Paisley, UK)
supplemented with SOmg.L1 gentamicin and 5mg.f' amphotericin B, then blotted dry
and weighed. After a second wash the tissue was placed on a square of capillary matting
in 1ml of tissue culture medium (RPMI 1640) containing antibiotics (50 1U penicillin,
SOpg-mf1 streptomycin), supplemented with insulin, transferrin (both 5pg.mf') and
sodium selenite (5ng.mf'). A comparable size of tissue from each section of the heart
was maintained in culture at 37°C for 24 hrs in humidified air/5% CO2. After the 24 hrs
900pl of culture medium was collected and stored at -20°C in 2ml Sarstedt tubes.
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Freeze drying of culture medium: The Sarstedt tubes of culture medium were covered
with Parafilm, the Parafilm had small holes punctured in it prior to being frozen at
-70°C. Once the samples were thoroughly frozen they were placed on a freeze drier (EC
Apparatus Thermo Life Sciences, Savant VLP 120 vacuum pump) and vacuum pump at
6-8 mbar pressure until dry (approximately 6hrs for 1ml), when the samples were dry the
pressure was decreased. The samples were removed, the tubes capped and stored at
-20°C. At the time of use this lyophilised culture medium was reconstituted in lOOpl of
dH20.
2.2.2. Non-Recovery Surgery
2.2.2.1. In vivo coronary artery ligation
Rats underwent ovx as previously described (Section 2.2.l.l) and anaesthetised.
Anaesthesia was induced by i.p. injection of sodium pentabarbitone (60mg.kg_1; Sagatal,
Rhone Merieux, UK). A 2cm longtitudal incision was made in the anterior tracheal
region, exposing the thymus glands. The thymus glands were separated allowing access
to the jugular vein. The left jugular vein was isolated and permanently ligated at the
proximal point, traction was added to the suture and it was secured to the table above the
head, a second ligation was made approximately 5-8mm distal to the initial ligation. A
small puncture was made in the vein and using a bent tipped 25G needle as a cannula
guide the vein was cannulated with a heparinised saline filled cannula (100 IU.ml" ;
0.75mm OD, Portex cannula, Harvard Apparatus, Kent, UK), for administration of
anaesthetic (25mg.kg_1; Sagatal, Rhone Merieux, UK).
The right carotid artery was located and isolated allowing the artery to be permanently
ligated at the proximal end and then secured to the table above the head. A second
ligature was placed 8-lOmm lower and traction was added to this ligation with the use of
needle holders. A further two ligations were placed in between the two most distal
ligations. A small hole was made in the temporally occluded artery. With the use of a
bent-tipped 25G syringe needle as a cannula guider the artery was cannulated with a
heparinised saline filled cannula (100 IU.ml1; 0.75mm OD, Portex cannula, Harvard
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Apparatus, UK). This cannula enabled the mean arterial blood pressure (MABP) to be
recorded via a Maclab system (MacLab/4e, AD Instruments). The middle two ligations
were secured prior to the traction being released from the most distal ligation enabling
the cannula to be further advanced into the vessel. At this time the proximal suture was
tied around the cannula and the middle two sutures were further secured.
The trachea was isolated and a ligature placed loosely around it prior to an incision
being made allowing a cannula to be inserted for intubation (1.65mm OD, Portex
cannula, Harvard Apparatus, UK). The rats were artificially ventilated with room air
using a respirator (Harvard Rodent ventilator, model 683, Harvard Apparatus, UK) with
the rate of 60 strokes.min"1 and a tidal volume of 1.5ml.l00g~'. This is sufficient to
maintain PCCE: 18-24mmHg; PO2: !00-130mmHg and pH within physiological limits:
7.4 units (Clark et al. 1980). The body temperature was maintained at 37 + 0.5°C with a
thermostatically controlled under-blanket (Homeothermic Blanket Control Unit, Harvard
Apparatus, UK).
After a short stabilisation period the LCA was ligated following a modified method
previously described by Seyle (Selye et al. 1960). A skin incision was made over the
thorax, the pectoral muscles were retracted to expose the thoracic wall. A thoracotomy
incision was made at approximately 5mm to the left of the sternum by cutting through
the 4th and 5th ribs, the pericardium was then cut to expose the heart. Gentle downward
pressure was applied with forceps to either side of the incision resulting in the heart
being exteriorised. A suture (5/0 Mersilk, round bodied, Ethicon, UK) was passed
around the LCA just below the atrial appendage. The heart was immediately replaced
into the thoracic cavity. A period of 20 mins was sufficient for the heart and all
haemodynamic variables to stabilise, after which both ends of the ligature thread were
passed through a short length of polythene tubing to form a reversible snare.
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Regional myocardial ischaemia was induced through tightening the snare and securing
the ligature to the workbench either side of the chest. Ischaemia could be visually
confirmed by the altered appearance of the myocardium to a state of cyanosis. Previous
work with radiolabelied microspheres has demonstrated that such a procedure reduces
the blood flow to the area-at-risk by 98% (Toombs et al. 1992). Throughout ischaemia
the MABP was recorded every 15 mins, an ECG was not recorded due to interference of
the signal. After 45 mins of ischaemia the snare was released, and the myocardium
allowed to reperfuse for 2 hrs. Throughout the reperfusion period the blood pressure was
recorded at 30 min intervals.
Tissue collection: At the end of the reperfusion period the LCA was re-occluded at the
same site and permanently tied. 1ml of Evans blue dye (Appendix 1.2i) was infused via
the left jugular vein, enabling the perfused myocardium to be stained and identification
of the area-at-risk (AAR; This protocol is illustrated in the diagram of Figure 2.5.). The
Evans blue dye stains the non-ischaemic myocardium and leaves the ischaemic AAR
pink and free from Evans blue (Figure 2.4). The heart was removed from the chest, snap
frozen then stored at -20°C. To assess myeloperoxidase (MPO) activity the RV was
removed after Evans blue perfusion. The remaining myocardium was separated into the
AAR and the non-ischaemic area, based on the Evan's blue dye staining the non-
ischaemic area. The AAR was sliced into 3-5mm slices weighed and stored at -20°C for
a maximum of 14 days prior to analysis.
Figure 2.4. Ischaemia-reperfused heart dyed with Evans blue.
A rat heart demonstrating the red AAR after ligation ofthe left coronary artery to induce















20 mins 45 mins 2 hrs
i k
In vivo: cannulation of jugular vein
& carotid artery, for infusion of
anaesthetic and Evans blue as well
as blood pressure measurement.
Perfusion
Figure 2.5. Schematic diagram of the experimental protocol for ligation of the
left coronary artery (LCA) in vivo and in vitro.
2.2.2.2. In vitro coronary artery ligation.
The in vitro model of ischaemia-reperfusion lacks infiltrating blood during the entire
protocol. Infiltrating neutrophils are therefore removed from the myocardium and it
eliminates them as a source of the difference between the treatment groups,
consequently making it clear to see if other protective mechanisms of E are through
actions directly on the myocardium or through the infiltrating secondary mechanisms.
Rats underwent ovx and prepared as previously described in Section 2.2.1.1. At the time
of surgery the rats were anaesthetised as described in section 2.2.2.1. The chest was
opened along the sternum, exposing the entire chest cavity. Heparin sulphate (50IU;
50IU.mr') was injected into the jugular vein to prevent thrombus formation in the
coronary arterioles. A ligature (5/0 W595 Mersilk, round bodied, Ethicon, UK) was
passed around the LCA prior to the heart being isolated. Upon removal from the chest
the heart was placed in 50ml ice cold heparinsed Krebs (50 lU.ml"1) Henseleit solution.
The aorta was cannulated and the heart retrogradely perfused via the aorta on a modified
Langendorff perfusion set up (Figure 2.6; Ferrari et al. 1996). Pre-filtered Krebs
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Henseleit solution (Appendix 1.1) was perfused through the heart at a constant rate of
lOml.min"1 (Gilson, minipuls 3.0) and at a constant temperature of 37°C, gassed with
95% O2/ 5% CO2. The perfusate did not contain any hormones and therefore the
experimental results were due to tissue retention and modifications from treatment prior
to perfusion. After a stabilisation period of 20 mins the LCA was reversibly occluded for
45 mins. The ligature was passed through polythene tubing (Portex, OD 2.16mm,
Harvard Apparatus, UK) and then clamped with a small vascular clamp. At the end of
this ischaemic period the snare was released and the ischaemic zone re-perfused for 2
hrs. At the end of the reperfusion period the LCA was permanently occluded and 1ml of
Evans blue dye infused via the injection arm to identify the AAR, as described in tissue
collection of Section 2.2.2.1 (Figure 2.7). A schematic diagram of this experimental
protocol is shown in Figure 2.5.
Figure 2.6. Modified Langendorff perfusion set up
Langendorffperfusion set up based on retrograde aortic perfusion of the isolated heart
under constantflow conditions with Krebs-Henseleit.
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Figure 2.7 Heart on the modified Langendorff perfusion set up with the left
coronary artery ligated and Evans blue dye perfused.
A typical rat myocardium having undergone acute ischaemia followed by reperfusion on
the Langendorffperfusion set up. Evans blue dye stains the non-ischaemic area, whilst
the pink zone beneath the ligature is the ischaemic zone.
2.3. Determination of infarct size and ceil death
2.3.1. Area-at-risk
To assess the effect of hormone treatment on myocardial damage histochemical staining
was used as an index of ischaemia-reperfusion injury. Myocardial injury was evaluated
with triphenyltetrazolium chloride-Evans blue technique modified from Ytrehus
(Ytrehus et al. 1994). In the presence of dehydrogenase enzymes in the non-necrotic
AAR the 2,3,5-triphenyltetrazolium-chIoride (TTC) is reduced to a bright red colour,
whilst the necrotic area that lacks dehydrogenase activity remains white. These areas can
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be differentiated from the non-ischaemic area of the heart that remains blue from the
Evans blue dye (Figure 2.8).
Hearts that had been stored at -20°C were defrosted on ice and rinsed in 0.9% saline
solution and cut into 2-3 mm slices from apex to base. The slices were then incubated at
37°C for 30 mins in TTC (Appendix 1.2ii). The slices of heart were fixed in 10%
formalin (Appendix 1.2iii) for 15 mins and then rinsed in dHiO allowing clearer area
definition. The ischaemic AAR was separated from the non-ischaemic area. The AAR
was then further divided into the necrotic and non-necrotic tissue. Each distinct area of
myocardium was blotted dry and weighed. The total AAR was expressed as a percentage
of the total heart weight and the necrotic area was expressed as a percentage of the AAR.
Non-necrotic zone Necrotic zone
Figure 2.8. Cross Sections of the rat myocardium.
2.3.2. Apoptotic cell detection
Cell necrosis of damaged cardiomyocytes results from CAL, a method for detecting
nectrotic tissue has been described in Section 2.3.1. Apoptosis through infiltrating
leukocytes also occurs within the infarcted region, thus eliminating damaged cells.
Apoptotic cells were measured and detected using a Deadend™ colorimetirc TUNEL
system (Promega, Southampton, UK). This system is able to detect apoptotic cells at the
single cell level by measuring the nuclear DNA fragmentation of cells, this is an
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important marker of apoptosis in most cell types. The TUNEL system end labels the
nucleotide fragments with a modified Tat-mediated dUTP Nick End Labelling (TUNEL)
assay. A biotinylated nucleotide is incorporated at the 3' OH end of the DNA, this is
then bound to streptavidin-HRP (horseradish-peroxidase) and detected using the
peroxidase substrate hydrogen peroxidase and 3-3'-diaminobenzidine (DAB;
Dakocytomation, Cambridgeshire, UK). The apoptotic nuclei stain a dark brown with
this method. This system of detecting apoptosis is limited as it is unable to differentiate
between necrotic and apoptotic cells, to confirm apoptotic cell death further studies
utilising caspase 3 would be required.
Sections were prepared as described in Section 2.4.2.1. The manufacturers method was
then followed for this assay.
2.4. Neutrophil infiltration measurement
2.4.1. Myeloperoxidase activity
2.4.1.1. Collection of control neutrophils
MPO is a lysosomal enzyme, predominantly stored in the azurophilic granules of
neutrophils. Lysosomes of monocytes also contain MPO, this is about one third of the
MPO present in neutrophils. The main role of MPO is that of a bacteriocidal agent, it
works by catalysing the reaction of hydrogen peroxide (H2O2) and chloride ions into
hydrochlorus acid thus destroying the bacteria. In addition to its bacteriocidal role it is
thought to play a role in down-regulating the inflammatory response. As the
predominant store of MPO is the azurophilic granules of neutrophils, it is a good
indicator of neutrophil infiltration into the investigated area.
Neutrophils harvested from the peritoneal cavity of rats were used as a positive Control
for the MPO assay. The isolation of neutrophils was carried out according to a method
previously described by Cunningham, with modifications (Cunningham et al. 1979). To
collect neutrophils from the peritoneal cavity, 15ml of casein (sodium salt) in 0.9% NaCl
was injected i.p into rats. This stimulates the accumulation of neutrophils within the
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peritoneum. 16-18 hrs later the rats were sacrificed by anaesthetic overdose (lOOmg kg"1
Sagatal, Rhone, UK). 25ml of sterile phosphate buffered saline (PBS) containing 0.2%
glucose and 20 IU.mf1 heparin was also injected i.p and massaged around to wash the
peritoneal cavity. The peritoneum was then opened and the lavage fluid aspirated and
collected in 50ml centrifuge tubes. The lavage fluid from each rat was kept separate and
the volume of each tube increased to 50ml with PBS. The lavage fluid cell suspension
was centrifuged for five mins at 400g and room temperature. The supernatent was
discarded, any red blood cells remaining in the neutrophil pellet were lysed by
resuspending the pellet in 10ml of ice cold 0.2% w/v NaCl solution for 20 seconds, after
which 10ml of ice cold 1.6% w/v NaCl was added to return the cells to isotonic
conditions. The cells were then centrifuged for 5 mins at 400g and room temperature,
the supernatant was discarded. The cells were washed with 50 ml PBS containing 0.1%
bovine serum albumin (BSA), to maintain their viability and decrease aggregation and
then centrifuged at 400g at room temperature for 5 mins. The supernatant was discarded
prior to a second wash of 10ml 0.1% BSA in PBS, this was centrifuged for 5 mins at
400g room temperature. The resulting pellet of neutrophils was then stored at -20°C
until required for assaying.
2.4.1.2 Myeloperoxidase activity assay
MPO extraction from isolated peritoneal neutrophils and heart tissue was carried out
according to a modification of the protocol previously described by Williams (Williams
et al. 1994). Briefly, the AAR or neutrophil suspension was homogenised (T8 Ultra-
turrax, Scienific Laboratory Supplies, UK) in 0.02M phosphate buffer (Appendix 1.3i;
SOmg.mf1). The homogenate was centrifuged at 10,000g for 15 mins at 4°C.
Centrifugation caused cell lysis but left the MPO granule intact and thus removed other
peroxidases such as haemoglobin peroxidase. The supernatant was discarded and the
pellet resuspended in 0.05M phosphate buffer containing 0.5%
hexacyltrimethylammonium bromide (HTAB; Appendix 1.3ii; lOOmg.ml"1). The
samples were then briefly homogenised for a second time. The HTAB is a detergent that
lyses the azurophilic granule consequently causing the release of MPO from the
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granules. The resulting homogenate was then taken through 4 cycles of freeze-thaw
followed by a 2 hr incubation at 60°C. MPO is heat stable, this property is exploited here
to eliminate inhibitory factors within the tissue which can mask the MPO activity. After
the 2 hr incubation a 10 second sonication was followed by a final centrifuge at 10,000g
and 4°C for 15 mins.
At the time of analysis for MPO activity the control samples (obtained as described in
Section 2.4.1.1) were thawed on ice and assayed. 30pl of the sample supernatent was
aliquoted into a 96 well plate and mixed with 200pl reaction buffer (Appendix 1.3iii).
The absorbance was measured at a wavelength of 405nm (Thermo Labsystems;
multiskan Ascent), over a period of 10 mins. A standard curve was constructed using
MPO from human leukocytes in sodium acetate 0.02M. MPO activity was defined as the
quantity of enzyme degrading lpmol of peroxide.min"1 at 25°C expressed in units per g
weight (U.g tissue"1).
2.4.2. Immuno staining and histochemistry
2.4.2.1. Tissue Preparation
After harvesting the organs they were fixed in 10% neutral buffered formalin for 24 hrs.
This fixative is a noncoagulant and therefore does not alter the fine network of tissue
proteins and results in clear histological detail upon staining. The tissue was then
transferred to 50% ethanol to remove the formalin and stored in 50% ethanol until
processing.
During processing the tissue was passed through a series of increasing concentrations of
ethanol to remove any resident water from between the protein network. The tissue was
then immersed in xylene, which removes ethyl alcohol from the tissues, which is
immiscible with paraffin. Finally the tissue was infiltrated with melted paraffin that
provides a supporting matrix for the tissue.
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The wax blocks with the hearts embedded were then cut into 5pm sections using a
microtome. Creases and folds were eliminated from the sections by floating the sections
out on a water bath (40°C). The water bath also assisted the transfer of the sections onto
TESPA (3-Aminopropyltriethoxy-saline; Appendix 1.8) coated or electrically charged
microscope slides (BDH Laboratory Supplies, Dorset, UK). The sections were air dried
and then incubated at 37°C overnight to assist adherence. Prior to using the sections for
any analysis they were treated by submersion in xylene (2x5 mins) to remove the wax.
The sections were then re-hydrated through decreasing concentrations of alcohol (100,
95, 70%, 2 mins each) to water.
2.4.2.2. Histological analysis by Haematoxylin and Eosin Stain
Haematoxylin and eosin is a general stain used to identify the cells present within a
section. The haematoxylin is a basic stain and therefore stains basophilic structures, such
as chromatin within the nucleus. In comparison eosin is an acidic stain and consequently
stains acidophilic structures, including collagen, muscle filaments and mitochondria.
The sections were prepared as described in Section 2.4.2.1 and then immersed in water
for 5 mins. The slides were passed through Harris's haematoxylin for 2 mins and rinsed
in tap water prior to 5 seconds in acid alcohol (Appendix 1.4i). The slides were then
rinsed in tap water again and immersed in Sotts tap water (Appendix 1.4ii). This
procedure differentiates the staining, the acid alcohol removes a uniform layer of
haematoxylin stain from the cell whilst the Scotts tap water ensures that the
haematoxylin stains the nucleus a distinct blue. After the Scotts tap water the slides were
briefly exposed to 100% ethanol prior to staining with eosin (0.5% alcohol solution) for
5 mins. The sections were finally washed in tap water and dehydrated through the
ethanol gradient and finally in xylene before mounting coverslips with DPX mount.
The sections were viewed under a light microscope (Ziess, Welwyn Garden City, UK)
for the detection of neutrophils and macrophages. The leukocytes could be differentiated
due to their distinct morphological differences. The neutrophils have a diameter of 6-
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8pm and a multi-lobed nucleus that stains blue with haematoxylin compared to the pink
cytoplasm with eosin. The neutrophils are differentiated from the macrophages which
are larger, typically 9-12pm in diameter, the cytoplasm stains a darker pink with a
kidney shaped nucleus that is eccentrically situated.
2.4.2.3. Immunohistochemistry
With the paraffin wax removed as described in Section 2.4.2.1, the sections were
incubated for 30 mins in 3% H202. Incubation with this peroxide removes the
endogenous peroxidases from within the tissue. The slides were then washed twice in
Tris buffered saline (TBS) for 5 mins and treated to block endogenous biotin activity.
Endogenous biotin activity was blocked by a 30 min incubation at room temperature
with blocking serum (Table 2.2). After this incubation the excess blocking serum was
removed and the sections were incubated at 4°C overnight with primary antibody,
diluted in blocking serum (Table 2.2).
The following day, the primary antibody was washed off with TBS and the secondary
antibody was added to the sections. Sections were incubated for 30 mins at room
temperature in the biotinylated secondary antibody (Table 2.2). The secondary antibody
was washed off in TBS to remove the excess unbound antibody. A 30 min incubation at
room temperature with ABC-HRP (Dakocytomation, UK) followed, this binds to the
biotinylated secondary antibody for detection. Sections were then washed in TBS again
and bound secondary antibody was visualised using DAB (Dakocytomation, UK), this
substrate reacts with the HRP to produce a brown stain, the colour change was
monitored microscopically. DAB is active for up to 20 mins, it was inactivated once
staining was apparent by washing the sections in water. The tissues were then
counterstained with haematoxylin, and mounted using pertex.
GR-1 was used as a histochemical marker for neutrophils. GR-1 is a myeloid
differentiation antigen, it is a glycosyl-phosphatidylinositol linked protein thus it
remains attached to the cytoplasmic membrane and can be released by a phospholipase.
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GR-1 is expressed in bone marrow of cells from a myeloid linage; the expression is
regulated through development. Monocytes express GR-1 transiently during their
development in bone marrow, however neutrophils express GR-1 both during
development in bone marrow and once matured in the periphery. This expression of GR-
1 makes it a good marker for neutrophils. Haematoxylin staining enabled the presence of
neutrophils to be confirmed through co-staining the multi-lobed cell nucleus with the
GR-1.
Once stained the sections were analysed and photographed at lOOOx magnification using
a laboratory microscope (Olympus BH-2 light microscope; Olympus Optical, London,
UK) fitted with a prior automatic stage (Prior Scientific Instruments Ltd., Cambridge,
UK). Neutrophil counting was performed with the use of Image-Pro Plus 4.5 with
Stereologer-Pro 5 plug-in software (Media Cybernetics UK, Wokingham, Berkshire,
UK). Ten points within the infarcted region of each heart were chosen at random by the
computer, the number of neutrophils within these areas was averaged for each heart
section. The same procedure was carried out in the RV as an internal control. In control
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2.5. MMP and TIMP expression and activity
2.5.1. SDS PAGE
SDS-PAGE (sodium dodecyl sulphate-polyacrylamide gel electrophoresis) gels were
used to detect secreted MMP expression and activity as well as TIMP activity post-MI in
the mouse myocardium.
The PAGE gel is formed by the polymerisation of acrylamide monomers into long
chains and cross-linking these chains using N,N'/-methylene bisacrylamide. The
polymerisation is initiated by free radicals produced from ammonium persulphate (APS)
in the presence of TEMED (A^MA.A'-tetramethylethylenediamine). The gel solution
was degassed to remove oxygen prior to adding the TEMED. Degassing the solution
enabled the production of reproducible gels because atmospheric oxygen scavenges the
free radicals and therefore inhibits polymerisation. SDS is an ionic detergent used to
dissociate the protein into individual peptides. The SDS saturates the peptides with a
negative charge so that all the peptides of the same length migrate with a uniform
negative charge during electrophoresis. The percentage of the gel refers to the
acrylamide-bis, this determines the pore size and density in the gel for the peptide
migration. A higher percentage of acrylamide-bis results in smaller pores and therefore
greater separation of smaller molecules. The APS is very hygroscopic and begins to
decay as soon as it is in solution with water, for this reason it was made up fresh every
morning.
The BioRad mini system (Hertfordshire, UK) with a discontinuous electrophoresis
system was used. The resolving gel was made up and allowed to polymerise with a layer
of sec-butanol (Appendix 1.6i) on top, this excluded oxygen from the surface. 7.5% or
12% w.v"1 SDS-PAGE gels were used as resolving gels. The stacking gel was made up
on the morning the gel was being run in the same way as the resolving gel (Appendix
1,7ii, iv and vi).
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Prior to being loaded on to the gels the samples were mixed with an equal volume of
sample application buffer (Appendix 1.5i and 1.6ii). The sample application buffer does
not alter the sample but allows the migration of the sample to be identified and traced.
Molecular weight markers were always loaded in to the final lane of the gel so that
proteins of unknown weight could be determined, whilst those of a known weight could
be identified. Broad range markers (-30-120 kDa; BioRad, UK) were loaded on to 7.5%
gels whilst low range markers (-20-120 kDa; BioRad, UK) were loaded onto gels of
12%. The molecular markers also enabled the separation to be visualised, ensuring that
the current had passed through the gel sufficiently. Once the samples were loaded onto
the gel, a constant voltage (100V) was passed through the gel until the dye front had just
reached the end of the gel.
2.5.2. Densitometric analysis
Once scanned the gels and blots were analysed using 'Quantity one' (BioRad software,
UK) allowing quantitative analysis of the density of bands and therefore the protein
expression or activity. The same area was used to analyse the density of bands in all the
gels. This allowed for comparisons of density between samples within each gel. Within
each gel a background reading was taken and subtracted from all the other readings, the
background reading was taken from in between lanes or at the edge where nothing had
been loaded onto the gel or transferred onto the membrane. Subtracting the background
eliminated the variance between gels, which allowed different gels to be collated and
compared.
2.5.3 Protein expression by Western blotting
Western blots were used to detect protein expression within the samples, collected as
described in Section 2.2.1.2. Once separated through electrophoresis the proteins bind to




Once mixed with application buffer (Appendix 1,6ii) the samples were passed through
reducing conditions (boiled for 5 mins and then centrifuged at 13,000g for 3 mins at
4°C) before being loaded onto the gel. The reducing conditions meant that the
conformation of the proteins passing through the gel were of a different shape and
conformation, for example the disulphide bonds were broken. This conformational shape
change results in a slight change in the molecular weight of the protein observed.
After approximately 2 hrs electrophoresis in tank running buffer (Appendix 1.6iii) when
the dye front had run off the gel, electrophoresis was stopped. The gel was then
equilibrated in transfer buffer (Appendix 1.6iv). This buffer was used to transfer the
separated proteins from the gel onto a nitrocellulose membrane. During tank transfer the
proteins are eluted from the gel and absorbed by the nitrocellulose membrane, the
proteins then cross link onto the membrane making them accessible for the antibody to
bind to. The transfer was set up so that the gel and membrane were sandwiched next to
each other between fibre pads and filter paper and then a continuous current of 100V
passed through it for 1 hr in transfer buffer (Appendix 1.6iv). When making the
sandwich of gel and membrane up prior to transfer, the molecular weight markers were
marked on the membrane. The markers were visible through the membrane, marking
them with a pin prick on the membrane ensured that their position on the membrane was
known if the marker bands did not transfer correctly.
After the transfer of proteins onto the nitrocellulose membrane the membrane was
blocked in blocking solution (Appendix 2) for 1 hr. The membrane was then exposed to
the specific primary antibody (Appendix 2) of interest for 2-2.5 hrs. Following this
incubation there was a wash cycle of 4 x 5 min washes and one 15 min wash in wash
buffer (Appendix 1.6vi) before incubation with the secondary HRP linked antibody
(Appendix 2). After a 1 hr incubation with the secondary antibody the membrane went
through a second wash cycle as above. The presence of proteins on the membrane was
detected using the 'enhanced chemiluminesence' (ECL) method. This detection is based
on the luminescent properties of luminol. HRP labelled antibody bound to the protein of
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interest on the nitrocellulose membrane catalyses the oxidation and excitation of
luminol. Excited luminol decays with a of 60 mins. As lumionol returns to its ground
state it emits light, this light is detected by exposing the membrane to photographic film,
this results in stronger dark bands at sights where there is more protein present. After
ECL detection the nitrocellulose membrane was incubated for 45 mins in stripping
solution (Appendix 1.6viii), to remove the antibodies from the membrane. The resulting
photographic film was scanned into the computer and analysed as described in Section
2.5.2.
Non-specific binding (NSB) was determined by incubating the nitrocellulose membrane
with blocking solution in place of the specific primary antibody. All primary antibodies
were diluted in 5% BSA-TTBS, 0.025% sodium azide (Appendix 1.6vii). Secondary
antibodies were diluted in TTBS.
2.5.3.1. MMP-13
Aliquots of the sample (15pl) were loaded on to a 7.5% SDS-PAGE gel. Due to the use
of a primary antibody raised in mouse against mouse there was a lot of NSB detected
(Figure 2.9a). The high back-ground NSB detected was due to other proteins within the
mouse genome that have a similar sequence to the specific MMP-13 sequence that the
antibody is designed to detect. To overcome the problem of excessive NSB masking the
result an additional 1 hr incubation prior to the primary antibody incubation was needed.
This additional incubation was with a 'mouse-on-mouse' (MOM) block (Vector labs,
Peterborough, UK), this additional block reduced masking of results by NSB (Figure
2.9b). This primary antibody detected MMP-13 protein as a band at -60 kDa and 48
kDa, the latent and active proteins respectively.
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MMP-13 Ab kDa Non-specific binding
120
100
Infarct Uterus 56 Infarct Uterus
B. MMP-13 Ab kDa Non-specific binding
120
100
Infarct Uterus 56 Infarct Uterus
Figure 2.9 Western Blot of MMP-13
The blot, using ECL detection (a.) without an additional incubation in MOM block and
(b.) with an additional incubation in MOM block.
2.5.3.2. TIMP-2
Aliquots of the samples (50p.l) were freeze dried, as described at the end of Section
2.2.1.2. This freeze drying and reconstitution in dT^O allowed for an equivalent of 50pl
to be loaded onto the gel. The samples that were loaded onto the gel were concentrated
2.5x. The expression of TIMP-2 was detected on a 12% SDS-PAGE gel. TIMP-2 is seen
as a band at -26 kDa, there is a small shift in size from that detected in the reverse
zymography, this is due to the reducing conditions in the Western blot compared to the
non-reducing in the reverse zymography.
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2.5.4. TIMP Activity by Reverse Zymography
Secreted TIMP activity was assessed by reverse zymography (Riley et al. 1999).
Reverse gelatin zymography identifies TIMP-1, -2, -3 and -4, however TIMP-1,
glyosylated TIMP-3 and TIMP-4 have similar molecular weights (28 kDa, 27 kDa and
30 kDa respectively) that cannot be discriminated against in the separation. The gel
contained gelatin (lmg.mf1) and a cell cultured medium containing MMP-2 activity
(from BHK-21 cells which constitutively secrete MMP-2; University Technologies Inc.),
therefore at the discrete sites of TIMP activity the MMP-2 within the gel was inhibited
and the gelatin not degraded, producing discrete dark bands.
An initial spectrum of secreted TIMP activity throughout all the regions of the heart was
obtained, from this specific regions thought to be of most relevance and importance to
LV remodelling were selected for reverse zymography. The chosen areas of
myocardium were the RV, the I area and the B zone. The I and B are the two areas
where most structural change and thinning is observed in the heart during MI and the
RV remains unaltered during infarction of the LV and is therefore a good internal
control.
The original samples (as prepared in Section 2.2.1.2) were concentrated; 20pl aliquots
were freeze-dried, as described in Section 2.2.1.2 then reconstituted in dLLO. This
allowed a volume that was 3.3x concentrated equivalent to 20pl to be loaded on to the
gel. The gels were subjected to electrophoresis in running tank buffer (Appendix 1.5ii)
for approximately 2 hrs as described in Section 2.5.1. The gels were washed for 2 hrs at
room temperature in wash buffer (Appendix 1.5iv) prior to an 18 hr digestion period in
digestion buffer (Appendix 1.5vii) at 37°C. Following digestion the gels were stained for
3 hrs in 0.5% Coomassie blue R250. This was followed by approximately 2 hrs in de-
stain solution (Appendix 1.5viii) to reveal dark bands of protein compared to the lighter
areas where the substrate within the gel had been digested. A sample of human amniotic
fluid collected at term in active labour and characterised previously was used as a
positive control (Riley et al. 1999). The mouse TIMP-1, unglycosylated TIMP-3 and
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TIMP-4 were seen as one band at approximately 30 kDa. TIMP-2 exhibited a molecular
weight of 21 kDa in the non-reducing conditions of reverse zymography and
unglycosylated TIMP-3 was seen as a discrete band at 21 kDa. The resulting gels were
rinsed in dH20 and then scanned into the computer and analysed as described in Section
2.5.2.
2.5.5. MMP activity by Gelatin Zymography
The activities of MMP-2 and MMP-9 secreted within the myocardium were assayed by
gelatin substrate zymography (Riley et al. 2001). Activity of MMP-2 and MMP-9 was
detected using lOpl aliquots of the sample (as prepared in Section 2.2.1.2) on an SDS-
PAGE gel containing gelatin (lmg.mf : Appendix 1.7i).
The samples were separated by electrophoresis for approximately lhr in running tank
buffer (Appendix 1,5ii), this was visually assessed by the dye front reaching the end the
gel. The gels were then washed in Triton wash buffer (Appendix 1.5iii) and incubated in
digestion buffer (Appendix 1.5iv) for 18 hrs at 37°C. After the incubation in digestion
buffer the gels were stained in Coomaise blue R250 for 3 hrs and finally destained as
described previously in Section 2.5.4. This process revealed discrete regions where the
gelatin had been degraded by the MMP gelatinase activity. A sample of human amniotic
fluid collected at term in active labour was used as both a positive and comparative
control. The human amniotic fluid has previously been characterised in the laboratory
(Riley et al. 1999). The resulting gels were rinsed in dH20 and then scanned into the
computer and analysed as described in Section 2.5.2.
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2.6 Oxidative stress detection by Electron Paramagnetic
Resonance
Oxidative stress is caused by reactive oxygen species, which include superoxide, singlet
oxygen, peroxynitrite and H2O2. It is defined as an imbalance between pro-oxidants and
anti-oxidants, with the former prevailing.
Detecting oxidative stress through the measurement of free radicals provides a clear
indication of the oxidative stress. Electron Paramagnetic Resonance (EPR) enables the
detection of free radicals. There are two approaches to EPR spectroscopy, they differ in
their method of stabilising the reactive free radical species long enough to be detected
(Vergely et al. 2003). The first of these methods is a 'freezing technique' where the
tissue is snap-frozen in liquid nitrogen. The freezing technique was largely developed by
Zweier et al., when investigating free radical generation in in vitro perfused post-
ischaemic rabbit hearts (Zweier 1988). This revealed an increased production of oxygen-
derived radicals following reperfusion and demonstrated the functionality of EPR in
recording this increase in free radicals. The freezing technique is however limited
because it only provides information on what is happening at a chosen time. The second
method of stabilising the reactive free radicals is through the use of spin-traps. The
development of spin-traps, molecules that react with free radicals to produce a stable
adduct which can then be detected by EPR, has provided an opportunity to investigate
the time course of radical production continuously. This technique has previously been
used to detect the brief oxidative burst that occurs in the first two minutes following
ischaemia-reperfusion in vitro isolated buffer perfused hearts (Wang et al. 1996; Zweier
et al. 1989).
EPR was used to detect and quantify the free radicals produced in a given sample. The
free radicals, which we were interested in are generally transient due to a very short half
live, for example superoxide has a half life of milliseconds and therefore difficult to
detect using instrumental analysis. EPR is able to detect the free radicals through the
formation of a more persistent radical, allowing the concentration of persistent radicals
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to accumulate. Persistent radicals can be formed from these transient free radicals
through a reaction with a spin-trap. The spin-traps used in this work are nitrogen centred
compounds based on hydroxylamines. Free radicals react with this to form the more
stable nitrogen centred adducts. During EPR measurement, the sample containing the
stable 'adduct' was placed in a magnetic field where it was irradiated with microwave
energy of a known wavelength.
During this study the l-hydroxy-3-carboxy-pyrrolidine (CP-H; Axxora, Ltd,
Nottingham, UK) spin-trap was used in EDTA solution. EDTA was necessary to counter
the effect of certain metal ions. CP-H is cell permeable, non-toxic and forms adducts
with the main free radicals involved in this study. CP-H also has a degree of resistance
to signal break down by endogenous antioxidants. In a sub set of experiments SOD was
also mixed with CP-H. The presence of SOD eliminates superoxide free radicals
predominantly produced by the neutrophils.
The EPR readings were recorded using the Magnettech MiniScope MS 200 which
operates in the X-Band Microwave frequency at approximately 9.5GHz, with MiniScope
Control 6.51 software. The EPR parameters used throughout were set as follows; BO
Field - 3356G, Sweep - 44G, Sweep Time - 30s, No. of passes - 1, Modulation
Amplitude - 1500mG, Microwave Power - 20mW.
After in vivo ischaemia-reperfusion of the rat myocardium as described in Section 2.2.1,
50IU of heparin was injected into the vena cava. The myocardium was removed into
50ml heparinised saline (50 IU.ml"1) prior to being retrogradely perfused via the aorta on
a Langendorff perfusion set up, as described in Section 2.2.2.2. The heart was allowed a
stabilisation period of 20 mins prior to the CP-H spin-trap (lOpl; 0.1M in EDTA, 0.01M
to give an excess of spin trap) being injected into the perfusate above the heart through
the injection arm of the Langendorff perfusion set up (Figure 2.6). 500pl of perfusate
(drops 6-11 after the injection of spin-trap) was then collected from the base of the heart
and incubated for 25 mins at 37°C before recording the signal produced from free
75
Chapter 2
radicals with EPR. This procedure was repeated 4 times, with 2 mins between each
sample collection. Spin-trap was firstly perfused through the myocardium with the LCA
occluded by the formation of a reversible snare (as described in Section 2.2.2.2),
therefore only the non-ischaemic myocardium was perfused. After 4 samples had been
collected from the non-ischaemic myocardium the reversible snare was released and the
ischaemic area perfused. The procedure of injecting spin-trap into the perfusate above
the heart and collecting 500pl of perfusate from the base of the heart was then repeated.
Perfusing the entire heart enabled the free radicals produced from the entire heart
including the ischaemic AAR to be measured and compared to the free radicals
produced from the non-ischaemic myocardium when the LCA was occluded.
In some experiments (n= 8) SOD was pre-mixed with CP-H prior to injecting it above
the heart (50pl of 5000U SOD with 10pl CP-H per sample) to assess the contribution of
superoxide radicals to the total radicals measured. SOD was only perfused through the
entire heart. All samples were compared to and corrected for the auto-oxidation of the
spin-trap in Krebs-Henseleit buffer, 500pl of Krebs-Henseleit buffer was collected from
the base of the heart and incubated with CP-H in the same fashion as the samples. After
all the perfusate samples had been collected, the LCA was permanently occluded and
Evans blue dye was perfused. The myocardium was then stored and analysed as
described in Section 2.2.2.2 and 2.3.1 respectively.
2.7. Statistical analysis
All statistical analysis was carried out using Graphpad Prism. Where appropriate a one¬
way ANOVA, two-way ANOVA or unpaired or paired two-tailed students t test and
Bonferroni post-hoc test was used to compare mean values between groups. Kaplan
Meier survival plots were analysed with a logrank test. All data is expressed as mean +




2.8. Drugs and Chemicals
All chemicals and drugs unless otherwise stated were obtained from Sigma-Aldrich.




THE INFLUENCE OF OESTROGEN AND OESTROGEN
RECEPTORS ON THE OUTCOME OF MYOCARDIAL




There are two known genomic E receptors that mediate Es' cellular responses. These are
discussed fully in Section 1.2.1.1. In the rat myocardium ERa and ERp are localised to
the nuclei of cardiomyocytes fibroblasts and coronary arteries (Grohe et al. 1998;
Jankowski et al. 2001; Nuedling et al. 2001; Saunders et al. 1997; Yang et al. 2004).
Similarly, human cardiomyocytes express ERa (Reviewed in Mendelsohn et al. 2005)
while ERP is expressed in cardiomyocytes and fibroblasts (Taylor et al. 2000).
Experimentally, administration of 17PE2 reduces the infarct size and inflammatory
response after ischaemia-reperfusion (Delyani et al. 1996; Hale et al. 1996; Squadrito et
al. 1997), this is discussed in Section 1.6.3. Isolated neutrophils express both ERa and
ERp (Stygar et al. 2006) but the receptor mediating the effects of E in reperfusion injury
has not been identified.
Experiments using the non-selective ER antagonist ICI 182 780 have demonstrated that
the 17pE2 induced reduction in infarct size is ER mediated, but they do not identify the
specific receptor involved (Booth et al. 2003; Dubey et al. 2001; Hayashi et al. 1995).
Attempts have been made to investigate the roles of ERa and ERp in the cardiovascular
system using mice genetically altered to remove the ERa. These mouse studies of global
ischaemia-reperfusion have reported that the protective properties of E are lost in ERKO
mice (Zhai et al. 2000). The findings from ERKO mice are limited due to compensatory
mechanisms (Karas et al. 2001). In this chapter, for investigation of the roles of ERa
and ERp, we used a novel ERa selective agonist, Org37445 and a novel ERp antagonist





The aim of the current study was to investigate the role of ERa and ERp in mediating
the effects of chronically administered 17(3E2 on infarct size, neutrophil infiltration and
oxidative stress following ischaemia-reperfusion in ovx rats. To study the properties of
ERa and ERp we used a novel ERa selective agonist, Org37445 and novel ERP
selective antagonist, Org44488. The preliminary aim of this study was to investigate the
sufficient dosage of 17PE2 to administer to rats after ovx to produce physiological
plasma E levels.
3.3. Methods
3.3.1. Dosing of 17p-estradiol
Rats (n=60) underwent ovx as described in Section 2.2.1 and were then randomly
assigned to receive either placebo or 17pE2. In a pilot study, the rats (n=17) assigned to
receive 17pE2 were divided into those receiving 1 or 2 17pE2 pellets. This pilot study
was designed to find the appropriate number of pellets to implant after ovx in order to
achieve the most physiologically relevant 17PE2 plasma concentration.
3.3.2. Administration of oestrogen receptor selective drugs
Rats underwent ovx as described in Section 2.2.1.1. After ovx the rats were randomly
assigned a treatment group as detailed in Table 3.1. The rats were dosed with the novel






E + ER{3 antagonist
Placebo + ERa agonist
Placebo + ERp antagonist
Table 3.1. Hormone and Selective Receptor drug Treatment Groups
Briefly, the selective ERa agonist has >50 fold selectivity for ERa over ERp. In an in
vitro gene transactivation assay (de Gooyer et al. 2003), the ERa agonist activated
luciferase expression in CHO cells transfected with recombinant human ERa with an
EC50 of 6.53 x 10"" M. The EC50 for activation of human ERp in the cell system was 5.5
x 10"9M. The ERp antagonist inhibited gene transactivation induced by 17PE2 in cells
expressing recombinant human ERP with an IC50 of 1.41 x 10"8M and did not inhibit
ERa-mediated gene activation up to 10"5M. This illustrates that Org44488 has a greater
than 100 fold selectivity for antagonising ERp compared to ERa.
In vivo the ERa agonist Org37445 or vehicle (5% (w/v) mannitol 0.5% (w/v) gelatin)
was administered twice daily (8am and 4pm) for 5 days prior to the experiment by
gavage at a dosage of 75 pg.kg"1. A final dose was administered on the morning of the
study. This choice of dose was based on previous observations in an in vivo rat anti-
osteoporosis assay (Ederveen et al. 1999, 2001). In this model Org37445 prevented bone
loss and stimulated uterine proliferation, both ERa mediated events. The ERp antagonist
or vehicle (phosphate buffered saline) was administered at a dose of lmg.kg"1 for 3 days
prior to the experiment by s.c injection (between 10 and 1 lam). A final dose was given
on the morning of the experiment. In previous studies (unpublished) this regime was
shown to achieve plasma levels of 300 nmol.L"1 of Org44488. Based on in vitro data this
should be sufficient to fully antagonise the effects of 17pE2 at ERp under our study
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Figure 3.1. Timescale ofsurgery and selective ER drug administration.
3.3.3. Ischaemia reperfusion
Ischaemia-reperfusion was carried out in vivo and in vitro as previously described in
Section 2.2.2.1 and Section 2.2.2.2, respectively.
3.3.4. Analysis of the Area-at-risk
The AAR was analysed after ischaemia-reperfusion by the modifed Evans blue-TTC
technique previously described in Section 2.3.1.
3.3.5. Analysis of neutrophil infiltration
The MPO activity, used as an indication of neutrophil infiltration into the ischaemic
region during reperfusion, was assessed as detailed in Section 2.4.1.2.
3.3.6. Measurement of oxidative stress
Oxidative stress within the entire heart and the ischaemic heart after ischaemia-
reperfusion was measured by EPR. A detailed description of the procedure used for EPR




There was a 80% survival rate in this study. There was one rat excluded from the study
due to an adverse reaction to the ERa agonist gavage regime, all the other mortalites
were during the ischaemia-reperfusion protocol.
3.4.1. Uterine weight and plasma concentration levels
Rats receiving pellets releasing 17(3E2 after ovx had a significantly greater plasma
estradiol level compared to ovx rats receiving placebo pellets (P<0.05; Figure 3.2a). The
rats that were assigned to receive two l7pE2 releasing pellets had a significantly higher
circulating level of plasma estradiol compared to rats that received a single pellet
(P<0.05; Figure 3.2a).
A. B.
Figure 3.2. The effect of 17(3E2 pellet supplementation on plasma estradiol and
uterine weight.
The influence of ovx followed by subcutaneous implantation ofplacebo and one or two
17(3E2 pellets on (A.) plasma estradiol concentration and (B.) uterine weight in rats.
Data was analysed with a one-way ANOVA followed by a Bonferroni post-hoc test and
is expressed as mean ±SEM; n= 5-6; *P<0.05, ***P<0.001.
Figure 3.2b illustrates that the level of circulating estradiol after ovx had a significant
effect on the uterine weight at the time of harvesting. Rats that received one or two
17PE? pellets after ovx had a significantly greater uterine weight than rats receiving a
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placebo pellet (P<0.001; Figure 3.2b). There was no significant difference between the
uterine weight of rats that received one or two 17pE2 releasing pellets (Figure 3.2b).
3.4.2. In vivo ischaemia reperfusion with different doses of
17pE2
Deprivation of 17pE2 or the concentration of 17pE2 replacement did not significantly
effect the myocardial AAR that resulted from in vivo ischaemia-reperfusion (Figure 3.3).
Placebo +17pE2 +2x17pE2
Figure 3.3. The Area-at-risk after ischaemia-reperfusion in the rat.
The AAR after in vivo ischaemia-reperfusion in rats with different circulating levels of
17(3E2- The AAR is expressed as a percentage ofthe total heart weight, these areas were
determined with TTC and Evans blue. The data is mean + SEM; analysed with a one¬
way ANOVA; n=6, 4for2xl7f3E2.
The necrotic area within the AAR was significantly decreased in rats treated with 17pE2
after ovx compared to placebo pellets (Figure 3.4). The reduction in necrotic tissue was
more marked with higher circulating levels of 17pE2 compared to placebo. However,
there was no significant difference between the necrotic tissue of rats that were receiving











Placebo +17pE2 +2x 17pE2
Figure 3.4. The necrotic myocardial tissue after in vivo ischaemia-reperfusion.
The necrotic tissue of the myocardium after in vivo ischaemia-reperfusion in the rat
expressed as a percentage of the AAR and the effect of varying 17[3E2 levels on the
amount of necrotic tissue, these areas were determined with TTC and Evans blue. The
data was analysed using a one-way ANOVA and a Bonferroni post-hoc test, it is
presented as mean + SEM; n=6, 4 for 2x17PE2; *P<0.05, **P<0.01.
3.4.3. Body and uterine weight after selective oestrogen
receptor agents
All the rats that were assigned to 17pE2 treatment in these studies received a single
pellet at the nape of the neck.
The body weight of all the animals was recorded at the time of ovx and at the time of
ischaemia-reperfusion. The mean body weight of rats at the time of ovx was 191.6 +
2.4g. There was no significant difference in body weight at the time of ovx and random
assignment to a treatment group. At the time of ischaemia-reperfusion, rats that received
17PEt or the ERa agonist Org37445 weighed significantly less than placebo/vehicle
treated rats (Table 1). Treatment with ERp antagonist Org44488 did not have any
influence on body weight when given to rats receiving placebo or 17PE2 (Table 3.2).
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The uterine weight of all animals was recorded at the experimental end point to confirm
the effective removal of the ovaries and successful hormone return in the appropriate
animals. Animals receiving placebo/vehicle had a significantly lighter uterus (P<0.05)
than those receiving either 17pE2 or placebo in combination with selective ERa agonist
Org37445 (Table 3.2). The ERP antagonist Org44488 did not have a significant effect
on the uterus weight when given to rats receiving placebo or 17pE2 (Table 3.2.).




Placebo + vehicle 278.0 ±6.4 0.04 ±0.01
17pE2 + vehicle 220.5 + 6.8*** 0.25 ±0.03***
17pE2 + ERP 216.6 + 4.1*** 0.23 ±0.02***
antagonist
Placebo + ERa 232.6 + 4.7*** 0.12 ± 0.03***
agonist
Placebo + ERP 279.0 ±8.9 0.05 ±0.01
antagonist
Table 3.2. Effect of 17pE2 and selective ER drugs on the body weight and uterine
weight after ischaemia reperfusion in the rat.
Data shown is mean ± SEM; Analysed using a one way ANOVA with a Bonferronipost-
hoc test, ***p< Q.OOl compared to placebo n=6-8.
3.4.4. In vivo ischaemia reperfusion
The MABP was not significantly different between treatment groups before ischaemia
(Table 3.3). Throughout ischaemia and reperfusion the MABP did not differ
significantly between treatment groups. At the onset of ischaemia there was a drop in
MABP, this then recovered during the initial 15 mins of ischaemia to pre-ischaemic
pressures and was maintained until the end of the experiment. Treatment with 17pE2 or
selective ER ligands did not have a significant effect on this pattern or on the MABP at
the end of the ischaemia and reperfusion periods (Table 3.3).
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Treatment Before Ischaemia Reperfusion 2hrs
ischaemia onset Reperfusion
Placebo + 73.1 ± 12.8 43.4 ±8.5 61.1 ± 14.2 55.4 ±5.6
vehicle
17pE2 + 88.1 ±4.1 51.2 ± 7.8* 60.0 ± 12.1 62.0 ± 10.3
vehicle
17PE2 + ERp 73.1 ± 13.4 52.3 ±4.9 56.0 ±5.4 60.2 ±4.5
antagonist
Placebo + 49.6+10.0 36.3 ±3.0 70.9 ± 10.4 60.3 ± 14.7
ERa agonist
Placebo + 65.0 ± 11.3 35.1 ±4.0 65.27 ±2.1 65.4 ±3.9
ERp
antagonist
Table 3.3. The MABP of rats during in vivo ischaemia reperfusion.
The effect of ovx and selective ER stimulation or ablation on the MABP during the
course of ischaemia-reperfusion. The MABP was analysed with a repeated measures
ANOVA within groups and a one-way ANOVA at selected time points. Values are mean
in mmHg + SEM; *P<0.05 compared to the treatment group before ischaemis. n =5 or
6.
The heart rate did not change significantly throughout ischaemia-reperfusion in any
treatment group. Different hormonal status only had a significant effect before ischaemia
when the heart rate was significantly higher in placebo treated rats with ERp antagonist




Treatment Before Ischaemia Reperfusion 2hrs
ischaemia onset Reperfusion
Placebo + 164.0+11.5 158.0 ± 11.5 166.0 ±8.4 144.0 ±7.6
vehicle
17PE2 + 152.0 + 7.4 168.0 ±7.6 178.0 ± 13.3 180 ± 13.5
vehicle
17PE2 + ERP 146.0 ± 11.8* 156.0 ±6.9 142.0 ±6.5 140.0 ±7.0
antagonist
Placebo + 146.4+14.9 136.8 ±9.0 160.8 ±4.8 159.0 ±5.7
ERa agonist
Placebo + 192.0 ±20.6 178.0 ±29.8 172.0 ±7.4 174.0 ±4.1
ERP
antagonist
Table 3.4. The heart rate of rats during in vivo ischaemia reperfusion.
The effect of ovx and selective ER stimulation or ablation on the rat heart rate during
the course of ischaemia-reperfusion. The heart rate was analysed using a repeated
measures ANOVA within groups and a one-way ANOVA followed by a Bonferroni post-
hoc test between groups; *P<0.05 compared to placebo + ER/3 antagonist at the same
time point. Values are mean + SEM; n =5 or 6.
The AAR in the placebo/vehicle treated group was 57.1 + 3.8 % of the total heart; the
AAR in the other treatment groups did not differ significantly from this (Figure 3.5). In
the in vivo experiments, 17pE2 significantly reduced the size of the necrotic zone within
the AAR compared to placebo/vehicle-treated ovariectomised rats (P<0.05; Figure 3.6).
Treatment with the ERP antagonist Org44488 did not significantly alter this 17pE2
induced decrease in necrotic tissue (Figure 3.6a). Treatment with the ERp antagonist
Org44488 after placebo treatment had no significant effect compared to vehicle (Figure
3.6a). Placebo-treated rats receiving the ERa agonist Org37445 also displayed a







Figure 3.5. The Area-at-risk after in vivo ischaemia reperfusion.
The area of myocardium at risk after in vivo ischaemia-reperfusion in the rat and the
influence 17(3E2 with or without selective (A.) ER/3 antagonist Org44488 and (B.) ERa
agonist Org37445 on this, expressed as a percentage of the total heart weight, these
areas were determined with TTC and Evans blue. The data was analysed using a (A.J
two-way ANOVA and (B.) a one-way ANOVA both followed by a Bonferroni post-hoc
test, it is expressed as the mean + SEM; n=6, 8for placebo + ER/3 antagonist.
Vehicle +ERp antagonist
Figure 3.6. The necrotic myocardium after in vivo ischaemia reperfusion.
The necrotic myocardium of rats having undergone in vivo ischaemia-reperfusion after
ovx and chronic treatment with 17/3E2 and selective (A.) ER/3 antagonist Org44488 or
(B.) ERa agonist Org37445. The necrotic myocardium is expressed as a percentage of
the AAR, these areas were determined with TTC and Evans blue. The data is presented
as the mean ± SEM. The data was analysed using a (A.) two-way ANOVA and (B.) a
one-way ANOVA both followed by a Bonferroni post-hoc test; **P<0.01; ***P<0.001
compared to placebo treatment; n—6, 8for placebo + ER/3 antagonist.
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3.4.5. In vivo neutrophil infiltration
Tissue MPO activity was measured and used as a marker of neutrophil infiltration
following reperfusion. Supplementation with 17(3E2 after ovx significantly (P<0.05)
reduced the amount of MPO activity detected in the AAR compared to that in hearts
from placebo/vehicle-treated rats (Figure 3.7). Dosing placebo-treated rats with the
selective ERa agonist Org37445 also significantly reduced the level of MPO activity
within the AAR, reproducing the effect of 17pE2 (P<0.05; Figure 3.7).
Figure 3.7. Myeloperoxidase activity within the area-at-risk after ischaemia
reperfusion.
The MPO activity in the myocardial AAR after in vivo ischaemia-reperfusion in the rat
and the influence of ovx and 17pEi or selective ERa stimulation on the activity. The
activity was measured at 405nm and is expressed as MPO activity per gram of
myocardial AAR. The data was analysed using a one-way ANOVA and a Bonferroni
post-hoc test, it is expressed as the mean ± SEM; *P<0.05; n=5, 6 for the placebo
treatment.
3n




3.4.6. Free radical production after in vivo ischaemia
reperfusion
Neutrophils are a major source of oxidative stress following reperfusion. Therefore any
change in neutrophil infiltration should be correlated with a reduction in free radical
production from the AAR. EPR was used to detect the influence of 17PE2, ERa agonist
and ERp antagonist treatment on free radical production by the reperfused AAR of the
myocardium following in vivo ischaemia-reperfusion. In hearts from placebo/vehicle
treated animals significantly more free radicals were detected in the perfusate collected
from the whole heart than in perfusate from the non-ischaemic myocardium alone,











Figure 3.8. The EPR signal from rat myocardium after in vivo ischaemia
reperfusion.
The EPR signal gained from the perfusate of the entire myocardium and from the
myocardium not at risk of infarction (ligated heart), after in vivo ischaemia-reperfusion.
The data was analysed using a paired two-tailed t-test and is expressed as the mean ±
SEM; **P<0.01; n=5.
The majority of the oxidant stress could be accounted for by superoxide radicals, as
administration of SOD along with the spin trap significantly decreased free radical










Figure 3.9. The EPR signal with and without SOD, from rat myocardium after in
vivo ischaemia reperfusion.
The EPR signal recorded from the perfusate of in vivo reperfused infarcted rat
myocardium in the presence and absence ofSOD. The data was analysed using a paired
two-tailed t-test; *P<0.05; the data is presented as the mean + SEM; n=7.
Significantly less free radicals were generated from the AAR of hearts from animals that
received 17(3E2 compared to those that received placebo/vehicle following ovx (P<0.01;
Figure 3.10). This influence of 17[3E2 was not modified in hearts from ER|3 receptor
antagonist treated rats (P<0.01; Figure 3.10). Rats that received placebo and the ERa
agonist Org37445 also had significantly (P<0.01; Figure 3.10.) decreased free radical
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Figure 3.10. The EPR signal from the AAR of rat myocardium exposed to various
ER stimulation prior to in vivo ischaemia reperfusion.
The mean ± SEM EPR signal from the AAR of rat myocardium after in vivo ischaemia-
reperfusion and the effect of chronic ovx and (A.) 17(3E2 treatment along with selective
ERp antagonist Org44488 (B.) or ERa agonist Org37445 treatment on the EPR signal.
The data was analysed using a (A.) two-way ANOVA and (B.) a one-way ANOVA both
followed by a Bonferroni post-hoc test; ***P<0.001 compared to placebo/vehicle
treatment, n=5-8.
3.4.7. In vitro ischaemia reperfusion
To determine whether selective activation of the ERa could also mimic the direct,
neutrophil independent cardioprotective influence of 17pE2 on the myocardium further
experiments were conducted in buffer-perfused hearts. The perfusion pressure in hearts
from placebo/vehicle-treated rats was not significantly different from placebo rats
chronically treated with ERa Org37445 treated rats (Table 3.5). The perfusion pressure
dropped at the onset of ischaemia but recovered during the first 15mins of ischaemia and
was then maintained at this level until the end of reperfusion.
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Treatment Before Ischaemia Reperfusion 2hrs
ischaemia onset Reperfusion
Placebo/Vehicle 48.6 + 3.1 27.2 + 2.8* 30.44 ±2.8 46.5 ±6.5
Placebo/ERa 45.0 ± 10.7 33.8 ±6.8 45.6 ±7.4 53.1 ±8.1
agonist
Table 3.5. Mean perfusion pressure of rat myocardium during in vitro ischaemia
reperfusion.
The mean perfusion pressure of rat myocardium subjected to in vitro ischaemia-
reperfusion and the effect ofovx and chronic 17(3E2 or selective ERa agonist Org37445
treatment on this. The data was analysed using a repeated measures ANOVA with a
Bonferroni post test within groups and a two-tailed unpaired t-test between groups;
*P<0.05 compared to placebo/vehicle before ischaemia; n=6. The data is presented as
mean in mmHg + SEM.
Figure 3.11. The area-at-risk in the rat myocardium after in vitro ischaemia
reperfusion.
The influence ofovx and chronic treatment with selective ERa agonist Org37445 on the
AAR in the rat myocardium after ischaemia-reperfusion in an in vitro neutrophil free
perfused set up. The AAR is expressed as a percentage of the total heart weight, these
areas were determined with TTC and Evans blue. The data was analysed using a two-
tailed unpaired t-test and is expressed as mean ± SEM; n=6.
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ERa agonist Org37445 treatment after ovx had no significant effect on the total AAR
compared to the placebo/vehicle treated group after in vitro ischaemia-reperfusion
(Figure 3.11). The AAR was also comparable to that seen in vivo. The necrotic area
within the AAR was significantly reduced in hearts taken from animals treated with
selective ERa agonist Org37445 compared to placebo/vehicle (P<0.01; Figure 3.12).
Figure 3.12. The necrotic myocardium of rats after in vitro ischaemia reperfusion.
The mean + SEM of the necrotic myocardium of rats that have undergone in vitro
ischaemia-reperfusion after ovx and chronic treatment with selective ERa agonist
Org37445 compared to complete deprivation of 17(3E2- The necrotic myocardium is
expressed as a percentage ofthe AAR, these areas were determined with TTC and evans




At the time of this study the role of ERa and ER(3 during chronic administration of
17pE2 in an experimental model of ischaemia-reperfusion was not known. Therefore, the
aim of this study was to identify the roles of ERa and ERp in mediating the
cardioprotection provided by chronic administration of 17pE2 in a model of ischaemia-
reperfusion. This is the first study to use a selective ERp antagonist to investigate the
role of ERs in ischaemia-reperfusion. Previous studies in mice have failed to provide a
clear answer as the protective effects of E in ischaemia-reperfusion are reported to be
lost in both ERKO (Wang et al. 2006) and BERKO mice (Gabel et al. 2005).
Consequently, we employed novel ER selective agonists and antagonists in the rat to
investigate the role of individual receptors. The main finding of this chapter was that
chronic administration of the selective ERp antagonist Org44488 with 17pE2 did not
attenuate the 17pE2 associated decrease in infarct size, neutrophil infiltration and
oxidative stress after ischaemia-reperfusion. We also found that chronic administration
of the selective ERa agonist Org37445 to placebo treated rats reproduced the 17pE2
mediated decrease in infarct size, neutrophil infiltration and oxidative stress. These
results suggest that ERa is the predominant ER involved in cardioprotection by 17pE2.
In order to study the role of the individual ERs during ischaemia-reperfusion the ovaries
which are the main natural source of E were removed and the rats were implanted with
pellets releasing a controlled level of 17pE2 or placebo. In the preliminary study, we
determined that implanting a single pellet releasing 0.05 mg.day"1 of 17pE2 was
sufficient to obtain a plasma E level significantly greater than placebo treated rats and in
the mid-range of physiological levels. In comparison the rats that received two 17pE2
pellets, and therefore double the daily 17pE2 had a plasma E concentration that was
equivalent to the high proestrus level (lOO-lSOpg.mf1). The pilot study also confirmed
that the low dose of 17pE2 had the same cardioprotective properties as the high dose,
they both failed to have a significant effect on the AAR but significantly decreased the
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necrotic area of the myocardium after ischaemia-reperfusion compared to the placebo
treated rats. We deemed that constant plasma E levels in the mid cycle range was of
greater physiological relevance than the higher levels. The result that the
cardioprotection provided by both doses of 17pE2 was comparable ensured the lower
dose of 17pE2 was suitable for the continuing study.
The model of ischaemia used causes damage to the myocardium due to hypoxia-induced
vasoconstriction and tissue necrosis (Jennings et al. 1983; Lefer 1987), as well as
reperfusion associated infiltration of activated inflammatory cells, increased oxidative
stress, calcium overload and reduced tissue ATP levels (Hudson 1994; McCord 1985;
Premaratne et al. 1993). It is well established that 17pE2 provides protection in
experimental models of ischaemia-reperfusion (Mendelsohn et al. 1999; Stumpf et al.
1977). Several mechanisms have been proposed to account for the protective effects of E
in this model (Levine et al. 1996; Lucchesi 1990; Meade et al. 1992; Stampfer et al.
1991; Sullivan et al. 1995; Wahl et al. 1983). Among these, stimulation of NO synthesis
and activity may play a central role (Rubanyi et al. 1997). Increased NO bioavailability
not only leads to increased vasodilation and reduction of hypoxia, but also contributes to
inhibition of inflammatory cell infiltration (Davies et al. 1995). As well as stimulated
NO bioavailability, E mediated protection is partly through inhibition of neutrophil
infiltration (Squadrito et al. 1997) and a reduction of oxidative damage to the
myocardium (Bush et al. 1987; Squadrito et al. 1997; Sugioka et al. 1987). This
protection is likely to involve attenuated pro-apoptotic JNK and p38 MAPK activity and
a simultaneous increase in anti-apoptotic ERK activity (Vilatoba et al. 2005; Wang et al.
2006), that lead to a reduced necrotic zone. Regulation of these pathways is likely to be
through non-genomic pathways and regulated through G-protein coupled receptors. In
the present study we confirmed that both infarct size and neutrophil infiltration, assessed
by myocardial myeloperoxidase activity, were reduced in treated animals.
The current results allow us to conclude that the cardioprotection displayed by 17(3E2
and ERa agonist Org37445 in this study is through both neutrophil dependent and
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independent mechanisms. The neutrophil dependent mechanisms that we can allude to
being important in this study are reduced neutrophil infiltration and consequently
oxidative stress.
Oxidative stress is an important cause of injury following tissue reperfusion. Previous
studies have used assays to detect the end products of oxidative damage (Barp et al.
2002; Persky et al. 2000). These experiments have concluded that treatment with 17PE2
decreases the oxidative stress and increases the level of SOD activity (Barp et al. 2002).
These methods of detecting free radical production and oxidative damage are not very
accurate because they record the resulting product. Detecting the free radicals directly
provides a better indication of their production. Therefore, in the present study we
additionally aimed to measure free radical release from the reperfused myocardium
using EPR. The methods of EPR with the advantages of it are discussed in Section 2.6.
This is the first time that EPR has been used to assess free radical production from hearts
that have undergone in vivo ischaemia-reperfusion. In vitro perfusion of hearts with the
CP-H spin trap after in vivo ischaemia-reperfusion was successful in detecting free
radical release. Free radical detection was significantly reduced when perfusion through
the AAR was prevented, identifying the AAR as the major site of free radical production
in these hearts. The most likely source of oxidative stress within the AAR is neutrophils
that have infiltrated during reperfusion (McCord 1985). In the present study the
reduction in EPR signal after dual perfusion of spin-trap and SOD demonstrates that the
majority of free radicals produced in the myocardium are super oxide anions, the
predominant free radical released from neutrophils (Tauber et al. 1977). Treatment with
17PE2 clearly reduced the oxidant signal generated in the myocardium after ischaemia-
reperfusion compared to placebo/vehicle treated rats. This reduction corresponds to the
reduction in neutrophil infiltration, seen by attenuated MPO activity in 17(3E2 treated
compared to placebo/vehicle treated animals. In the reperfused heart, damaged
mitochondria are also a source of oxidative stress, through disruption of the electron
transfer chain (Lesnefsky et al. 2001) and may contribute here. 17(3E2 has previously
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been shown to reduce the oxidative stress from isolated rat mitochondria (Stirone et al.
2005) and may be an additional mechanism of inhibited oxidative stress in the current
model of damage. 17pE2 also up-regulates endogenous antioxidant systems, such as
glutathione peroxidase and SOD through enhanced MAPK and NFkB activity (Borras et
al. 2005). The pathways involved here are likely to involve a non-genomic ER. Thus
free radical scavenging may also be enhanced following chronic treatment with 17pE2.
Cardioprotection of 17(3E2 and ERa activation in particular, through a neutrophil
independent mechanism acting within the myocardium can be alluded to due to the in
vitro results in this study. Neutrophil independent mechanisms may involve the action of
fibroblasts within the myocardium as these are known to express ERs (Lee et al. 1998;
Mahmoodzadeh et al. 2006).
The principal aim of this study was to identify the roles of ERa and ERp in mediating
the cardioprotective effects of E. ERa is responsible for the stimulation of epithelial cell
proliferation in the uterus that results in the observed increase in uterine weight of rats
treated with 17pE2 or ERa agonist (Frasor et al. 2003). ERa also mediates the 17pE2
induced attenuation of food intake and weight gain (Roesch 2006). Administration of the
ERa agonist Org37445 increased uterine and decreased body weight, consistent with
successful activation of this receptor. The ERp antagonist Org44488 had no significant
effect on the uterine or body weight of rats treated with 17pE2 consistent with a lack of
blockade of ERa.
The ERp antagonist Org44488 did not show any significant effects when administered
with placebo. The ERp antagonist Org44488 did not attenuate the effects of 17pE2 on
infarct size, or the decrease in free radical detection after treatment with 17pE2> which
suggests that it is ERa that mediates the attenuated infarct size and free radical
production in the myocardium after ischaemia-reperfusion. ERp has been detected in the
rat heart (Grohe et al. 1998; Jankowski et al. 2001; Yang et al. 2004), and it has been
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implicated in mediating cardioprotection following trauma-haemmorhage (Yu et al.
2006). ER(3 is also highly expressed in the neonatal and developing heart when it is
under going development, after which the expression decreases (Jankowski et al. 2001).
However, it does not appear to have a role in mediating cardioprotection by E following
ischaemia-reperfusion. The results of the present study suggest that 17pE2 is more likely
to act through stimulation of ERa in the rat heart. ERa expression is low in the neonatal
rat heart and increases to a relatively high level in the adult heart (Jankowski et al.
2001). Thus suggesting that ERa modulates the mature myocardium and acute effects,
such as those we detected in this study. This conclusion is supported by the fact that the
ERa agonist Org37445 reproduced the in vivo and in vitro cardioprotective effects of
17pE2, including attenuated neutrophil infiltration, oxidative stress and cell necrosis, all
the parameters that were measured in the current study.
In another recent study, acute administration of the selective ERa agonist (4,4,4-4
propyl-(lH)-pyrazole 1,3,5-triyltrisphenol-PPT) PPT 30 minutes before ischaemia and
reperfusion reduced infarct size in the rabbit, while the ERp agonist DPN (2,3-bis(4
hydroxyphenyl propionitrole-DPN) failed to provide any cardioprotection (Booth et al.
2005). In this study, cardioprotection via stimulation of ERa was linked to a reduction
of C-reactive protein (CRP) deposition within the infarct area. Recently a study has
demonstrated that CRP can enhance infarct damage following permanent ligation of the
coronary artery in the rat (Pepys et al. 2006). Reduction of CRP deposition is also likely
to be a feature of protection following chronic stimulation of ERa in the present study.
CRP is thought to be a predictor of cardiovascular events (Khreiss et al. 2004), I believe
that caution should be maintained regarding the use of CRP levels as an indication of
protection or detriment to the infarct. Plasma levels of CRP are elevated upon a host of
injuries and are therefore difficult to specifically relate to myocardial injury (Yaron et al.
2006. A further note for caution is highlighted by the observation that weight loss such
as that seen in 17(E2 treated rats is known to reduce plasma CRP{Selvin, 2007 #137;
Zouki et al. 2001). Therefore, additional mechanisms will also contribute e.g. enhanced
100
Chapter 3
expression of endothelial nitric oxide synthase and reduced expression of adhesion
molecules, effects of E that reduce neutrophil infiltration (Delyani et al. 1996; Squadrito
et al. 1997), and have previously been linked to activation of ERa (Schrepfer et al.
2006; Tan et al. 1999).
Stirone et al have recently reported that activation of ERa in isolated mitochondria from
cerebral arteries inhibits oxidative stress, and that this property of ERa is abolished in
the presence of ICI-182 780 (Stirone et al. 2005), this is a further potential mechanism
through which ERa activation may attenuate oxidative damage in the myocardium. The
results of the in vitro study show that there is also neutrophil independent
cardioprotection following chronic stimulation of ERa.
The current study is the first study to demonstrate, using a novel combination of ERa
agonist and ERp antagonist, that the cardioprotective properties of 17pE2 in a rat model




MEDROXYPROGESTERONE ACETATE INHIBITS THE
CARDIOPROTECTIVE EFFECT OF OESTROGEN IN




Experimental models of CVD and injury support the concept that E has protective
properties within the cardiovascular system. Within rat and mouse models of ischaemia-
reperfusion E is known to reduce myocardial injury, due at least in part to its ability to
reduce neutrophil infiltration into the ischaemic myocardium (Kolodgie et al. 1997;
Squadrito et al. 1997; Zhai et al. 2000). Prior to the results of the double blinded
randomised clinical trials in 2002 (Hulley et al. 1998; Rossouw et al. 2002) there had
been limited research on the effect of progestogens on the cardioprotective properties of
E. Progestogens are added to ERT to circumvent detrimental cell proliferation in the
uterus, which arises from uninhibited E treatment in women having undergone a
hysterectomy. Progestogens have their own biological effects, the limited studies prior to
commencing this one provided evidence of them acting synergistically with E, having no
influence and or antagonising Es' effects (Hanke et al. 1996; Simoncini et al. 2003).
MPA has frequently been used in the clinical trials carried out to date and has proved
particularly problematic. Several experimental and clinical studies have shown that
MPA can negate the positive effects of E on endothelial function (Wakatsuki et al. 2001)
and its ability to attenuate neointima formation following vascular injury (Levine et al.
1996).
4.2. Aim
The aim of the present study was to investigate the influence of MPA on the proven
protective effect of 17(3E2 in an experimental model of ischaemia-reperfusion injury. We
hypothesize that co-administration of MPA with 17{3E2 attenuates the cardioprotective
properties of 17pE2 during ischaemia-reperfusion in the rat. Hearts from ovx rats
chronically treated with hormones were studied both in vivo and in vitro, to determine





In house pellets were used during this study. The pellets were made using silicon tubing
(2.4mm diameter), cut to 2-3mm in length. NuSil RTV silicon adhesive was used to seal
one end prior to filling the tubing with 17PE2 or MPA. 3mg of 17PE2 or MPA was used
per pellet, once filled the second end of the tubing was sealed with NuSil RTV silicon
adhesive. Placebo pellets were left empty. Once the adhesive had dried the filled and
sealed pellets were stored in sterile saline at 4°C. These in-house pellets have been used
previously in experimental models investigating the effect of 17pE2, and were
demonstrated to achieve a plasma level of E within physiological limits (less than 500
pg/ml; Fink et al. 1998)
4.3.2. Hormone Administration
Female rats (n=6l) were prepared for surgery as described in Section 2.2 and then under
went ovx as described in Section 2.2.1.1. Rats that were randomly assigned to MPA or
17pE2 hormone treatment received a pellet containing MPA or 17pE2 respectively. Rats
assigned to the combined hormone treatment of 17PE2 and MPA were implanted with 2
separate pellets, one containing 17PE2 and one with MPA.
4.3.3. Experimental Ischaemia reperfusion
In vivo and in vitro ischaemia-reperfusion was induced at least 14 days after ovx surgery
and pellet supplementation, as described in Section 2.2.2.1 and 2.2.2.2 respectively.
4.3.4. Analysis of myocardial tissue
The myocardial AAR was determined and analysed after in vivo and in vitro ischaemia-
reperfusion as described in detail in Section 2.3.1. Neutrophil infiltration in the AAR
was also measured after in vivo ischaemia-reperfusion through an MPO activity assay,




This study had a 77% survival rate. All the mortalities were during the ischaemia-
reperfusion period, there were not any mortalities during ovariectomy.
4.4.1. Body and Uterine weight
There was no significant difference between the body weights of rats in the different
treatment groups at the beginning of the study (Table 4.1). At the end of the study, ovx
rats treated with 17(3E2 weighed significantly less than animals receiving placebo or
MPA alone (P<0.01, Table 4.I.). Co-administration of MPA failed to influence this
effect of 17PE2. Treatment with 17pE2 also resulted in an increase in uterine weight
relative to placebo treatment (PO.OOl, Table 4.1.). MPA had no effect on uterine weight







(% of final body weight)
Placebo 199.6 + 6.7 272.8 + 9.4 0.092 + 0.01
17PE2 199.5 + 5.2 231.0 + 8.4** 0.262 + 0.02**
MPA 191.6 + 8.5 254.4+ 11.6 0.120 ±0.01
17PE2 + MPA 202.7 ±6.7 229.8 + 4.4** 0.272 ± 0.02**
Table 4.1. Body and uterine weights of the rat, the effect of 17PE2 and MPA.
Pre-surgeiy andfinal body weight of rats used in vivo, in vitro andfor the MPO study.
Final body weights are a minimum of 14 days post ovariectomy and hormone
supplementation. The uteri were weighed up on removal from the animal at the end of
the experiment. The uteri were dried in tissue prior to being weighed. Values shown are
mean + S.E.M, the data was analysed using a one-way ANOVA with a Bonferroni post
hoc test was used, **P<0.01; n= 14-19.
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4.4.2. In vivo ischaemia reperfusion
No treatment significantly altered the size of the AAR (Figure 4.1.). Despite there being
no difference in the overall AAR, treatment with 17PE2 alone significantly reduced the
necrotic zone within it, compared to placebo treatment (P<0.05, Figure 4.2.). Treatment
with MPA and 17pE2 in combination resulted in a significantly (P<0.05) larger necrotic
zone compared to that in animals treated with 17pE2 alone, such that there was no longer
protection relative to placebo treatment (P= NS compared to placebo, Figure 4.2.).
80n
P 17pE2 MPA 17pE2
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Figure 4.1. The AAR after in vivo ischaemia-reperfusion in the rat.
The AAR after in vivo ischaemia-reperfusion in the rat, it is expressed as a percentage of
the total heart weight. Data was analysed using a One-way ANOVA; data shown is
mean + SEM; n= 4-5.
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Figure 4.2. Necrotic myocardium after in vivo ischaemia-reperfusion.
The necrotic area ofthe myocardium, expressed as a percentage ofthe AAR after in vivo
ischaemia-reperfusion in the rat. Data was analysed using a one-way ANOVA with a
Bonferroni post-hoc test; data shown is mean + SEM; *P<0.05; n-4-5.
The MABP before ischaemia in the placebo treated group was 71.8 + 4.0 mmHg, this
was not significantly different between treatment groups (Table 4.2). There was a
significant (P<0.05) drop in pressure at the onset of ischaemia, the MABP recovered
during the first 30 mins of ischaemia to values not significantly different to before the
onset of ischaemia. The MABP remained constant throughout reperfusion but dropped
off at the end of reperfusion (Table 4.2). None of the treatments influenced the
characteristic change in blood pressure following ischaemia or reperfusion (Table 4.2).
The heart rate remained relatively constant throughout ischaemia-reperfusion and was
not significantly different between treatment groups (Table 4.3).
107
Chapter 4
Treatment Before Ischaemia onset Reperfusion 2hrs
ischaemia Reperfusion
Placebo 71.3 ± 7.8 40.9 ±4.0* 72.5 ± 11.5 37.2 ±5.0**
17pE2 76.9 + 9.3 42.4 ±5.5** 65.9 ±7.8 48.0 ±5.8*
MPA 72.9 + 8.2 44.8 ± 5.4* 62.6 ±8.2 43.3 ±6.3*
17pE2 + MPA 67.0 ±6.4 35.9 ±5.8* 52.0 ±9.3 37.5 ± 11.7*
Table 4.2. MABP during in vivo ischaemia reperfusion.
The mean arterial blood pressure (MABP) in mmHg throughout ischaemia-reperfusion
in the rat. The data was analysed using a repeated measures ANOVA within groups and
a one-way ANOVA between groups at each time point. The ANOVA was followed by a
Bonferroni post-hoc test, the values shown are mean ± SEM; **P<0.01 *P<0.05; n= 4-
6.
Treatment Before Ischaemia Reperfusion 2hrs
ischaemia onset Reperfusion
Placebo 361.8 ±3.8 365.4 ±34.3 393.6 ±39.4 357.0 ±32.3
17pE2 407.8 ±41.2 394.8 ±36.2 426.0 ±48.6 338.7 ±30.8
MPA 327.8 ±36.3 334.5 ±24.6 335.2 ±28.8 297.6 ± 32.2
17pE2 + MPA 339.3 ±36.8 323.0 ±36.3 360.0 ±37.6 383.0 ±30.1
Table 4.3.The heart rate during in vivo ischaemia reperfusion.
The mean heart rate during ischaemia-reperfusion in the rat. The data was analysed
using a repeated measures ANOVA within each group and a one way ANOVA between




To further investigate the effect of MPA on the protective properties of 17PE2, the MPO
activity within the myocardial AAR after in vivo ischaemia-reperfusion was determined.
MPO activity is a good indication of the neutrophil infiltration into the area.
Supplementation with 17pE2 significantly reduced the amount of MPO activity in the
AAR compared to placebo supplementation (P<0.05; Figure 4.3.). MPA
supplementation alone did not significantly alter the MPO activity compared to placebo
treatment. However, when MPA and 17PE2 were supplemented in combination the
amount of MPO activity in the AAR was significantly increased compared to treatment
with 17PE2 alone (P<0.05, Figure 4.3.).
17PE2 NPA 17pE2
+ MPA
Figure 4.3. Myeloperoxidase (MPO) activity in the AAR.
MPO activity in the AAR of the myocardium after in vivo ischaemia-reperfusion in the
rat. Data was analysed using a one-way ANOVA and Bonferroni post-hoc test; data
shown is mean + SEM; *P<0.05; n=6-4.
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4.4.4. In vitro ischaemia reperfusion
A similar pattern was seen as in vivo. The size of the AAR in vitro was comparable to
that in vivo and again there was no significant difference between the AAR in any
treatment group (Figure 4.4).
80-|
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Figure 4.4. The AAR after in vitro ischaemia reperfusion.
The myocardial AAR expressed as a percentage of the total heart weight after in vitro
ischaemia-reperfusion in the rat. Data was analysed using a one-way ANOVA; data
shown is mean + SEM; n= 5-7.
Figure 4.5 shows that treatment with 17PE2 tended to reduce the necrotic zone in
comparison to placebo after in vitro ischaemia-reperfusion, although this failed to reach
significance (P=0.057). Treatment with MPA alone did not significantly alter the
necrotic zone relative to placebo. There was however, a significant (P<0.05) increase in
the necrotic area within the AAR in the group treated with 17PE2 and MPA in





Figure 4.5. The necrotic myocardium after in vitro ischaemia-reperfusion.
The necrotic area of the myocardium, expressed as a percentage of the AAR, of the rat
heart after ischaemia-reperfusion in vitro. Data was analysed using a one-way ANOVA
and a Bonferronipost-hoc test; data shown is mean ± SEM; *P<0.05; n=5-7.
There was no significant difference between treatment groups in the coronary perfusion
pressure before the onset of ischaemia (Table 4.4). There was a drop in perfusion
pressure at the onset of ischaemia, this was only significant in the placebo treated group
(P<0.05; Table 4.4). The perfusion pressure then recovered during ischaemia to
pressures similar to those before ischaemia. The pressure then remained relatively
constant throughout reperfusion. None of the treatment groups altered these




Treatment Before Ischaemia Reperfusion 2hrs
ischaemia onset Reperfusion
Placebo 64.1 ±4.4 38.9 ±2.6# 47.6 ±4.6 46.5 ±4.4
17(3E2 64.1 +9.4 44.8 ±7.7 51.1 ±6.8 45.4 ±8.5
MPA 76.0 + 8.1 47.8 ±3.4 63.5 ±6.6 63.4 ±8.6
17PE2 + MPA 92.0 ± 12.4 62.7 ± 8.7 72.4 ± 12.3 78.8 ±20.5*
Table 4.4. Mean perfusion pressure of the rat myocardium through out in vitro
ischaemia reperfusion.
Mean perfusion pressure in mmHg of the rat myocardium through out the period of in
vitro ischaemia-reperfusion on the Langendorff The data was analysed using a repeated
measures ANOVA within groups and a one-way ANOVA between groups at each time
point. The ANOVA was followed by a Bonferroni post-hoc test. Data shown is mean +





The main aim of this chapter was to investigate the effect of MPA on the
cardioprotective effects of 17(3E2 in a model of ischaemia-reperfusion. The results of this
chapter demonstrate that the ability of chronically administrated 17pE2 to protect rat
hearts from ischaemia-reperfusion injury in vivo and in vitro is inhibited by the co¬
administration of MPA. The 17PE2 mediated decrease in necrotic area in vivo and in
vitro as well as the attenuated neutrophil infiltration are antagonised by the co¬
administration of MPA.
MPA is a synthetic progesterone. MPA is used in HRT because it has increased
bioavailability and is metabolised slower than progesterone (Mathrubutham et al. 1981),
thus lower doses are required. The slower metabolism is due to an additional methyl and
acetate group, which means that MPA has to be hydrolysed prior to metabolism and that
it is a poorer substrate for 5-alpha reductase. Progesterone is also a precursor to other
steroids, the synthetic analogue does not act as a precursor. Therefore when MPA is
administrated hormones downstream are not unintentionally increased (Ottoson et al.
1984).
Large scale prospective double-blinded studies, such as the WHI (The Women's Health
Initiative Study Group 1998), HERS (Hulley et al. 1998; discussed in Section 1.9) and
'Estrogen Replacement and Atherosclerosis' (ERA) trial (Herrington et al. 2000) have
failed to demonstrate cardiovascular benefits of HRT regimes in post-menopausal
women (Langer 2002). Such findings were not expected and contradicted those obtained
from observational studies of ERT and experimental results of 17PE2 in the
cardiovascular system (Bush et al. 1987; Falkeborn et al. 1992; Henderson et al. 1991).
These discrepancies lead to a hypothesis that progestogens may inhibit the beneficial
properties of E. Such a hypothesis has lead to a number of studies that have investigated
the potential interactions between E and progestogens (Adams et al. 1997; Gorodeski et
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al. 1998; Koh et al. 2004; McNeill et al. 2002; Minshall et al. 1998; Oishi et al. 2004;
Simoncini et al. 2004).
In the current study myocardial injury following ischaemia and reperfusion was reduced
in ovx rats that were treated with I IfiEi compared to those receiving placebo. Previous
studies have demonstrated the protective effects of 17PE2 in experimental models of
myocardial ischaemia-reperfusion (Kolodgie et al. 1997; Squadrito et al. 1997; Zhai et
al. 2000). The proposed mechanisms for 17PE2 mediated protection in this model are
discussed previously in Section 3.5. However, when co-administered with MPA, the
17PE2 induced cardioprotective properties were clearly inhibited. The amount of
necrotic tissue after ischaemia-reperfusion in MPA and 17pE2 treated rats was
comparable to the placebo treated rats.
The reduced levels of MPO activity within the myocardial tissue after treatment with
17pE2 indicates that there was an attenuated inflammatory response and neutrophil
infiltration. This finding is in agreement with previous observations that 17PE2
attenuates neutrophil infiltration (Squadrito et al. 1997). The 17pE2 mediated decrease in
neutrophil infiltration was negated when MPA and 17PE2 were co-administered. The
increase in MPO activity, almost reached placebo levels, thus suggesting the inhibition
of neutrophil infiltration into the AAR by 17pE2 was impaired by MPA. However, in
this model attenuated neutrophil infiltration is clearly not the only mechanism sufficient
to explain the protective effects of 17pE2.
In isolated buffer perfused hearts from rats receiving 17pE2 there was a tendency for
myocardial injury to be reduced compared to rats receiving placebo. The protective
properties displayed by 17pE2 in vitro were not as marked as in vivo. The advantage of
using an in vitro ischaemia-reperfusion set up is discussed in Section 2.2.2.2. The anti¬
oxidant and vasodilator properties of E may have an important influence here (Babiker
et al. 2002). The tendency for 17PE2 to decrease the in vitro myocardial damage in this
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study, suggests that in vivo mechanisms such as neutrophil infiltration, adhesion and
activation play a significant role in the protection displayed by E but that these work in
synergy with in vitro mechanisms. The co-administration of 17PEt and MPA in vitro led
to a significantly greater necrotic area than that in rats treated with 17(3E2 alone. This
result demonstrates that MPA must also be having an effect on the other protective
mechanisms of E that we see in vitro. These results in vitro depend upon the hormone
treatment having an effect upon the tissue during the period prior to perfusion as the
perfusate did not contain any hormones.
Interestingly MPA did not prevent all systemic effects of E. While body weight was
characteristically reduced in E treated rats (Beckett et al. 2002), MPA had no influence
on body weight either alone or in combination with E. Similarly, MPA had no influence
on the uterine weight. E stimulated the proliferation of uterine epithelial cells (Bigsby et
al. 2004), both in the absence and presence of MPA. MPA has previously been reported
to act systemically and to prevent these effects of E (Di Carlo et al. 1984; McNeill et al.
2002). Elowever, the present findings suggest that the level of MPA administered in this
study was only sufficient to inhibit E in the heart, suggesting that a more sensitive
mechanism is involved. In this study a control group of rats were treated with MPA
alone, this treatment did not have a significant effect on any of the parameters measured
in this study.
Several mechanisms have been proposed to account for the interactions between
progestogens and other steroid hormones. The androgenic progestogen, MPA, was
recently shown to impair E receptor signalling in endothelial cells (Simoncini et al.
2004), leading to a reduction in its ability to increase NO bioavailability (Oishi et al.
2004). MPA also has antagonistic properties at glucocorticoid receptors, leading to an
increased ability of human leukocytes to express the adhesion molecule ICAM-1
(Simoncini et al. 2004). The binding of E to ERs is also reported to be inhibited by MPA
(Di Carlo et al. 1983) and progestogens like MPA are reported to down regulate ER in
target tissues (Chwalisz et al. 1998; Di Carlo et al. 1984). Complete inhibition of E
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binding to its' receptors seems an unlikely explanation for the observations in the
present study as this would also have limited the effects of 170E2 on the body weight
and uterine proliferation, unless ERs in cardiovascular target tissue are down regulated
at a lower concentration of MPA than that required in other target tissues. Impaired
receptor signalling and interaction with other steroid receptors that may co-operate with
E are attractive alternative hypotheses. A reduction by MPA on the ability of E to
increase NO bioavailability, would lead to impairment of the vasodilatory and anti¬
inflammatory effects of E in this ischaemia-reperfusion injury model. Indeed,
progestogens have previously been shown to interfere with E induced enhancement of
coronary flow (Gorodeski et al. 1998) and endothelium-dependant dilation (Chataigneau
et al. 2004; Wakatsuki et al. 2001). Inhibition of neutrophil infiltration would also be
enhanced by MPA via reduced NO availability and also by increased expression of
adhesion molecules like ICAM-1. More recently MPA has been shown to act through
the progesterone receptor within the CVS to inhibit the beneficial properties of E (Iruela-
Arispe et al. 1996; Karas et al. 2001; Mercuro et al. 1999; The writing group for the
PEPI trial 1995). Such binding within this study would account for the attenuated
cardiovascular effects but the unabated systemic effects on body and uterine weight.
Previous studies of this sort have used either more (Levine et al. 1996; Oishi et al. 2004)
or less (Mensah-Brown et al. 2004) MPA compared to E. For this initial study we
decided to use equal amounts to investigate the impact of MPA on E's protection of the
myocardium. In the WHI 4x more MPA than E was administered. However, the results
in this chapter have demonstrated that at these concentrations the effects of E on the
myocardium are more sensitive to MPA than its effects on body weight and uterine
weight. The dose of MPA administered is clearly influential, Hanke et al demonstrated
that the ability of 17PE2 to attenuate atherosclerotic plaque development in rabbits was
inhibited by high doses of a progesterone but not at lower doses (Hanke et al. 1996).
There is also evidence that lower doses of both E and progestogens are more beneficial
and eliminate some of the detrimental effects, particularly increased thrombogenesis
(Stevenson 2000). New clinical trials such as the 'Kronos Early Estrogen Protection
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Study' (KEEPS) that has commenced recently is investigating the use of lower hormone
doses the dosing regime of this study is 0.459mg.day"' of E and 200mg of a progesterone
for only 12 days of the month (Harman et al. 2005).
It is clear from this study that MPA, when co-administered in vivo with E has the ability
to negate the protective effects of E in the myocardium. These data further suggest that
interactions between E and progestogens, like MPA, can lead to inhibition of Es' anti¬
inflammatory effects and enhanced inflammatory cell accumulation, as well as





THE ROLE OF OESTROGEN DURING REMODELLING




It is surprising that pre-menopausal women are reported to have higher acute mortality
following MI compared to age-matched men, this is discussed in Section 1.8 (Vaccarino
et al. 1999). Also mentioned in Section 1.8, ovx female mice supplemented with 17pE2
have increased mortality in the acute period following MI (Sharif 2002; van Eickels et
al. 2003) and impaired remodelling (Smith et al. 2000) compared to those supplemented
with placebo.
In the mouse model of MI, the major cause of acute sudden death is rupture of the LV
free wall at the infarct border (Cavasin et al. 2003). The incidence of this cardiac rupture
is increased by 17PE2 in ovx female mice (Sharif 2002; van Eickels et al. 2003). This
observation suggests that 17PE2 might interfere with the process of infarct healing that
eventually results in formation of a collagen rich scar and stabilisation of the infarct site.
The process of infarct healing involves inflammatory cell infiltration, ECM degradation
by MMPs, angiogenesis, myofibroblast proliferation and collagen synthesis as described
in chapter 1 (Blankesteijn et al. 2001; Lindsey et al. 2002). Cardiac rupture begins at 3
days after MI (Figure 5.1). Therefore the disrupted remodelling is likely to primarily
involve the earliest stages of remodelling prior to myofibroblast proliferation around
four days post-MI, collagen synthesis and angiogenesis around seven days after MI.
Several studies have linked MMP activity to the incidence of rupture, and in particular
activity of MMP-2 and MMP-9 (Ducharme et al. 2000; Hayashidani et al. 2003). At the
time of rupture it is plausible that the MMPs are at there most active, playing a major
role in the breakdown of the ECM and consequently fatal rupture. E is known to regulate
MMP activity in the reproductive tract (Marbaix et al. 1992) and non-reproductive
tissues, such as vascular smooth muscle and tumour cells (Potier et al. 2001; Wingrove
et al. 1998). However, little is known about the influence of E on MMPs or the principal
regulators of their activity, the TIMPs (Spinale 2002) in the heart. The extent of the
initial inflammatory response has also been suggested as a determinant of the incidence




Figure 5.1. Kaplan-Meier survival plot.
The mortality rate in ovx mice treated with 17(3E2 after Ml is significantly greater than
in mice receiving placebo after ovx. The significant increase in mortality is observed
from day 3-8 and is due to cardiac rupture. Mice surviving up to day 10 post-MI have a
much greater chance of survival and are unlikely to suffer fatal cardiac rupture.
Logrank test, P=0.04, n=21. (Previous studies in our lab; Sharif2002)
5.2. Aims
The aim of the present study was to investigate if 17PE2 modifies the early infarct
healing and remodelling post-Mi and if this leads to an increase in the incidence of
cardiac rupture.
To investigate the effect of 17pE2 on the remodelling process neutrophil infiltration and
myocardial necrosis were measured at 2 days after MI, this is when neutrophil
infiltration is at a maximum and therefore most likely to be of importance within the
remodelling. The expression and activity of MMPs and TIMPS were measured at 4 days
after Ml. We hypothesised that due to a higher incidence of cardiac rupture in mice
around this time point that the MMP activity would be at a maximum then and that this





Female mice (n=59) aged 13 weeks, were prepared for surgery as described in Section
2.2. The mice then underwent ovx as described in Section 2.2.1.1 and were randomly
assigned to receive placebo or 17(3E2 pellets subcutaneously at the nape of the neck. The
mice were allowed to recover as detailed in Section 2.2.1.1.
5.3.2. Myocardial Infarction
One week after ovx, MI was induced in the 14 week old female mice. The MI procedure
is outlined in detail in Section 2.2.1.2.
5.3.3. Determination of infarct size and necrotic cell death
Two days after MI the mice (n=12) were anaesthetised as detailed in Section 2.2.1.2.
The heart was removed from the chest and processed using TTC analysis as described in
Section 2.3.1 without Evans blue dye.
5.3.4. Determination of apoptotic cell death and neutrophil
infiltration
The apoptotic cell death and myocardial neutrophil infiltration were also recorded at two
days post-MI. At the time of harvesting the tissue, the mice (n=15) were anaesthetised as
described in Section 2.2.1.2. The hearts were removed from the chest and rinsed in water
before being weighed and cut in half transversely from apex to base. The hearts were
then processed for immunohistochemistry analysis as described in Section 2.4.2.1.
Apoptotic cell death was analysed using a TUNEL detection kit (Promego, UK), as
described in Section 2.3.2. Neutrophil infiltration was quantified by
immunohistochemistry. Haematoxylin and eosin staining was used initially to identify
the cells present in the infarct, this protocol is explained in Section 2.4.2.2. To further
analyse and quantify the neutrophil infiltration into the ischaemic myocardium a specific
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neutrophil marker, GR-1 antibody was used in immunohistochemistry. This protocol is
detailed in Section 2.4.2.3.
5.3.5. MMP and TIMP analysis
Four days after MI the mice (n=32) were sacrificed as described in Section 2.2.1.2. The
myocardium was sectioned and cultured for 24 hours in culture medium, this protocol is
detailed in Section 2.2.1.2. After 24 hours the culture medium was freeze-dried and
stored, as described in detail in Section 2.2.1.2. MMP activity was analysed using
gelatin zymography, detailed in Section 2.5.5. The activity of TIMPs was quantified
using reverse gelatin zymography, this protocol is detailed in section 2.5.4. The
expression of MMP-13 and TIMP-2 was analysed and quantified using western blotting,




5.4.1. Mortality rate post myocardial infarction
In the initial study with an end point of 2 days post-MI, for the investigation of
neutrophil infiltration and apoptotic cell death there were no premature deaths.
Throughout the 4 day time course of the second study experimental MI caused
premature death in 22% of the placebo group and 38% of the l7pE2 group (P=NS).
5.4.2. Necrotic and apoptotic tissue post myocardial infarction
Histological analysis of mouse hearts taken 2 days post-MI showed a significant
increase in infarct size compared to control operated mice. The infarct size was
determined by the weight of necrotic tissue, this significant increase was significantly
reduced with administration of l7pE2, compared to placebo treated mice (PO.OOl;
Figure 5.2a). l7pE2 treatment also decreased the number of TUNEL positive cells in the




Figure 5.2. Necrotic tissue and apoptotic cells 2 days post myocardial infarction.
(A.) The necrotic area ofthe mouse myocardium 2 days post-MI or control surgery. The
necrotic area was assessed using tri-phenyltetrazolium chloride. The data shown is
expressed as a percentage of the total heart weight. (B.) Histogram of TUNEL staining,
showing the percentage of apoptotic cells within the infarcted myocardium. Ten areas
within the infarct were assigned at random and the number of TUNEL positive cells
averagedfor each heart The data shown is mean + SEM and was analysed using an (A.)




5.4.3. Neutrophil infiltration post myocardial infarction
Two days after MI neutrophils were detected in the infarcted LV through haematoxylin
and eosin staining. Figure 5.3 highlights the presence of neutrophils in the infarcted
myocardium compared to the non-infarcted RV. For quantifying the neutrophils within
the infarcted LV a specific immunohistochemistry approach was taken using a GR-1
antibody.
Figure 5.3. Haematoxylin and eosin stain of infarcted myocardium.
Haematoxylin and eosin stain of (A.) the RV and (B.) the infarcted LV 2 days after
myocardial infarction. The heart is from a mouse that had previously had an ovx and
implantation ofplacebo pellet. There are no neutrophils visible in the R V, in the L V the
arrows highlight some ofthe neutrophils present.
Immunohistochemistry using a specific GR-1 antibody clearly illustrated the presence of
neutrophils within the infarcted LV (Figure 5.4). Very few GR-1 positive cells were
visible in control-operated hearts or in the RV of infarcted hearts. Treatment with 17pEo
significantly (P<0.05) reduced the number of neutrophils infiltrating into the infarcted
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Figure 5.4.Neutrophil infiltration post myocardial infarction
Neutrophil infiltration in the infarcted LV 2 days post-MI. GR-1 immunohistochemistry
staining ofthe infarcted region of (A) placebo treated mice and (B) 17/3E2 treated mice,
with arrows denoting GR-1 positive cells. (C) Neutrophil infiltration into the left
ventricle (LV) of infarcted mice ± 17/3E2 treatment. Data shown is mean ± SEM,
expressed per pm2 as viewed at xlOOO magnification. The data was analysed using a
two-way ANOVA with a Bonferroni post hoc, ***P<0.0001; n=4 per group.
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5.4.4. Detection of MMP-13 expression
Western blot analysis (Figure 5.5a) demonstrated a low basal expression of MMP-13
protein in control hearts and in the non-infarcted RV four days post-MI (Figure 5.5b).
Expression of MMP-13 in the infarct zone was significantly increased four days
following MI surgery (Figure 5.5c; P<0.05). This increase in MMP-13 expression
following MI was significantly reduced in mice receiving 17pE2, such that levels were
comparable to those in placebo treated non-infarcted hearts (Figure 5.5c). Interestingly,
treatment with 17(3E2 also reduced MMP-13 expression in control hearts. In contrast to
the heart, expression of MMP-13 in the uterus was significantly increased by treatment
with 17j3E2 relative to placebo (P<0.01; Figure 5.5d).
Figure 5.5. The influence of MI and 17pE2 on secreted MMP-13 from myocardial
tissue and uterus.
(A.) A typical Western blot showing MMP-13 expression, in reducing conditions in the
RV or the region corresponding to the infarcted L V (lnf) ofovx MI and control operated
mice receiving either placebo or 17(3E2. The expression ofMMP-13 in the uterus ofmice
receiving placebo or 17(TEi was used as in internal control. MMP-13 corresponds to a
protein band ~48 kDa. Histograms of the relative densitometric values for MMP-13
expression in the (B.) right ventricle, (C.) infarct and (D.) uterus. Data shown is the
mean ±_ SEM; it was analysed using a two-way ANOVA followed by a Bonferroni post-




5.4.5. Detection of MMP-2 and MMP-9 activity
Gelatin zymography of culture medium conditioned by regions from all hearts showed
the presence of bands of gelatinase activity at 92 kDa, 72 kDa and 66 kDa,
corresponding to latent MMP-9, latent and active MMP-2, respectively (Figure 5.6a).
Following MI, the secreted enzymatic activity of MMP-2 significantly (P<0.001)
increased 3-4 fold in the I and B zones of the myocardium relative to comparable areas
in control hearts and to the non-infarcted RV of the same heart (Figure 5.6b). There was
a more marked, 10-20 fold increase in secreted activity of MMP-9 in the I and B zones
compared to control hearts and to the RV of the same heart (P<0.001; Figure 5.6c).
Treatment of mice with 17PE2 had no significant effect on the secreted activity of MMP-
2 or MMP-9 in any area of control hearts and did not alter the activity in MI hearts
(Figure 5.6b and c). In the uterine tissue from the same animals, 17pE2 had no influence
on secreted MMP-2 activity (Figure 5.6b) but consistently increased secreted MMP-9
activity (PO.OOl; Figure 5.6c).
Figure 5.6. The influence of MI and 17PE2 on secreted MMP-2 and MMP-9
activity.
(A) A typical gelatin zymogram showing secreted MMP- 2 and MMP 9 activity from the
right ventricle (RV), non-infarcted left ventricle (LV), infarcted LV (Infi, septum (Sep)
and uterus (Ut) from mice 4 days post-MI or equivalent regions from control mice.
Gelatinase activity at 92 kDa, 72 kDa and 66 kDa corresponds to MMP-9 and to latent
and active forms ofMMP-2 respectively. The influence of 17fiE2 on the activities of (B.)
MMP-2 and (C.) MMP-9 secreted from the infarct, infarct border, RV or uterus of
C57B6J/I29sv at 4 days post MI or in corresponding regions from control hearts and
uterus. Data is correctedfor tissue weight and is shown as mean + SEM. The data was
analysed using a two-way ANOVA followed by a Bonferroni post-hoc test ***P<0.001,
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5.4.6. Detection of TIMP activity and expression
Reverse gelatin zymography demonstrated secreted activity of TIMP-1, glycosylated
TIMP-3 and TIMP-4 at -28 kDa, TIMP-2 activity at ~21 kDa and unglycosylated
TIMP-3 activity at -24 kDa (Figure 5.7a). The secreted activity of TIMP-1, glycosylated
TIMP-3 and TIMP-4 could not be individually resolved, due to their close molecular
weights (28, 27 and 30 kDa respectively). Following MI there was a significant (P<0.05)
increase in the activity of all TIMPs secreted from the infarct zone compared to control
operated mice (Figure 5.7), this increase in activity was particularly marked for TIMP-2
(Figure 5.7b). This was confirmed by Western blots and a trend for increased TIMP-2
protein expression after MI compared to control operated mice (Figure 5.9).
Treatment with 17pE2 significantly (P<0.05) increased secreted TIMP-2 activity in the
infarct zone of MI mice and the corresponding area of control mice compared to placebo
treated mice (Figure 5.7b). However, 17pE2 did not alter the expression of TIMP-2
protein within the infarct zone of MI or the corresponding area of control mice (Figure
5.9). The increased unglycosylated TIMP-3 activity post-MI was enhanced in the
presence of 17pE2 (Figure 5.7d), while 17PE2 had no significant effect on the summated
activity of TIMP-1, glycosylated TIMP-3 and TIMP-4 (Figure 5.7c).
In the uterus all four TIMPs showed a trend towards increased secreted activity when
treated with 17pE2 compared to placebo treated animals, although only TIMP-2 activity
was significantly enhanced (P<0.05; Figure 5.8).
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Figure 5.7. TIMP activity after myocardial infarction.
(a.) A typical reverse zymmogram of TIMP -I, glycosylated -3 and —4 activity at -28
kDa, unglycosylated TIMP -3 at -26 kDa and TIMP-2 at -21 kDa, in the right ventricle
(RV), infarct (Inf), border (Bor) and uterus (Ut) after myocardial infarction. The mice
had previously undergone ovx + 17(3E2 supplementation. Histogram of the relative
activity of (b.) TIMP-2, (c.) TIMP-1, glycosylated TIMP-3 and TIMP-4 and (d.)
unglycosylated TIMP-3. Data shown is mean + SEM, Two-way ANOVA followed by
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Figure 5.8. The influence of 17PE2 on secreted TIMP activity from the uterus
The secreted activity of TIMP-1, unglycosylated TIMP-3 and TIMP-4, TIMP-2 and
TIMP-3 from the uterus after ovx and placebo or 17(3E2 treatment. The data is
corrected for tissue weight and is shown as relative densitometric units; mean +_
SEM and was analysed using a paired two-tailed t-test and a Bonferroni post hoc







Figure 5.9. TIMP-2 expression after myocardial infarction
The influence ofMI and 17f3E2 on TIMP-2 expression in the left ventricle measured
by Western blot. Data is corrected for tissue weight and is shown as relative





In this chapter we aimed to investigate the influence of 17pE2 on myocardial
remodelling post-MI. The results from this chapter show that 17pE2 suppresses cell
necrosis, apoptosis, inflammation and MMP-13 activity in the infarcted region of the
heart post-MI. The activity of MMP-2 and MMP-9 post-MI is not however reduced in
parallel with suppression of cell death and inflammation in 17pE2-treated mice. The
activity of all the TIMPs is increased post-MI. TIMP-2 activity is increased after 17pE2
treatment in animals having undergone MI or not. An exaggerated stimulus for matrix
degradation and disrupted cardiac remodeling may lead to destabilization of the forming
scar and result in death due to rupture.
The murine model of MI is characterised by the occurrence of sudden death due to
cardiac rupture, occurring between 3-8 days after MI (Gao et al. 2005; Tao et al. 2004).
To date studies of rupture have linked its incidence to larger infarcts (Gao et al. 2005),
an enhanced inflammatory response and subsequent MMP activation post-MI (Cavasin
et al. 2004; Sun et al. 2004). Male gender is also associated with an increased likelihood
of rupture (Gao et al. 2005) and this has been attributed to the presence of testosterone
(Cavasin et al. 2003; Cavasin et al. 2004; Cavasin et al. 2006). Recently, it has been
shown that chronic administration of 17pE2 significantly enhances the risk of rupture
following MI in female mice (Sharif 2002; Smith et al. 2000; van Eickels et al. 2003),
although the reasons for this are unclear. The aim of the present study was to determine
if 17PE2 regulates the ECM degradation during the acute remodelling post-MI.
The initial identification of neutrophils in the infarcted myocardium with haematoxylin
and eosin staining enabled a good indication of the cells present at two days post-MI.
The staining with haematoxylin and eosin was not sufficiently clear for the
quantification of neutrophil infiltration into the infarct. The subsequent use of a
neutrophil specific, GR-1 antibody, detailed in Section 2.4.2.3 with haematoxylin stain
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provided clearer identification of neutrophils within the infarct. The clearer
identification of neutrophils enabled their infiltration to be quantified.
Infarct size is reduced in mice treated with 17PE2 relative to placebo treated controls.
We have shown that following MI 17pE2 reduced the necrotic area by on average 53
percent. This is in agreement with previous reports (van Eickels et al. 2003), this is at
least partly due to a reduction in apoptotic cardiomyocyte death, an effect of 17pE2 that
has recently been attributed to activation of phospo-ser423-Akt and ERK 1/2 (Patten et al.
2006; Vilatoba et al. 2005), this is likely to be through a non-genomic pathway. The
inflammatory response, indicated by the presence of GR-1 positive cells, was also
suppressed in the infarct of mice treated with 17PE2 compared to placebo. This
correlates with effects of 17PE2 in previous studies of both acute ischaemia-reperfusion
(in the preceding chapters) and chronic MI (Cavasin et al. 2004). Inhibition of NFkB
transcription (Evans et al. 2001) and enhancement of endothelial cell expression of Fas
ligand are thought to contribute to reduction of neutrophil infiltration by 17pE2 (Amant
et al. 2001). Previous studies in both animals and humans show that topical application
of E results in accelerated wound healing (Ashcroft et al. 1999), with characteristics
similar to those described during the early infarct healing phase. In the myocardium,
wound healing is reported to be more efficient in normally cycling females following MI
than in males (Cavasin et al. 2004). It may be that chronic elevation of E in the present
study results in formation of a scar that is unable to adapt to the constant pressure
changes, resulting in rupture. Assessing the collagen and more specifically the collagen
cross-linking within the infarct area would provide an indication to the stability of the
infarct. In this model of MI collagen is typically observed from day 7 onwards (Small et
al. 2005). Therefore, the samples in this study that were collected at 2 days post MI did
not show any sign collagen when stained with van Geison (data not shown). This would
be a good study to carry out for a better understanding of the scar formed, in terms of the




E can influence the activity of matrix degrading enzymes in non-cardiac tissues
(Helvering et al. 2005; Potier et al. 2001). Given the clear evidence that MMP activity is
a determinant of the extent of rupture post-MI in the mouse myocardium (Ducharme et
al. 2000; Hayashidani et al. 2003; Heymans et al. 1999; Tao et al. 2004), it seemed
probable that changes in matrix degrading activity by 17(3E2 may also influence scar
stability in the heart.
Expression of MMP-13 is constitutively low in the myocardium, but is increased by four
days after Ml, when it is likely to be secreted by proliferating fibroblasts (Xiaoquang Liu
1997). Treatment of mice with 17PE2 decreases the MI associated increase in MMP-13,
and this may suggest suppression of fibroblast proliferation by 17pE2. However, the
decrease in MMP-13 expression was also observed in control mice, demonstrating that
17pE2 has additional direct effects on MMP-13 expression, that are independent of MI
(Lu et al. 2006).
In the present study, the secreted activities of MMP-2 and MMP-9 were significantly
increased after MI in the infarct and infarct border, in agreement with earlier studies
(Heymans et al. 1999; Tao et al. 2004). Increased MMP-9 activity has been shown to
coincide temporally with neutrophil infiltration and it is expressed in neutrophils and
macrophages found in the infarct region at four days post-MI (Heymans et al. 1999;
Lindsey et al. 2001). MMP-2 is constitutively expressed within the heart and has a role
in ECM turnover. Infiltrating inflammatory cells also express MMP-2 and are a likely
source of the increased activity post-MI in the mouse myocardium (Hayashidani et al.
2003; Tao et al. 2004). Hearts from animals treated with 17pE2 had a significant
reduction in neutrophil infiltration following Ml. Given the apparent importance of these
cells as a source of gelatinase activity, it was surprising that there was no consequent
reduction in MMP-2 or MMP-9 activity in these hearts. Myocytes can also express
gelatinases in the heart post-MI and these are likely to be an alternative source of MMP-
2 and MMP-9 activity in the present study (Romanic et al. 2001). The evidence linking
gelatinase activity to the incidence of cardiac rupture is very strong, based on studies
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using inhibitors and KO mouse models (Ducharme et al. 2000; Hayashidani et al. 2003;
Heymans et al. 1999). However, in the present study, MMP-2 and MMP-9 activity was
not modified by 17pE2, suggesting that this is not the pathway primarily responsible for
its enhancement of cardiac rupture. Recently, Nahrendorf et al have also observed a
decreased inflammatory response with a concomitant increase in MMP-9 protein in the
myocardium post-MI, and this was also associated with an increase in the incidence of
rupture (Nahrendorf et al. 2006). The inflammatory response is likely to be important
during the initial remodelling period for the removal of necrotic tissue.
TIMPs exert largely un-discriminated inhibition on MMP activity, preventing complete
degradation of the ECM, therefore the activity of both TIMPs and MMPs is vital for
ECM maintenance. MI resulted in a significant increase in the activity of all four known
TIMPs in the infarct region (Cleutjens et al. 2002; Peterson et al. 2000). Treatment with
17pE2 had no influence on expression of TIMP-2, as shown by Western blotting, but
stimulated a further increase in its activity within the infarct zone. Activity of TIMP-3
was also enhanced by E. Previous studies have reported that TIMP-2 activity is
enhanced via stimulation of ERK 1/2 pathway (Munshi et al. 2004). Interestingly, E is
known to increase the expression of ERK 1/2 in mice (Vilatoba et al. 2005), it is likely
this could be a mechanism of regulating TIMP-2 activity in the myocardium. The impact
of increased TIMP-2 and -3 activity after 17pE2 treatment on scar stability is unclear and
likely to depend on the complexes formed with MMPs. While TIMPs are inhibitors of
MMP activity, recent evidence has emerged suggesting that TIMP-2 can also activate
pro-MMP-2 into the active enzyme (Baker et al. 2002; Rapti et al. 2006). TIMPs also
have functions in cells that are independent of their action upon MMPs (Lovelock et al.
2005). TIMP-2 and -3 might also influence wound healing through their ability to
directly enhance fibroblast proliferation and differentiation; there is an increase in
fibroblasts at the infarct border post-MI (Lovelock et al. 2005).
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The results of this study confirm that 170E2 has cardioprotective properties related to
reduction of cell apoptosis and inflammation in the acute phase following MI. The
mechanisms for this protection are discussed previously in Section 3.4. However,
despite this, administration of 17(3E2 can result in destabilisation of the ischaemic zone,
rendering it prone to rupture. The data demonstrate that enhancement of matrix
degradation by MMPs cannot account for this effect of 170E2. In fact the weight of
evidence supports suppression of overall MMP activity by 17pE2. Thus the mechanism
of rupture is distinct from that previously reported in males (Cavasin et al. 2003;
Cavasin et al. 2004; Cavasin et al. 2006). Previous experimental studies of MI in mice
have reported a higher systolic BP in males who also have a higher rate of LV rupture
compared to normal cycling females (Cavasin et al. 2004). In a previous study we have
shown that the current dose of 17PE2 administered to ovx mice increases the BP
compared to ovx females receiving placebo, therefore it is possible that the
haemodynamics post-MI have a significant effect on the rate of rupture (Ness 2005).
It is clear from clinical and experimental studies that E can have long-term benefit in
slowing progression to heart failure (Beer et al. 2006; Smith et al. 2000). The reduction
in infarct size and inflammatory response reported here will contribute to this protection








Due to the observed lower incidence of CVD in pre-menopausal women compared to
their age-matched men and post-menopausal women E was proposed to protect against
CVD. These suggestions were supported by the first observational clinical trials
(Stampfer et al. 1985), but yet results from randomised controlled clinical trials suggest
that HRT treatment is not beneficial within the cardiovascular system and even increases
the risk of a cardiovascular event in the first year (Hulley et al. 1998; Rossouw et al.
2002). Data recorded on in-hospital mortality also suggests that pre-menopausal women
are more likely to succumb to detrimental remodelling in the acute period after MI
(Vaccarino et al. 1999). Numerous animal models have reported the cardioprotective
properties of E within the vasculature and heart (Smith et al. 2000; Squadrito et al. 1997;
Williams et al. 1992).
At the time of starting this research, shortly after the WHI clinical trial results were
published, limited research had been carried out on the effect of progesterone analogues
on the cardiovascular properties of E (Hanke et al. 1996; Wakatsuki et al. 2001). During
the course of my research extensive analysis has been carried out on the data obtained
from the WHI trial (Grimes et al. 2002; Herrington et al. 2003). The WHI and similar
clinical studies are now widely accepted but the experimental design continues to be
scrutinised and the results raising specific questions that may help direct existing
hormone treatment in the most appropriate way to women who will benefit most. Chief
amongst these is the age of recipients, the delay in commencing HRT and the
cardiovascular health at the time of commencing treatment. Sub-group analysis has
made it apparent that younger females benefit from HRT whilst older women with more
advanced CHD have no benefit or fare worse (Grodstein et al. 2006). The average age of
the study population in the WHI and HERS was 60-65 years and all had been post¬
menopausal for at least 6 months. Re-analysis of the 'nurses health study' has provided
evidence that most benefit from HRT is seen in younger women (Manson et al. 2006)
and sub-group analysis of the WHI ERT arm shows a strong trend in cardioprotection in
the 50-59 years age group (Manson et al. 2003; Salpeter et al. 2004). Young women
141
Chapter 6
with POF have endothelial dysfunction that is normalized with hormone replacement
treatment (Kalantaridou et al. 2006). Age and CHD are associated with endothelial
dysfunction (Seals et al. 2006), experimental studies have shown reduced ER expression
in such arteries (Losordo et al. 1994; Post et al. 2003). E is also known to be detrimental
in the latter stages of atherosclerotic plaque development (ESHRE Capri workshop
group 2006). Experimental studies utilising animals of different ages at the time of ovx
and commencing E replacement at various time points after ovx would help to associate
these differences with the results seen in clinical trials. The studies carried out in this
thesis only looked at animals at one age and all of these received the replacement
hormones at the time of ovx. In our investigation using mature animals, we
demonstrated that MPA reversed the 17PE2 mediated reduction in necrotic tissue and
neutrophil infiltration. These experimental results demonstrate possible mechanisms for
the failure of clinical HRT studies. A recent clinical trial. The 'Early Versus Late
Intervention Trial with Estradiol' (ELITE) is designed to specifically investigate the
differences between peri- and post-menopausal women, it will run for 5 years, reporting
in 2010 (ELITE 2005).
The dose and route of E administration are also increasingly recognised as being of
importance in determining the response to hormone replacement. There is now some
evidence that a lower dose of E than that used in some of the earlier trials may reduce a
number of the detrimental effects seen in previous trials, particularly increased
thrombogenesis (Stevenson 2004). The WHI and HERS trials both used oral
administration of their hormone regimes. However, transdermal administration may be
more physiological and preferable. Transdermal application avoids the first pass effects
in the liver, providing more constant blood levels and importantly a more physiological,
pre-menopausal estradiol :estrone ratio (Sturdee 1999). Administration by the
transdermal route has been shown to avoid the increased risk of thromboembolism (Post
et al. 2003) and pro-inflammatory state that have been associated with oral
administration (Lakoski et al. 2005; Manson et al. 2006), whilst apparently retaining the
beneficial effects of E on endothelial function (Blumel et al. 2003). The experimental
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studies carried out in this thesis all used subcutaneous hormone replacement, this is the
most common method of hormone replacement after experimental ovx and could be a
reason for the discrepancies observed between experimental and clinical trials. The
controlled double-blind study KEEPS, is designed to test the importance of the route of
administration. The study is designed to run for five years, until 2010 and include
women between the age of 40 and 55 years old (Kronos 2006).
The cellular mechanisms of E within the CVS have also received enhanced interest since
the clinical trial results (Dubey et al. 2004; Manson et al. 2003). Improved knowledge of
which ER E acts through to mediate it's cardioprotective effects may help us target
specific receptors to attain the desired benefit from pharmacological methods.
Experimental studies in genetically-modified mice have provided some confusing
information, this could be due to a large degree of variability between species and
disease models (Mendelsohn 2002). For example, E is known to be cardioprotective
following injury and this has been variously attributed to both ERa (Wang et al. 2006)
and ERp (Gabel et al. 2005; Korte et al. 2005). The genetic difference between mouse
species is not only evident in experimental studies of 17PE2 but also studies of
myocardial remodelling and MMP expression and activity (Gao et al. 2005). For
example, MMP-2 mRNA is decreased in C57/B16/J aortic VSMC after treatment with E,
yet is increased in C3Fl/HeJ VSMC. The effect on MMP-9 mRNA expression was also
different in the two cell lines; E decreased MMP-9 in C3Fl/HeJ VSMC but had no
effect in C57/B16/J VSMC MMP-9 activity (Shi et al. 2003). The genetic variability
limits the relevance of studies in mice and the ability to correlate them to humans.
At the time of commencing this thesis the ER responsible for E mediated protection and
the attenuated inflammatory response had not been identified. Due to the limited
availability of selective ER agonists the majority of research into the individual ERs had
been carried out in KO mice (Gabel et al. 2005; Karas et al. 1999; Korte et al. 2005;
Wang et al. 2006). Increased availability of selective ER agonists and the development
of novel ER antagonists has enabled increased research into the role of individual ERs
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including their function in other experimental animals, such as rats and rabbits (Booth et
al. 2005; Pelzer et al. 2005). This is the first time that a novel ER antagonist has been
used to investigate the role of individual ERs within the myocardium. In the initial
investigation into the role of individual ERs after ischaemia-reperfusion we found that
ERa mediates the cardioprotective properties of 17(3E2. We were able to show this
through the use of a novel ERp antagonist Org44488, administered to rats treated with
17PE2. We then confirmed these results with the use of a novel ERa agonist Org37445.
The protection obtained with 17PE2 was similar to that obtained in previous studies
using the same model (Squadrito et al. 1997). Acute administration of an ERa agonist
was recently shown to mediate reduced cell death during ischaemia-reperfusion in
rabbits (Booth et al. 2005). Our study demonstrated the chronic effects of ERa
stimulation in vivo and in vitro, which enabled us to investigate the combined genomic
and non-genomic protection displayed by 17PE2 in the presence and absence of
neutrophils. In the current studies we were unable to identify which pathways were
responsible for the displayed protection.
Understanding the role of individual ERs within the CVS is unlikely to result in ER
specific compounds being used in humans because the side effects would be too large.
The ability to activate ERs in selective tissues is now possible through the selective
stimulation of co-activators with 'selective oestrogen receptor modulators' (SERMs).
SERMs exhibit some tissue specificity in their effects. For example, raloxifene has
similar properties to E in the CVS such as lowering of LDL and improvement of
endothelial function, while being antagonistic to Es proliferative effects in the uterus and
breast. Clinical trials to date using SERMs have resulted in conclusions of a null effect
on CVD, yet again the age of administration could be the key (Barrett-Connor et al.
2006; Blumenthal et al. 2004; Mosca et al. 2001; Somunkiran et al. 2006).
In contrast to the protective properties of 17PE2 during acute ischaemia-reperfusion, it is
associated with increased detrimental events after chronic MI. Prior to commencing this
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thesis we (Sharif 2002) and others (van Eickels et al. 2003) had reported that
experimentally mice receiving 17pE2 compared to placebo prior to MI have a higher
mortality rate due to cardiac rupture. MMP-2 and MMP-9 activity had previously been
linked to increased cardiac rupture within the LV (Ducharme et al. 2000; Hayashidani et
al. 2003). The relevance of 17pE2 during cardiac rupture and the remodelling period
preceding it had not been studied previously. Since starting this thesis the activity and
expression of MMPs and TIMPs during this intense remodelling period have been
investigated (Tao et al. 2004). The conclusions drawn from our studies are that 17pE2
disrupts myocardial remodelling through decreased neutrophil infiltration and an
attenuated initial inflammatory response. Treatment with 17pE2 also resulted in a
decreased necrotic area and MMP-13 expression but did not have any effect on MMP-2
and MMP-9 activity. Despite these apparent protective mechanisms the detrimental
inflammatory response may be more dominant in the remodelling period and lead to the
observed significant elevated levels of cardiac rupture. The MMP activity is clearly not
the only factor in cardiac rupture. Controversially, experiments that have compared the
mortality between normal cycling female and male mice have reported an increased
rupture rate in males and a detrimental effect of testosterone compared to E (Cavasin et
al. 2004). In the study by van Eickels, which also showed 17(3E2 to increase cardiac
rupture the ovx mice receiving 17(3E2 had plasma E2 levels of 81 + 13 pg.mf ; like our
study, this is at the high end of the physiological range. The discrepancy in these results
may therefore be due to the continuous high levels of 17pE2 compared to the non-ovx
cyclic females with lower plasma E2 levels. E2 may become detrimental at continuous
high plasma levels. This discrepancy is consistent with a speculation of the failure of the
clinical trails of HRT, which provided continuous levels of hormones. Prior to the
menopause the plasma level of E in females is cyclical. Like HRT treatment,
experimental models using ovx animals and subcutaneous 17pE2 pellets maintain a
continuous plasma E level. Mice supplemented with 17pE2 used in this study and others
may be limited in their physiological relevance due to the continuous high level of
circulating E. The plasma E level obtained in the current study using mice was in the
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physiological range, although it was at the high end of pro-oestrus levels. For mice to
have such high levels of E continuously is not physiological. The plasma E levels
obtained in the rats during this thesis were closer to mid-cycle physiological levels. In
our experimental study the rats received 17pE2 replacement immediately after ovx and
natural E deprivation. The 17PE2 administrated at a constant level in our studies was
cardioprotective. When MPA was co-administered the protective properties of 17pE2
were lost, studies that use various doses of 17pE2 and MPA would determine if the dose
of hormone has a significant effect on myocardial protection, as it does in atherosclarotic
plaque development (Hanke et al. 1996).
Gender differences in neutrophils could also account for some of the discrepancies, there
are significantly fewer neutrophils detected in female mice compared to male mice (Tao
et al. 2004). This finding is in agreement with the studies within this thesis. Increased
macrophage expression in the mouse model of MI is typically observed from around day
four onwards when it temporally co-localised with MMP-2 (Tao et al. 2004);
interestingly there are fewer macrophages detected at this time point in female mice
compared to males (Cavasin et al. 2004). We did not study the infiltration of
macrophages in the infarct region because we were interested in the neutrophil
infiltration which occurs earlier and therefore did not leave the mice four days post-MI
when immunohistochemistry analysis was carried out. It would be interesting to see if
the same pattern of infiltration is true in the ovx mice and whether this is a key
difference in the remodelling process.
The finding that the AAR was consistent between all the treatment groups in the
different studies, suggests that the experimental procedure was reliable and reproducible,
and cannot therefore be accountable for the observed differences in the necrotic tissue
between treatment groups. The lack of significant differences between the
haemodynamics of the treatment groups means that these can also be eliminated for




Limitations of the studies performed in this thesis include the low blood blood pressure
and heart rate in chapter 4. The low haemodynamics are likely to be due to over
anaesthetising the rats, a reason for his could be that the Sagatal was going off. When
Sagatal goes off the animals take longer to go under and therefore anaesthetic top-ups
are more likely to be administered. A further limitation in this study involves the
administration of the ERa agonist in the comparison to the 17(3E2 treatment. Treatment
with 17PE2 is administered continuously after ovx and elimination of endogenous E, in
comparison ERa is administered after a period of E deprivation and placebo treatment.
A direct comparison group for the ERa group would involve implanting the 17(3E2
pellet after a period of total E deprivation. The wide range of effects 17PE2 has within
the CVS (Mendelsohn et al. 1999) makes the interpretation of results difficult to
interpret and exact mechanisms to be pin-pointed. The use of KO models has limited
physiological relevance due to wide spread compensatory mechanisms; for this reason
traditional pharmacological inhibitors are able to give a better understanding.
Further work developing the findings from this thesis would provide interesting results
and continue to enlighten us into the cellular mechanisms of selective ERs. Exploiting
the use of selective agonists, it is necessary to administer a chronic ERp agonist to rats
and analyse the effect this has on the outcome of ischaemia-reperfusion. This experiment
would complete work within this thesis to distinguish between the roles of individual
receptors within the myocardium during injury. In light of experiments such as Jakowski
and others that demonstrate E alters ER expression I think it would be interesting to
examine the expression of both ERa and ERp before and after ischaemia-reperfusion in
the rat myocardium.
In the current thesis we only investigated the effect of 17PE2 on the myocardial
remodelling post Ml. Utilising the current model to asses the properties of collagen
(type of collagen and extent of cross-linking) and the fibroblasts in the infarct and at the
border around 4-7 days after MI would also help us understand how 17PE2 is altering the
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wound healing and scar formation. It would be interesting to utilise the selective ER
agonists and antagonist in this model and find out which ER the effects of E are being
mediated through in this model. Recently ERa was reported to suppress MMP-13
promoter activity in a rabbit cell line (Lu et al. 2006), it'll be interesting to see if this is
the case in the myocardium. The use of MMP inhibitors in conjunction with E in the
murine model of MI will also provide some more indication into the role of E in their
regulation and the importance of this in light of the present findings.
The overall aim of this thesis was to gain better understanding into the mechanisms and
interaction of E in the heart. In summary, our findings are that ERa mediates the in vivo
and in vitro 17pE2 mediated decrease in neutrophil infiltration, oxidative stress and cell
death in the rat model of ischaemia-reperfusion. We also show that the 17pE2 mediated
attenuation of cell death and neutrophil infiltration after ischaemia-reperfusion is
attenuated by co-administration of MPA. Finally we demonstrate that 17pE2 disrupts the
acute remodelling process post-MI. The disruption results in detrimental remodelling
and an increased incidence of cardiac rupture. These results may be attributed to the
anti-inflammatory properties of 17pE2 that beneficially protect against ischaemia-
reperfusion. Thus, the same mechanism that protects the myocardium from ischaemia-


















pH 7.4; filtered through waterman paper.
1.2 Solutions for measurement of myocardial infarct size
i. Evan's blue dye
Component Concentration
Evan's blue dye 1% w/v (in 0.9% saline)
ii. 2,3?5-triphenyltetrazolium
Component Concentration





40 % formalin 10 ml
NaCl 9 % w/v
Made up in 90 ml dH20.
1.3 Buffers and solutions for extraction of MPO from rat heart
tissue and neutrophils






Adjust to pH 7.4 with NaOH





Make up Na2HP04 in 4ml and add to 196 m NaH2P04. Adjust to pH 5.4 with NaOH
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0.05 M 7 ml
0.05 M 13ml



























1.5 Gelatin Zymography/ Reverse Zymography
i. Sample Application Buffer
Component Concentration
Glycerol 20 % w/v
SDS 2.0 % w/v
Bromophenol blue 0.04 % w/v









Adjust to pH 8.0 with 5N HCl





Adjust to pH 7.5 with 5N HCl
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v. Gelatin Zymography Triton X-100 wash
2.5% Triton X-100 in TBS 1:10
Appendix 1







Adjust to pH 7.6 with 5N HC1








Glacial acetic acid 10%
Water 60%
ix. Staining solution





Equal volumes of sec-butanol and distilled water (50 ml) were shaken for 3 minutes to
mix them. The solution was then allowed to settle (approximately 3hrs) prior to use. The
top layer is used to layer on the top of gels whilst they polymerise, forming a straight
top. This prevents a wavy line (if water alone is used) or the butanol drawing the water
from the gel (if butanol is used alone).
ii. Sample application Buffer
Component Concentration
Tris 1.5 % w/v
SDS 4.0 % w/v
Dithiothretiol (DTT) 2.0 % w/v
Bromophenol blue 0.05 % w/v
Adjust to pH 6.75 with 5N HCl, stored at -20°C



















Adjust to pH 7.4 with 5N HCl
vi. TTBS Wash buffer (as used)
Tween 20 0.05 % v/v min TBS xl

















i. Resolving gel 7.5 % (for 2 gels 0.75 mm thick)
Component Volume
ddH20 3.85 ml
Tris l .5 M pH 8.8 2.5 ml
Gelatin 10 mg/ml 1.0 ml
10 % SDS 100 pi
10 % ammonium persulphate 50 pi
Acrylamide/Bis 2.5 ml
TEMED 5 pi
N.B Gelatin was dissolved in the microwave prior to addition.
ii. Stacking gel 4% (for 2 gels 0.75 mm thick)
Component Volume
ddfEO 3.05 ml
Tris 0.5 M pH 6.8 1.25 ml
10% SDS 50 pi






iii. Resolving gel 12 % (for 2 gels 0.75 mm thick)
Component Volume
ddH20 1.69 ml
Tris 1.5 MpH 8.8 2.5 ml
Gelatin 10 mg/ml 1.0 ml
10 % SDS lOOpl
10 % ammonium persulphate 50 pi
Acrylamide/Bis 4.0 ml
Solution A 0.66 ml
TEMED 5 pi
iv. Stacking gel 5% (for 2 gels 0.75 mm thick)
Component Volume
ddH20 2.89 ml
Tris 0.5 M pH 6.8 1.25 ml
10% SDS 50 pi







Component Volume (7.5%) Volume (12%)
ddH20 9.7 ml 6.7 ml
Tris 1.5 MpH 8.8 5.0 ml 5.0 ml
10 % SDS 200 pi 200 pi
10 % Ammonium persulphate 100 pi 100 pi
Acrylamide/Bis 5.0 ml 8.0 ml
TEMED 10 pi 10 pi
vi. Stacking gel 4% (for 2 gels 1.5mm thick)
Component Volume
ddH20 6.1 ml
Tris 0.5 M pH 6.8 2.5 ml
10% SDS 100 pi





1.8 Aminopropyiethoxysaline (TESPA) slide coating
Bathe slides for 10 seconds each in the following solutions:
1. 10% HC1 in 70% ethanol
2. DEPH20
3. 100% acetone
Air dry the slides, then take through the following, 10 seconds each:
4. 2% TESPA in acetone
5. 100% acetone
6. 100% acetone
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Medroxyprogesterone acetate inhibits the cardioprotective effect
of estrogen in experimental ischemia-reperfiision injury
Helen L. Jeanes, BSc,1* Payong Wanikiat, PhD,1'2* Isam Sharif, PhD,1 and Gillian A. Gray, PhD1
Abstract
Objective: Results from recent clinical trials of estrogen and progestogen therapy (EPT) suggest
that some progestogens may interfere with the cardiovascular benefits of estrogen (E). The aim of
this study was to investigate whether medroxyprogesterone acetate (MPA) modifies the protective
effect of E in experimental ischemia-reperfusion (1R) injury in vivo and in vitro in the rat.
Design: Ovariectomized female Wistar rats (250-280 g, n = 61) received E, MPA, E and MPA, or
placebo subcutaneously. Fourteen days later, hearts were isolated and perfused with Krebs
Henseleit for in vitro experiments or left in situ for in vivo experiments. In both cases, the left
coronary artery was occluded for 45 minutes, followed by 2 hours of reperfusion.
Results: In vivo E significantly reduced the necrotic zone of reperfused hearts (21.8% ± 1.7% of
area at risk) compared with placebo (42.8% ± 4.8% area at risk; P < 0.05). This protection was
reversed by co-administration of MPA with E (necrotic zone 38.2% ±6.1% area at risk). The
influence of E on neutrophil infiltration was demonstrated by its ability to reduce myocardial
myeloperoxidase activity (0.2 ± 0.1 U/g tissue) relative to placebo (1.3 ± 0.5 U/g tissue; P < 0.05).
Myocardial myeloperoxidase activity was significantly increased to 1.1 ±0.3 U/g tissue in rats
receiving E and MPA. Elowever, MPA also reversed the protective effect of E in neutrophil-ffee
buffer-perfused hearts, suggesting that additional mechanisms are involved.
Conclusion: In this study, we showed that the administration of MPA can inhibit the effects of
E that lead to protection of the myocardium from reperfusion injury and that this involves both
neutrophil-dependent and neutrophil-independent mechanisms.
Key Words: Estrogen - Medroxyprogesterone acetate - Myocardium - Ischemia.
Cardiovascular disease is the leading causeof mortality and morbidity in women.1Although the rate of cardiovascular diseaseis lower in prem nopausal wome than in
age-matched men, it increases significantly postmeno-
pause, reaching levels found among men. The observed
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gender difference and time of onset suggest that
estrogen (E) withdrawal and, consequently, E de¬
ficiency, is an important risk factor. This is supported
by observational studies showing postmenopausal es¬
trogen therapy (ET) to be beneficial.2'3 However, ET is
only suitable for women who have undergone hyster¬
ectomy, as it can increase the risk ofendometrial cancer.
For this reason, most women receive E concurrently
with a progestogen analog such as medroxyprogester¬
one acetate (MPA) in estrogen and progestogen therapy
(EPT) to reduce this risk. The results of several recent
large-scale clinical trials comparing ET with EPT have
stimulated debate regarding the potential detrimental
influence of progestogens in EPT.4'5 Evidence is now
emerging that MPA may interact with E at a cellular
level, inhibiting its favorable effects.6"8
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ESTROGEN. MEDROXYPROGESTERONE ACETATE, AND MYOCARDIUM
n experimental models, E reduced myocardial injury
;r ischemia and reperfusion, at least in part as a result
its ability to reduce neutrophil infiltration into the
hemic myocardium.9"'' The aim of the present study
s to investigate whether the acute interactions reported
ween MPA and E in vitro7 could be reproduced after
onic in vivo delivery, by investigating the influence
MPA on the proven protective effect of E in ex-
imental ischemia-reperfusion injury. Hearts from
iriectomized rats chronically treated with hor-
nes were studied both in vivo and in vitro to de-
nine the relative importance of systemic and local
tactions.
MATERIALS AND METHODS
rhis investigation conformed to the Guide for the
:e and Use of Laboratory Animals published by the
ited States National Institutes of Health (NIH
)lication No 85-23, revised 1996) and with the
ited Kingdom Home Office guidelines as outlined
:he Animals (Scientific Procedures) Act 1988. The
dies were approved by the University of Edinburgh
ical review committee. All animals were housed in
mtrolled environment with a 12-hour light/dark cycle
h constant temperature (21 °C ± 2°C) and humidity,
I they were fed a standard laboratory diet and tap
ter ad libitum.
"emale Wistar rats weighing 210 to 280 g (n = 61;
arles Rivers Laboratories) were bilaterally ovariec-
tized (halothane 4% induction, 1 % to 1.2% mainte-
ice). Briefly, the ovaries were exposed via a dorsal
ision and tied off with a 5/0 silk ligature, then
toved. The wound was closed using 5/0 silk ligature
I 5-mm metal clips. The rats were then randomly
igned to a treatment group, and sterile silicon pellets
itaining either E (3 mg; n = 14), MPA (3 mg; n= 13),
- MPA (n = 15), or placebo (n = 19) were implanted
icutaneously. All rats underwent ovariectomy to
ure that the endogenous supply of E was removed,
1 each treatment group only received supplemented
mones from the implanted pellets. Implanted pellets
re been used previously and were demonstrated to
lieve a plasma level of E within physiological limits
500 pg/mL).12 The animals were allowed to recover
m anesthesia and were given buprenorphine hydrox-
chloride (0.5 mg/kg) subcutaneously for analgesia.
:s were weighed every 3 days until the end of the
leriment to ensure that they gained and maintained
ight and to determine the influence of hormone
iplementation.
At least 14 days later, the rats were anesthetized
(50 mg/kg sodium pentobarbitone intraperitoneally;
Sagatal, Rhone Merieux, UK) and prepared for either
in vivo or in vitro experiments.
In vivo
The carotid artery and jugular vein were cannulated
to measure blood pressure and to deliver additional
anesthetic as required. The rats were intubated and
ventilated with room air (60 strokes/min, 0.1 mL/g).
Temperature was maintained at 37°C via a thermostat¬
ically controlled under-blanket, and the chest was then
opened at the fourth intercostal space. The heart was
removed from the chest by applying gentle pressure to
either side of the incision (with forceps), and a 5/0 silk
ligature was placed around the left coronary artery
(LCA). The heart was returned to the chest, and the
animals were allowed a 20-minute stabilization period
before ischemia was induced using a reversible snare.
After 45 minutes of ischemia, the snare was released,
and the myocardium was reperfused for 2 hours. At the
end of this reperfusion period, the LCA was perma¬
nently occluded, and 2 mL of Evans blue (1% in saline)
was infused via the jugular vein to determine the area at
risk (AAR) of infarction. The heart was then cut in half
transversely through the nonischemic area and stored at
— 70°C for later measurement of ischemic damage or
myeloperoxidase (MPO) activity. The uterus was removed
and weighed to confirm appropriate hormone delivery.
Myeloperoxidase assay
Neutrophil infiltration and accumulation in the
myocardium was assessed using MPO activity as a
measure.13 In this study, the hearts were separated
into the AAR and nonischemic area before storage at
— 70°C. At the time of analysis, the AAR was homo¬
genized in buffer containing 20 mM sodium phosphate
buffer (pH 4.7), 0.015 M EDTA, and 0.1 M sodium
chloride, then centrifuged at 10,000 rpm for 15 minutes
at 4°C. The supernatant was discarded and the pellet
was resuspended. The samples were homogenized for
a second time in sodium phosphate buffer (pH 5.4)
containing 0.5% hexacyltrimethylammonium bromide.
This was then taken through four cycles of freeze-thaw,
a 10-second sonication, and 15-minute centrifugation at
10,000 rpm, 4°C. A portion of this supernatant (30 p,L)
was aliquoted into a 96-well plate and mixed with
200 |xL 0.05 M citrate phosphate buffer (pH 5) containing
o-dianisidine dihydrochloride and 0.0015% hydrogen
peroxide. The absorbance was measured at a wavelength
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of405 nm during a 20-minute period. MPO activity was
defined as the quantity of enzyme degrading 1 (xmol of
peroxide per minute at 25 °C expressed in units per gram
of weight.
In vitro
The chest was opened, and a 5/0 silk ligature was
passed around the LCA before the heart was isolated. At
this time, the uterus was also removed and weighed. The
aorta was cannulated, and the heart was retrogradely
perfused via the aorta using a modified Langendorff
set up.14 Prefiltered Krebs Henseleit solution [pH 7.4
containing (in mM] NaCl 118, KC1 4.7, CaCl2 3.0,
MgS04 1.2, KH2P04 1.2, EDTA 0.5, NaHC03 25 and
glucose 11 ] was perfused through the heart at a constant
rate of 10 mL/min and at a constant temperature of37°C,
gassed with 95% Oz/5% C02. After a stabilization pe¬
riod of 20 minutes, the LCA was reversibly occluded
in the same way as in vivo; ie, 45 minutes of ischemia
followed by 2 hours of reperfiision. The ligature was
then retied, and 2 mL of Evans blue dye (1% in saline)
was perfused via the injection arm to identify the AAR.
The heart was then cut in half transversely through
the nonischemic area and stored at — 70°C for later
analysis.
Measurement of infarct size
Myocardial damage and the impact of treatment were
assessed using triphenyltetrazolium chloride-Evans blue
technique15 with some modifications. In brief, the left
half of the heart was cut into 2- to 3-mm transverse
slices from the apex to the base in 1% saline. The slices
were then incubated at 37°C for 15 minutes in 2,3,5-
triphenyltetrazolium chloride (1% weight/volume in
normal saline). The color was fixed in 10% formalin for
10 minutes, and the sections were rinsed in 1 % saline
for 10 minutes. The heart was split into three distinct
areas: the nonischemic area stained blue from the initial
Evans blue perfusion and the two zones of the AAR,
the pink non-necrotic and whiter necrotic zones. The
distinct areas were separated, blotted dry, and weighed.
Statistical analysis
Statistical analysis was performed using PRISM
software (GraphPad, CA). One-way analysis of vari¬
ance and a Tukey post hoc test were applied to compare
data. Statistical difference was taken as P < 0.05.
All chemicals and drugs were supplied by Sigma-
Aldrich.
RESULTS
Body and uterine weight
There was no significant difference among the body
weight of rats in the different treatment groups at the
beginning ofthe study (Table 1). At the end of the study,
ovariectomized rats treated with E weighed signifi¬
cantly less than animals receiving placebo or MPA
alone (P < 0.01; Table 1). Co-administration of MPA
failed to influence this effect of E.
E treatment also resulted in an increase in uterine
weight relative to placebo {P < 0.001; Table 1). MPA
had no effect on uterine weight when administered
alone and had no influence on the ability ofE to increase
uterine weight.
In vivo
No treatment significantly altered the size of the
AAR (Table 1). Although there was no difference in the
overall AAR, treatment with E alone significantly
reduced the necrotic zone within it, compared with
placebo treatment (P < 0.05; Fig. 1 A). Treatment with
MPA and E in combination resulted in a significantly
(P < 0.05) larger necrotic zone compared with that in
animals treated with E alone, such that there was no
longer protection relative to placebo treatment (Fig.
1 A). The size ofthe necrotic zone in rats receiving MPA
alone was not significantly different from the necrotic
zone in placebo-treated animals.
TABLE 1. Effect of treatments on body weight and the area at risk after myocardial infarction
Initial body Final body Uterine weight AAR % heart AAR % heart
Treatment weight (g)° weight (g)" (% of body weight)" (g) (in vivo) (g) (in vitro)
P 199.6 ± 6.7 272.8 ±9.4 0.1±0.01c 62.3 ± 6.8 70.4 ± 4.5
E 199.5 ± 5.2 231.0 ±8.4t 0.3 ± 0.02 54.6 ± 3.6 67.3 ± 6.7
MPA 191.6 ± 8.5 254.4 ±11.6 0.1±0.01c 64.9 ±6.1 63.8 ± 2.5
E + MPA 202.7 ± 6.7 229.8 ± 4.4* 0,3 ± 0.02 63.7 ± 5.0 70.8 ± 4.8
P, placebo; E, estrogen alone; MPA, medroxyprogesterone acetate alone; E + MPA, combination of hormone treatments; AAR, area at risk.
Data shown as mean ± SEM.
"Body weight and uterine weight, n = 14-19; AAR, n = 4-8.
bP < 0.01 compared with placebo.
CP < 0.001 compared with E-supplcmented group.
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1. The effect ofovariectomy followed by chronic hormone therapy
l) myocardial necrotic area after ischemia-reperfiision in vivo. The
tic zone is expressed as a percentage ofthe total area at risk (AAR)
B) myocardial myeloperoxidase (MPO) activity in the AAR of rats
cted to ischemia-rcperfusion in vivo. Data are expressed as U/g
;. Data shown as mean ± SEM. One-way analysis of variance with
/ post hoc, *P < 0.05. n = 4-6 per group. P, placebo; E, estrogen;
, medroxyprogesterone acetate; E 4- MPA, estrogen and medroxy-
sterone acetate.
MPA and E were given in combination, the amount of
MPO activity in the AAR was significantly increased
compared with treatment with E alone (P < 0.05;
Fig. IB).
In vitro
We found a pattern similar to that seen in vivo. The
size of the AAR in vitro was comparable to that in vivo;
there was no significant difference among the AAR in
any treatment group (Table 1). Figure 2 shows that
treatment with E tended to reduce the necrotic zone
compared with placebo, although this failed to reach
significance (P = 0.057). Treatment with MPA alone
did not significantly alter the necrotic zone relative to
placebo. There was however, a significant (P < 0.05)
increase in the necrotic area within the AAR in the
group treated with E and MPA in combination,
compared with treatment with E alone (Fig. 2).
All groups had a significant (P < 0.05) decrease in
coronary perfusion pressure at the onset of ischemia,
from 74.1 ± 4.6 mm Hg to 48.0 ± 3.2 mm Hg, which
recovered during the first 30 minutes of ischemia. None
of the treatments altered these characteristic changes in
perfusion pressure throughout ischemia and reperfusion.
DISCUSSION
Large-scale prospective, double-blinded studies,
such as the Women's Health Initiative,16 Heart and
Estrogen/progestin Replacement Study (HERS),17 and
Estrogen Replacement and Atherosclerosis (ERA) trial18
have failed to demonstrate the cardiovascular benefits
of EPT regimens in postmenopausal women. Such
he mean blood pressure before ischemia was 71.8 ±
mm Hg and was not significantly different among
ment groups. There was a significant (P < 0.05)
ease in pressure at the onset of ischemia (to 40.5 ±
nm Hg) that increased within 30 minutes of ische-
to values not significantly different from those
re the onset of ischemia. None of the treatments
lenced the characteristic change in blood pressure
• ischemia or reperfusion.
•loperoxidase assay
implementation with E significantly (P < 0.05)
ced the amount of MPO activity in the AAR
pared with placebo (Fig. IB). MPA supplementa-
alone did not significantly alter the MPO activity
pared with placebo treatment. However, when
*
P E VPA E + MPA
FIG. 2. Myocardial necrotic area after in vitro ischemia-reperftision. The
necrotic zone is expressed as a percentage of the total area at risk (AAR).
P, placebo; E, estrogen; MPA, medroxyprogesterone acetate; E + MPA,
estrogen and medroxyprogesterone acetate. Data shown as mean ± SEM.
One-way analysis of variance with Tukey post-hoc *P < 0.05; n = 5-8.
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findings were not expected and contradicted those
obtained in observational studies of ET.3,20,2' These
discrepancies lead to a hypothesis that progestogens
may inhibit the beneficial properties of E. This has led
to a number of studies that have investigated potential
interactions between E and progestogens.6"8,22"25 Re¬
cently it was reported that MPA inhibited E-induced NO
production when administered acutely to cultured cell
lines.6,7 The current findings clearly demonstrate that
the ability of E to protect hearts from ischemic injur,'
when chronically administered in vivo to ovariecto-
mized rats is also inhibited by the co-administration
of the progestogen MPA.
The protective effects of E in experimental models
of myocardial ischemia-reperfusion9" and vascular
injury are well known.26,27 In the present study, myo¬
cardial injury after ischemia and reperfusion was
reduced in ovariectomized rats that had been treated
with E compared with those receiving placebo. Damage
to the myocardium in this model results from hypoxia-
induced vasoconstriction and tissue necrosis28,29 and
from reperfiision-associated infiltration of activated
inflammatory cells, increased oxidative stress, calcium
overload, and reduced tissue adenosine triphosphate
levels.30"32 Several mechanisms have been proposed to
account for the protective effects ofE in this model.33"36
Among these, stimulation of NO synthesis and activity
may play a central role.37 Increased NO bioavailability
not only leads to increased vasodilation and reduction
of hypoxia, but also contributes to the inhibition of
inflammatory cell infiltration.38 In the present study,
reduction of reperfiisinn damage in vivo by E was
associated with a reduction in tissue levels of MPO,
indicative of a reduction in neutrophil infiltration, in
agreement with previous observations.9 However, this
mechanism alone is clearly not sufficient to explain
the protective effects of E found in this model. In
hearts isolated from E-treated rats and perfused with
neutrophil-free buffer in vitro, myocardial damage also
tended to be reduced relative to that in hearts from
placebo-treated rats, although to a lesser extent than
in vivo. The antioxidant and vasodilator properties of
E may have an important influence.39
Administration of the progestogen MPA in place ofE
had no influence on any of the parameters investigated
in the present study. However, when co-administrated
with E, MPA clearly inhibited E's protective effects in
the heart. The necrotic zone of hearts from animals
treated with E and MPA was comparable to that of
placebo-treated animals, both in vivo and in vitro. In
addition, in the in vivo experiments, MPO activity was
almost reversed to placebo levels on co-administration
of MPA with E, which indicates that inhibition of
neutrophil infiltration by E was impaired. Interestingly,
MPA did not prevent all systemic effects ofE. Although
body weight was characteristically reduced in E-trcated
rats,40 MPA had no influence on body weight either
alone or in combination with E. Similarly, MPA had
no influence on uterine weight. E stimulated the pro¬
liferation ofuterine epithelial cells41 in both the absence
and presence of MPA. MPA has previously been re¬
ported to act systomically and to prevent these effects
of E.22,42 However, in the present study, the level of
MPA administered in this study seemed sufficient only
to inhibit E in the heart, which suggests that a more
sensitive mechanism is involved.
Several mechanisms have been proposed to account
for the interactions between progestogens and other
steroid hormones. The androgenic progestogen MPA
was recently shown to impair E receptor signaling in
endothelial cells,6 leading to a reduction in its ability to
increase NO bioavailability.7 MPA also has antagonistic
properties at glucocorticoid receptors, leading to an
increased ability of human loulcocytcs to express the
adhesion molecule ICAM-1.6 The binding of E to its
receptors is also reported to be inhibited by MPA,43 and
progestogens like MPA are reported to down-regulate
the E receptor in target tissues.42,44 Complete inhibition
of E binding to its receptors seems an unlikely expla¬
nation for the observations in the present study, as this
would also have limited the effects of E on the body
weight and uterine proliferation, unless E receptors in
cardiovascular target tissue are down-regulated at a
lower concentration of MPA than that required in other
target tissues. Impaired receptor signaling and in¬
teraction with other steroid receptors that may co¬
operate with E arc attractive alternative hypotheses.
A reduction by MPA on the ability of E to increase
NO bioavailability would lead to impairment of the
vasodilator)' and anti-inflammatory effects of E in this
ischemia reperfusion injur)' model. Indeed, progestogens
have previously been shown to interfere with E-induced
enhancement of coronary flow23 and endothelium-
dependant dilatation.45,46 Inhibition ofneutrophil infiltra¬
tion would also be enhanced by MPA via reduced NO
availability and by increased expression of adhesion
molecules like ICAM-1.
CONCLUSION
It is clear from this study that, when co-administered
in vivo with E, MPA has the ability to negate the
protective effects of E in the myocardium. These data
further suggest that interactions between E and pro¬
gestogens such as MPA can lead to inhibition of E's
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-inflammatory effects and enhanced inflammatory
accumulation, as well as enhancement of other
ergistic mechanisms that protect the tissue more
ctly from ischemic injury.
REFERENCES
Pelzer T, Shamim A, Neyses L. Estrogen effects in the heart. Mol
Cell Biochem 1996; 160-161:307-313.
Grodstein F, Manson JE, Colditz GA, Willctt WC, Speizcr FE,
Stampfer MJ. A prospective, observational study of postmeno¬
pausal hormone therapy and primary prevention of cardiovascular
disease. Ann Intern Med 2000;133:933-941.
Bush TL, Barrett-Connor E, Cowan LD, ct al. Cardiovascular
nortality and noncontraccptive use of estrogen in women: results
ifom the Lipid Research Clinics Program Follow-up Study.
Circulation 1987;75:1102-1109.
vlanson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and
he risk of coronary heart disease. N Engl J Med 2003;349:523-
>34.
Dubey RK, Imthurn B, Zacharia LC, Jackson EK. Hormone
•eplacement therapy and cardiovascular disease: what went wrong
tnd where do we go from here? Hypertension 2004;44:789-
795.
iimoncini T, Mannella P, Fornari L, et al. Differential signal
ransduction of progesterone and medroxyprogesterone acetate in
luman endothelial cells. Endocrinology 2004;145:5745-5756.
Dishi A, Ohmichi M, Takahashi K, et al. Medroxyprogesterone
icetate attenuates estrogen-induced nitric oxide production in
luman umbilical vein endothelial cells. Biochem Biophys Res
:ommun 2004;324:193-198.
Coh KK, Sakuma I. Should progestins be blamed for the failure of
lormone replacement therapy to reduce cardiovascular events in
andomized controlled trials? Arterioscler Thromb Vase Biol
004;24:1171-1179.
'.quadrito F, Altavilla D, Squadrito G, et al. 17Bcta-oestradiol
educes cardiac leukocyte accumulation in myocardial ischacmia
eperfusion injury in rat. Eur J Pharmacol 1997;335:185-192.
Colodgie FD, Farb A, Litovsky SH, et al. Myocardial protection of
ontractile function after global ischemia by physiologic estrogen
eplacement in the ovariectomized rat. J Mol Cell Cardiol 1997;
9:2403-2414.
Jiai P, Eurell TE, Cotthaus R, Jeffery EH, Bahr JM, Gross DR.
iffect ofestrogen on global myocardial ischcmia-reperfusion injury
i female rats. Am J Physiol Heart Circ Physiol 2000;279:H2766-
12775.
ink G, Sumner BE, McQueen JK, Wilson H, Rosie R. Sex steroid
ontrol of mood, mental state and memory. Clin Exp Pharmacol
*hysiol 1998;25:764-775.
lullane KM, Kraemer R, Smith B. Myeloperoxidase activity as
quantitative assessment of neutrophil infiltration into ischemic
lyocardium. J Pharmacol Methods 1985;14:157-167.
Lubanyi G, Kovach AG. Effect ofhypoxia on mechanical properties
f isolated rat heart: comparison of the effects of hypoxic and
istotoxic hypoxia. Acta Physiol Acad Sci Hung 1980;55:215-
25.
e Lorgeril M, Rousseau G, Basmadjian A, Latour JG. Lignocaine
lexperimental myocardial infarction: failure to prevent neutrophil
ccumulation and ventricular fibrillation and to reduce infarct size.
ardiovasc Res 1988;22:439-446.
he Women's Health Initiative Study Group. Design of the
/omen's Health Initiative clinical trial and observational study.
'ontrol Clin Trials 1998:19:61-109.
[ulley S, Grady D, Bush T. Randomized trial of estrogen plus
rogestin for secondary prevention of coronary heart disease in
ostmenopausal women: Heart and Estrogen/progestin Replace-
lent Study (HERS) Research Group. JAMA 1998;280:605-613.
18. Herrington DM, Reboussin DM, Brosnihan KB. Effects ofestrogen
replacement on the progression of coronary-artery atherosclerosis.
N Engl J Med 2000;343:522-529.
19. Langer RD. Hormone replacement and the prevention of cardio¬
vascular disease. Am J Cardiol 2002;89:36E-46E [discussion 46E].
20. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in
users of estrogen replacement therapy. Arch Intern Med 1991; 151:
75-78.
21. Falkeborn M, Pcrsson I, Adami HO. The risk of acute myocardial
infarction after oestrogen and oestrogen-progestogen replacement.
Br J Obstet Gynaecol 1992;99:821 -828.
22. McNeill AM, Zhang C, Stanczyk FZ, Duckies SP, Krause DN.
Estrogen increases endothelial nitric oxide synthase via estrogen
receptors in rat cerebral blood vessels: effect preserved after
concurrent treatment with medroxyprogesterone acetate or pro¬
gesterone. Stroke 2002;33:1685-1691.
23. Gorodeski GI, Yang T, Levy MN, Goldfarb J, Utian WH. Modu¬
lation of coronary vascular resistance in female rabbits by estrogen
and progesterone. J Soc Gynecol Invest 1998;5:197-202.
24. Minshall RD, Stanczyk FZ, Miyagawa K, et al. Ovarian steroid
protection against coronary artery hyperreactivity in rhesus
monkeys. J Clin Endocrinol Metab 1998;83:649-659.
25. Adams MR, Register TC, Golden DL, Wagner JD, Williams JK.
Medroxyprogesterone acetate antagonizes inhibitory effects of
conjugated equine estrogens on coronary artery atherosclerosis.
Arterioscler Thromb Vase Biol 1997;17:217-221.
26. Sullivan TR Jr, Karas RH, Aronovitz M, et al. Estrogen inhibits the
response-to-injury in a mouse carotid artery model. J Clin Invest
1995;96:2482-2488.
27. Levine RL, Chen SJ, Durand J, Chen YF, Oparil S. Medroxypro¬
gesterone attenuates estrogen-mediated inhibition of neointima
formation after balloon injury of the rat carotid artery. Circulation
1996;94:2221-2227.
28. Lefer AM. Physiologic and pathophysiologic role of cyclo-
oxygenase metabolites of arachidonic acid in circulatory disease
states. Cardiovasc Clin 1987;18:85-99.
29. Jennings RB, Rcimer KA. Factors involved in salvaging ischemic
myocardium: effect of reperfusion of arterial blood. Circulation
1983;68(2 Pt 2):I25-I36.
30. McCord JM. Oxygen-derived free radicals in postischemic tissue
injury. N Engl J Med 1985;312:159-163.
31. Prcmaratne S, Limm W, Mugiishi MM, Piette LH, McNamara JJ.
Quantitative assessment of free-radical generation during ischemia
and reperfusion in the isolated rabbit heart. Coronary Artery Dis
1993;4:1093-1096.
32. Hudson KF. A phenomenon of paradox: myocardial reperfusion
injury. Heart Lung 1994;23:384-393.
33. Meade TW, Bcrra A. Hormone replacement therapy and cardio¬
vascular disease. Br Med Bull 1992;48:276-308.
34. Wahl P, Walden C, Knopp R, et al. Effect of estrogen/progestin
potency on lipid/lipoprotein cholesterol. N Engl J Med 1983;308:
862-867.
35. Lucchesi BR. Modulation of leukocyte-mediated myocardial reper¬
fusion injury. Ann Rev Physiol 1990;52:561-576.
36. Stampfer MJ, Colditz GA. Estrogen replacement therapy and
coronary heart disease: a quantitative assessment of the epidemi¬
ologic evidence. Prev Med 1991;20:47-63.
37. Rubanyi GM, Freay AD, Kauser K, et al. Vascular estrogen
receptors and endothelium-derived nitric oxide production in the
mouse aorta: gender difference and effect ofestrogen receptor gene
disruption. J Clin Invest 1997;99:2429-2437.
38. Davies MG, Fulton GJ, Hagen PO. Clinical biology ofnitric oxide.
Br J Surg 1995;82:1598-1610.
39. Babiker FA, Dc Windt LJ, van Eickels M, Grohe C, Meyer R,
Doevendans PA. Estrogenic hormone action in the heart: regulatory
network and function. Cardiovasc Res 2002;53:709-719.
40. Beckett T, TchemofA, Toth MJ. Effect ofovariectomy and estradiol
replacement on skeletal muscle enzyme activity in female rats.
Metabolism 2002;51:1397-1401.
Menopause, Vol. 13, No. 1, 2006 85
Copyright © The North American Menopause Society.
Unauthorized reproduction of this article is prohibited.
JEANES ETAL
41. Bigsby RM, Caperell-Grant A, Berry N, Nephew K, Lubahn D. Estrogen 44. Chwalisz K, Stockemann K, Fritzemeier KH, Fuhrmann U.
induces a systemic growth factor through an estrogen receptor- Modulation of oestrogenic effects by progesterone antago-
alpha-dependent mechanism. Biol Reprod 2004;70:178-183. nists in the rat uterus. Hum Reprod Update 1998;4:570-583.
42. Di Carlo F, Racca S, Conti G, et al. Effects of long-term 45. Chataigneau T, Zerr M, Chataigneau M, et al. Chronic treatment
administration of high doses of medroxyprogesterone acetate on with progesterone but not medroxyprogesterone acetate restores the
hormone receptors and target organs in the female rat. J Endocrinol endothelial control of vascular tone in the mesenteric artery of
1984;103:287-293. ovariectomized rats. Menopause 2004;11:255-263.
43. Di Carlo F, Gallo E, Conti G, Racca S. Changes in the binding 46. Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Effect of
of oestradiol to uterine oestrogen receptors induced by some medroxyprogesterone acetate on endothelium-dependent vasodila-
progesterone and 19-nor-testosterone derivatives. J Endocrinol tion in postmenopausal women receiving estrogen. Circulation
1983;98:385-389. 2001;104:1773-1778.
86 Menopause, Vol. 13, No. 1, 2006
Copyright © The North American Menopause Society.
Unauthorized reproduction of this article is prohibited.
Appendix 2
MEDROXYPROGESTERONE ACETATE INHIBITS THE CARDIOPROTECTIVE
EFFECT OF OESTROGEN AFTER ISCHAEMIA-REPERFUSION IN THE RAT.
Helen Jeanes, Isam Sharif, Payong Wanikiat & Gillian A Gray, Centre for Cardiovascular
Science, The University of Edinburgh, Hugh Robson Building, George Square, Edinburgh, EH8
9LD, UK.
Cardioprotection by oestrogen (E) is clear from epidemiological studies in pre- and post¬
menopausal women, as well as in animal models. However recent clinical trials, such as
the Women's Health Initiative (WH1) and the Heart and Estrogen/Progestin
Replacement Study (HERS), have demonstrated that hormone replacement therapy
(HRT) which contains a mixture of both E and medroxyprogesterone acetate (MPA),
does not protect postmenopausal women from cardiovascular disease and could actually
increase the incidence rate (Herrington et al., 2003).
The aim of the current study was to investigate whether MPA can modify the
cardioprotective effect of E in a rat model of ischaemia-reperfusion.
Female rats (Wistar 150-200g, n=45) underwent ovariectomy (OVX). Pellets containing
E alone, MPA alone, E + MPA or placebo were then implanted subcutaneously. At least
14 days later, hearts were removed for in vitro perfusion or rats were prepared for in vivo
studies. In both cases the left coronary artery (LCA) was reversibly occluded for 45
minutes and then reperfused for 2 hours. The LCA was re-occluded and Evans blue
perfused through the heart for identification of the area-at-risk (AAR). Myocardial
damage assessed in sections of frozen heart using triphenyl tetrazolium chloride.
AAR after reperfusion was not significantly different between any treatment group,
being 68 + 1.5 % in vitro and 61 ±2% in vivo. E reduced the necrotic zone both in
vivo, (see Figure 1) and in vitro, from 45 + 5% of AAR to 25 + 2% of AAR. MPA itself
failed to modify the infarct size. However, when given together MPA inhibited the
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cardioprotective effect of E, both in vivo (see Figure 1) and in vitro (necrotic zone 52 +
6%, P<0.05 versus E alone).
Placebo E MPA E + MPA
Treatment
Figure 1. Ischaemic damage in vivo.
(n=5, 4 for MPA. **/?<0.01, *p<0.05
Tukey following 1-way ANOVA).
These confirm cardioprotection by E, and show that protection is negated on co¬
administration of MPA, both in vivo and in vitro buffered perfused hearts. This maybe
due to altered neutrophil infiltration in vivo but other mechanisms e.g. antioxidant
effects may also contribute in vitro. MPA may act through modification of E receptor
synthesis or of E binding to them.
Herrington, D.M. et al. (2003) Atherosclerosis, 166, 203-212
This research was funded by the British Heart Foundation (FS03114).
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170-ESTRADIOL MODIFIES THE PROFILE OF MYOCARDIAL MMP AND
TIMP DURING HEALING POST-MYOCARDIAL INFARCTION IN MICE
H.L.Jeanes1'2, I.Sharif1, A.Kozak1, R.Leask2, E.Bruce1'2, S.C.Riley2 & G.A.Gray1.
'CCVS & 2CRB, University of Edinburgh, QMRI, Edinburgh, UK
Pre-menopausal women have significantly greater acute mortality post-myocardial
infarction (MI) than age-matched men. Ovariectomised (OVX) mice receiving 170-
estradiol (E2) have significantly greater mortality post-MI due to cardiac rupture
compared to placebo (P) treated mice. Matrix metalloproteinases (MMP) regulate
turnover of the extracellular matrix (ECM), MMP activity is regulated by the tissue
inhibitors of metal loproteinases (TIMPs). E2 regulates activity and expression of MMP
in a number of tissues, it's effects in the myocardium are unknown.
The aim of the present study was to determine the impact of E2 on infarct size,
neutrophil infiltration, expression and secreted activity of the gelatinases MMP-2 and -
9, the collagenase MMP-13 and the TIMPs during infarct healing post-MI.
OVX female C57B6J/129sv (n=34) had E2 or P releasing pellets implanted
subcutaneously and eight days later MI or sham surgery. Neutrophil infiltration and
infarct size were determined at 2 days post-MI by immunohistochemistry and
triphenyltetrazolium chloride respectively. Secreted activity of MMP-2 and -9 were
assayed by gelatin zymography, TIMP activity was assayed by reverse zymography,
expression of TIMP-2 and MMP-13 was determined by western blotting in tissue
removed at 4 days post-MI.
MI significantly (P<0.001) increased neutrophil infiltration, the secreted activity of
MMP-2 and MMP-9 and MMP-13 expression in the infarct (P<0.05). E2 reduced both
infarct size and neutrophil infiltration, but had no influence on gelatinase activity. E did
reduce the expression of MMP-13 and increased TIMP-2 activity.
These results show E2 increases sudden death due to cardiac rupture despite reducing
damage to the myocardium post-MI and subsequent neutrophil infiltration. The
continued stimulation of MMP-2 and -9 activity in E2 treated hearts may contribute to
destabilisation of the healing infarct, resulting in deficient repair and rupture.
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